Novel direct dried blood spot-based approaches for forensic toxicology and clinical applications by Sadones, Nele
                                         
 
 
                                         
 
 
 
Novel direct dried blood spot-based approaches 
for forensic toxicology and clinical applications 
 
 
 
Nele SADONES 
2017 
 
 
 
Promoters: Prof. Dr. Christophe Stove & Prof. Dr. Willy Lambert 
 
Thesis submitted to obtain the degree of Doctor in Pharmaceutical Sciences  
  
  
II 
 
 
  
  
  
III 
 
Copyright 
The author and the promoters give authorization to consult and copy parts of this thesis for personal use only. 
Any other use is limited by the laws of copyright, especially concerning the obligation to refer to the source 
whenever results are cited from this thesis.  
 
De auteur en promotoren geven de toelating dit proefschrift voor consultatie beschikbaar te stellen en delen 
ervan te kopiëren voor persoonlijk gebruik. Elk ander gebruik valt onder de beperkingen van het auteursrecht, 
in het bijzonder met betrekking tot de verplichting uitdrukkelijk de bron te vermelden bij het aanhalen van 
resultaten uit dit proefschrift.  
 
Ghent, 2017,  
 
The promoters,         
 
 
Prof. Dr. Christophe Stove    Prof. Dr. Willy Lambert 
 
 
The author, 
 
 
Nele Sadones 
 
 
 
 
  
  
IV 
 
  
  
  
V 
 
Dankwoord  
Een woord van dank aan iedereen die rechtstreeks of onrechtstreeks heeft bijgedragen tot dit werk.  
 
Vooreerst wil ik mijn promotoren prof. Christophe Stove en prof. Willy Lambert bedanken. Zonder hen kon ik 
uiteraard nooit starten aan een doctoraat. Dank u wel om mij deze kans te geven! Jullie constructieve feedback 
heeft in belangrijke mate bijgedragen tot het realiseren van dit werk. Bedankt prof. Stove om het vele 
schrijfwerk telkens opnieuw kritisch te verbeteren. Gezien je overvolle agenda heb je hiervoor heel wat uren 
van je slaap opgeofferd. Prof. Lambert, bedankt voor de steun de voorbije jaren. Zowel op professioneel als op 
menselijk vlak ben je een voorbeeld.  
 
Bedankt aan alle collega’s waarmee ik heb samengewerkt. Dit werk is ook een deel van jullie. Jullie hebben er 
allemaal op een of andere manier voor gezorgd dat dit tot stand kwam. Ik kon steeds bij jullie terecht. In het 
bijzonder wil ik hierbij Jolien en Sofie bedanken om me te steunen! Jullie begrepen me met weinig woorden. 
Uitermate belangrijk aangezien ik niet zo’n grote spraakwaterval ben ;-) Ann-Sofie, bedankt om me in te leiden 
in de wereld van de GC. Filip, bedankt om de gasflessen te vervangen. Ook bij heel wat andere praktische 
problemen was een ingenieur soms iets handiger dan een apotheker ;-) Ook wil ik de thesisstudenten 
bedanken voor de vele analyses die ze uitgevoerd hebben en Annelies, sorry als ik jouw strakke planning moest 
doorbreken voor het uitvoeren van heel wat PCR-reacties. 
 
Iedereen die betrokken was bij de verschillende studies wil ik natuurlijk ook bedanken. Ann-Sofie, Michelle 
Wood, Dr. Archer, Dr. Dargan, Dr. Wood en prof. Neels wil ik bedanken voor hun bijdrage aan de GHB studie. 
Eveneens een woord van dank aan prof. Van Bortel en Elien voor de vlotte samenwerking en het opzetten van 
de gabapentine studie. Pieter en Sara, dank u wel, om mee te helpen bij het verzamelen van stalen. Prof. 
Delanghe wens ik te bedanken voor het delen van zijn haptoglobine kennis. Het 24 uurs-labo van UZ Gent 
verdient ook een speciaal woord van dank voor de vele bloedafnames en het uitvoeren van de hematocriet 
bepalingen. 
 
Jolien verdient natuurlijk nog een extra woord van dank. Zij was immers het creatieve brein die de kaft heeft 
ontworpen. Dikke merci Jolien! Zonder jou zou het een blanco kaft geweest zijn ;-) 
 
Mama, papa en Ben, 1000x bedankt! Geen woorden om te beschrijven hoe dankbaar ik jullie ben.  
  
  
  
VI 
 
  
  
  
VII 
 
Table of contents 
List of abbreviations .......................................................................................................................................... XI 
 
Aim and outline of the thesis ............................................................................................................................. 1 
 
Chapter 1: Analysis of abused substances using dried blood spots .................................................................. 11 
1.1 Introduction ............................................................................................................................................ 13 
1.2 Paper used and volume spotted .............................................................................................................. 16 
1.3 Analytical techniques .............................................................................................................................. 17 
1.4 Extraction................................................................................................................................................ 17 
1.5 Lower limit of quantification (LLOQ)........................................................................................................ 19 
1.6 Validation................................................................................................................................................ 20 
1.7 Comparison with other biological matrices ............................................................................................. 21 
1.8 Stability ................................................................................................................................................... 23 
1.9 Applications ............................................................................................................................................ 23 
1.9.1 Driving under the influence of drugs ................................................................................................ 23 
1.9.2 Cannabinoids ................................................................................................................................... 24 
1.9.3 Cocaine and metabolites ................................................................................................................. 25 
1.9.4 Opiates ............................................................................................................................................ 27 
1.9.5 Non-opiate opioids .......................................................................................................................... 29 
1.9.6 Benzodiazepines and Z-drugs ........................................................................................................... 30 
1.9.7 Amphetamine and analogues (methamphetamine, MDMA, MDA and MDEA) ................................. 33 
1.9.8 Gamma-hydroxybutyric acid ............................................................................................................ 33 
1.9.9 Ketamine and norketamine ............................................................................................................. 34 
1.9.10 New psychoactive substances ........................................................................................................ 35 
1.9.11 Alcohol markers ............................................................................................................................. 35 
1.9.12 Cotinine ......................................................................................................................................... 37 
1.10 Conclusion ............................................................................................................................................ 38 
1.11 References ............................................................................................................................................ 40 
 
Chapter 2: Correlation of GHB concentrations between vDBS and cDBS ......................................................... 49 
2.1 Introduction ............................................................................................................................................ 51 
2.2 Materials and methods ........................................................................................................................... 51 
2.2.1 Samples ........................................................................................................................................... 51 
2.2.2 Analytical procedures ...................................................................................................................... 52 
2.2.3 Storage experiment ......................................................................................................................... 52 
2.2.4 Data analysis .................................................................................................................................... 52 
2.3 Results and discussion ............................................................................................................................. 53 
2.4 Conclusion .............................................................................................................................................. 58 
2.5 References .............................................................................................................................................. 59 
 
Chapter 3: Microwave-assisted on-spot derivatization of polar low molecular weight compounds................ 61 
3.1 Introduction ............................................................................................................................................ 63 
3.2 Materials and methods ........................................................................................................................... 65 
3.2.1 Chemicals and reagents ................................................................................................................... 65 
3.2.2 Preparation of calibrators and quality control samples .................................................................... 65 
  
  
VIII 
 
3.2.3 Instrumentation............................................................................................................................... 65 
3.2.4 Sample preparation ......................................................................................................................... 66 
3.2.5 Analytical parameters ...................................................................................................................... 66 
3.2.6 Validation ........................................................................................................................................ 71 
3.2.6.1 Microwave calibration ............................................................................................................. 71 
3.2.6.2 Analytical evaluation................................................................................................................ 71 
3.2.7 Application ...................................................................................................................................... 72 
3.3 Results and discussion ............................................................................................................................. 73 
3.3.1 Sample preparation ......................................................................................................................... 73 
3.3.1.1 Optimization of the sample preparation .................................................................................. 73 
3.3.1.2 Final sample preparation ......................................................................................................... 76 
3.3.2 Analytical parameters ...................................................................................................................... 76 
3.3.2.1 Optimization of injection solvent ............................................................................................. 76 
3.3.2.2 Optimization of injection temperature .................................................................................... 77 
3.3.2.3 Optimization of flow rate ......................................................................................................... 77 
3.3.2.4 Optimization of purge activation time ..................................................................................... 78 
3.3.2.5 Optimization of pulsed splitless injection and pulse time ......................................................... 79 
3.3.3 Validation ........................................................................................................................................ 79 
3.3.3.1 Microwave calibration ............................................................................................................. 79 
3.3.3.2 Linearity, precision and accuracy ............................................................................................. 80 
3.3.3.3 Selectivity, carry-over and dilution integrity............................................................................. 83 
3.3.3.4 Stability.................................................................................................................................... 83 
3.3.3.5 DBS-specific parameters .......................................................................................................... 83 
3.3.4 Application ...................................................................................................................................... 84 
3.4 Conclusion .............................................................................................................................................. 86 
3.5 References .............................................................................................................................................. 88 
 
Chapter 4: Correlation between gabapentin blood and serum concentrations ............................................... 93 
4.1 Introduction ............................................................................................................................................ 95 
4.2 Experimental ........................................................................................................................................... 96 
4.2.1 Chemical reagents and stock solutions ............................................................................................ 96 
4.2.2 Study set-up and sample collection ................................................................................................. 96 
4.2.3 DBS analysis ..................................................................................................................................... 96 
4.2.4 Data analysis .................................................................................................................................... 98 
4.3 Results and discussion ............................................................................................................................. 98 
4.4 Conclusion ............................................................................................................................................ 101 
4.5 References ............................................................................................................................................ 102 
 
Chapter 5: Relevance of BHB analysis in forensic toxicology.......................................................................... 105 
5.1 Introduction .......................................................................................................................................... 107 
5.2 Materials and methods ......................................................................................................................... 108 
5.2.1 Chemicals and stock solutions ....................................................................................................... 108 
5.2.2 Samples ......................................................................................................................................... 108 
5.2.3 BHB analysis .................................................................................................................................. 108 
5.3 Results and discussion ........................................................................................................................... 109 
5.4 Conclusion ............................................................................................................................................ 115 
5.5 References ............................................................................................................................................ 116 
 
  
  
IX 
 
Chapter 6: Haptoglobin genotyping by direct PCR on dried blood spots ........................................................ 119 
6.1 Introduction .......................................................................................................................................... 121 
6.2 Materials and methods ......................................................................................................................... 121 
6.2.1 Samples ......................................................................................................................................... 121 
6.2.2 Hp genotyping ............................................................................................................................... 122 
 6.2.2.1 Primers .................................................................................................................................. 122 
 6.2.2.2 PCR reaction .......................................................................................................................... 122 
6.2.2.3 Gel electrophoresis and visualization ..................................................................................... 122 
6.2.3 Determination of the Hp A-61C polymorphism .............................................................................. 123 
6.3 Results and discussion ........................................................................................................................... 123 
6.4 Conclusion ............................................................................................................................................ 125 
6.5 References ............................................................................................................................................ 126 
 
Chapter 7: Broader international context, relevance and future perspectives .............................................. 127 
 
Chapter 8: Conclusion and summary .............................................................................................................. 137 
 
Samenvatting ................................................................................................................................................. 145 
 
Appendix  ....................................................................................................................................................... 151 
Appendix 1.................................................................................................................................................. 153 
Appendix 2.................................................................................................................................................. 177 
 
Curriculum vitae ............................................................................................................................................. 191 
  
  
  
X 
 
  
  
XI 
 
List of abbreviations 
1,2-BD  1,2-butanediol 
1,4-BD  1,4-butanediol 
6-MAM  6-monoacetylmorphine 
% RE  % residual error 
ACN  Acetonitrile 
ACP  2-amino-5-chloropyridine 
BE  Benzoylecgonine 
BHB  Beta-hydroxybutyric acid 
BSTFA  N,O-bis(trimethylsilyl)trifluoroacetamide 
C  Complete DBS 
cDBS  Capillary DBS 
CE  Cocaethylene 
d  Days 
DAD  Diode array detection 
DBS   Dried blood spot(s) 
DEG  Diethylene glycol 
DFSA   Drug-facilitated sexual assault 
DNA  Deoxyribonucleic acid 
DRUID  Driving under the influence of drugs, alcohol and medicines 
DUID  Driving under the influence of drugs 
EBF  European Bioanalysis Forum  
ECME  Ecgonine methylester 
EDDP  2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine 
EMA  European Medicines Agency 
EMCDDA European Monitoring Centre for Drugs and Drug Addiction  
EMDP  2-ethyl-5-methyl-3,3-diphenylpyrroline 
EME  Electromembrane extraction 
FAEE   Fatty acid ethyl esters 
FDA  Food and Drug Administration 
FID  Flame ionization detection 
GBL  Gamma-butyrolactone 
GC  Gas chromatography 
GC-MS   Gas chromatography coupled to mass spectrometry 
GHB   Gamma-hydroxybutyric acid 
h  Hours 
Hct  Hematocrit 
  
  
XII 
 
HFB  Heptafluorobutanol 
Hp  Haptoglobin 
HPLC  High performance liquid chromatography 
HRMS   High resolution mass spectrometry 
HS-GC-FID Headspace sampling-gas chromatography-flame ionization detection 
i.d.  Internal diameter 
IQ Consortium The International Consortium for Innovation and Quality in Pharmaceutical Development  
IS  Internal standard(s) 
LC  Liquid chromatography 
LC-DAD  Liquid chromatography-diode array detection 
LC-FLUO  Liquid chromatography-fluorescence detection 
LC-HRMS(/MS) Liquid chromatography-high resolution (tandem) mass spectrometry 
LC-(MS/)MS  Liquid chromatography coupled to (tandem) mass spectrometry 
LLE  Liquid-liquid extraction 
LLOQ  Lower limit of quantification 
LOD  Limit of detection 
MDA  3,4-methylenedioxyamphetamine 
MDEA   3,4-methylenedioxy-N-ethylamphetamine 
MDMA   3,4-methylenedioxymethamphetamine 
MeOH  Methanol 
MEPS   Microextraction packed sorbent 
mRNA  Messenger ribonucleic acid 
MS  Mass spectrometry 
MSTFA  N-methyl-N-(trimethylsilyl)trifluoroacetamide 
MTBSTFA N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide 
M3G  Morphine-3-glucuronide 
M6G  Morphine-6-glucuronide 
n.a.  Not applicable 
NA  Not analyzed/ not available 
NS  Not studied 
P  Punch  
PAE  Prenatal alcohol exposure 
PCR  Polymerase chain reaction 
PEth  Phosphatidylethanol 
PG  Propylene glycol 
PK  Pharmacokinetics 
PP   Protein precipitation 
QC  Quality control 
  
  
XIII 
 
RBC  Red blood cell 
RECOV  Recovery 
RIA   Radioimmunoassay 
RT   Room temperature 
SAMPLE PREP Sample preparation 
SCD  Sample collection device 
SIM  Selected ion monitoring 
SPE   Solid phase extraction 
STA  Systematic toxicological analysis 
TAE  Tris-acetate-ethylenediaminetetra-acetic acid 
TBME  Tert-butyl methyl ether  
TDM   Therapeutic drug monitoring 
TFAA  Trifluoroacetic anhydride 
THC  Δ9-tetrahydrocannabinol 
THC-COOH Tetrahydrocannabinol carboxylic acid 
THC-OH  11-hydroxy- Δ9-tetrahydrocannabinol 
U(H)PLC  Ultra-performance liquid chromatography 
ULOQ  Upper limit of quantification 
VAMS  Volumetric absorptive microsampling 
vDBS  Venous DBS 
w  Weeks  
 
  
  
  
XIV 
 
  
  
  
1 
 
 
 
AIM AND OUTLINE OF THE THESIS 
 
 
 
  
  
  
2 
 
 
 
 
 
 
 
 
 
 
Aim and outline of the thesis 
 
  
3 
 
Dried blood spots (DBS) are the common thread throughout this work. They have been used in both an 
analytical context and for the development of a genotyping method.  
 
DBS sampling is a microsampling technique in which a drop of capillary blood, derived from a finger or heel 
stick, is collected on special filter paper. This approach has been used successfully in newborn screening since it 
was introduced in the 1960s by Guthrie and Susi to determine phenylketonuria in neonates [1]. During the last 
decade, thanks to the development of more sensitive analytical techniques, DBS sampling -and microsampling 
in general- has gained its place in a lot of other fields, amongst which pharmaco- and toxicokinetics [2-5]. In 
toxicokinetics the relationship between the systemic exposure to a compound and the harmful effects of this 
compound is determined. In the preclinical context, DBS-based toxicokinetics offer both an improvement in 
animal welfare, as well as a financial benefit. Consequently, a lot of pharmaceutical companies and contract 
research organizations have undertaken efforts to utilize microsampling (liquid or DBS-based) as an alternative 
to plasma or serum in the (pre)clinical phases of the drug discovery process. DBS do not only have a potential 
for the analysis of therapeutic drugs, they are also suitable for the detection of drugs of abuse, as outlined in 
Chapter 1, which serves as an Introductory Chapter to DBS in general, with a particular focus on DBS 
applications in toxicology. More specifically, the analysis of abused substances is discussed, along with the 
associated benefits, limitations and challenges. While the focus of this Introductory Chapter primarily lies on 
forensic applications, it is clear that the determination of drugs of abuse may also have a potential for e.g 
newborn screening, more specifically to assess prenatal exposure to toxic compounds, or for therapeutic drug 
monitoring (TDM). 
 
The increased use of DBS sampling in the clinical arena is the logical consequence of the many advantages 
associated with this sampling technique [6]. Indeed, DBS sampling is a very easy and inexpensive way of taking 
a representative sample, which can even be performed by the patient himself in his home environment or in 
remote areas, eliminating the need for a trained phlebotomist [7-9]. Moreover, the dried matrix improves the 
stability of most compounds [10-13], enabling more cost-effective transport and storage; DBS samples are 
generally transported via regular mail [9,14] and can often be stored at ambient temperature for prolonged 
periods of time. Since only small volumes of blood -typically between 10 and 80 µL- are collected, the DBS 
sampling technique is highly suitable for the collection of samples during preclinical and toxicokinetic studies 
involving animals. DBS sampling certainly confines to the principles of the 3R’s (replacement, reduction and 
refinement), as fewer animals are needed and sampling procedures are refined using DBS [15,16]. In addition, 
the advantage of small blood volumes, combined with the possibility to collect samples by a minimally invasive 
finger- or heelprick, creates a high potential for the use of DBS in pediatric studies as well [17,18]. Another 
benefit of using DBS instead of liquid samples is that pathogens that may be present in blood are deactivated 
upon drying, strongly reducing the risk of infection [19]. Furthermore, from the analytical point of view, the 
process of generating DBS can also be considered as a simple sample preparation procedure [20,21]. Indeed, 
many analytes can selectively be extracted from the cards, often allowing straightforward and automatable 
processing and analysis [22-27]. Despite the numerous applications using DBS and the many advantages 
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associated with this sampling procedure, DBS sampling still faces some important challenges. Box 1 summarizes 
the advantages and challenges associated with DBS sampling [6].  
 
Box 1. Advantages and challenges associated with DBS sampling. 
Advantages Challenges 
 Ease of sampling, enabling sampling at home 
 Cost-effective sampling, transport and 
storage of samples 
 Improved compound stability 
 Small blood volumes 
 Minimally invasive sampling 
 Reduced risk of infection 
 Simplification of sample preparation 
procedures 
 Suitability for automation of sample 
processing and analysis 
 Correlation between venous and capillary 
blood concentrations 
 Adequate sampling 
 Contamination risk 
 Lack of sensitivity 
 Chromatographic effect and influence of the 
site of punching 
 Influence of spotted blood volume 
 Hematocrit effect 
 
A first concern is whether venous and capillary blood concentrations of an analyte are equivalent. Obviously, 
this is an aspect that needs to be evaluated on a case-by-case basis and may depend on the aim of the study 
(e.g. setting up a toxicokinetic profile versus measurement of trough levels). This concern, which is inherent to 
any non-venous sampling technique, has been addressed in several recent publications [7,28-37]. In these 
comparative studies, both capillary DBS (cDBS) (obtained by a fingerprick) and venous blood (obtained by 
classical venipuncture) are collected. The latter is analyzed as such and/or is used to generate venous DBS 
(vDBS). A cross-comparison between vDBS and venous blood allows to investigate the validity of the DBS 
approach. Although equal analyte concentrations are expected -there is only a difference in presentation- the 
entire process of spotting, drying and storing the samples may have an influence on the analytical result (a so 
called “DBS effect”). A cross-comparison between cDBS and vDBS concentrations allows to evaluate if there is a 
difference between capillary and venous blood. Capillary blood is a mixture of blood obtained from venules, 
arterioles and capillaries. Differences between capillary and venous blood may be due to the time of sampling 
as well as to the physicochemical characteristics of the analyte. E.g. small compounds which are highly lipid-
soluble and have a low protein binding capacity can easily cross through the capillary walls into the interstitial 
and intracellulair fluids, inducing an arteriovenous difference in the early distribution phase. While for many 
abused substances, a proof-of-principle of “detectability” in DBS has been demonstrated, there is a paucity of 
reports that have actually compared venous-capillary concentrations. In Chapter 2, we set out to do this for 
gamma-hydroxybutyric acid (GHB), a drug which is misused in the dance scene and which has also been 
associated with drug-facilitated sexual assaults [38].  
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Other concerns associated with DBS-based sampling are the acquisition of correctly obtained samples, 
contamination risk, the chromatographic or volcano effect, the site of punching and sensitivity issues in case of 
analytes at very low concentrations [6]. The latter implies the implementation of sensitive analytical techniques 
for DBS analysis. Although in many cases liquid chromatography coupled to (tandem) mass spectrometry (LC-
MS(/MS)) is the most appropriate technique, gas chromatographic coupled to mass spectrometry (GC-MS) 
methods are still being used [39,40]. They offer the advantage that a wide range of compounds with widely 
varying polarity can be analyzed using one single standard configuration. However, to achieve adequate 
sensitivity with GC-MS, DBS analysis may involve derivatization [40]. As this additional sample preparation step 
is considered as laborious and time-consuming, improvements to simplify and/or shorten this step are 
warranted. In this context, we wished to speed up a procedure that had previously been established in our 
laboratory, coined “on-spot derivatization” in which derivatization reagents are directly applied to DBS [41]. 
Given the known advantages of “microwave derivatization” in terms of shortening derivatization times, we 
aimed at combining “on-spot derivatization” with “microwave derivatization”, thereby ensuring a minimal, 
economic and fast sample workup and high sample throughput (Chapter 3). We particularly focused on 
analytes where GC-MS may be competitive with LC-MS/MS because of challenges with detection and/or the 
need to use special configurations for LC-MS/MS-based detection. Apart from applying the newly developed 
approach on DBS obtained from potential GHB positive cases, we also aimed at applying this approach on real 
samples for the assessment of other polar low molecular weight compounds, more particularly the anti-
epileptic drug gabapentin (Chapter 4) and for the ketone body beta-hydroxybutyric acid (BHB) (Chapter 5). 
While for gabapentin, the DBS-based approach is primarily relevant from a sampling-point-of-view, for BHB, 
the advantage primarily lays in the simplification of sample preparation. 
 
We aimed at evaluating the DBS-based approach for a therapeutically applied compound, gabapentin, for a 
variety of reasons (Chapter 4). First, gabapentin is, just like GHB, structurally related to the inhibitory 
neurotransmitter gamma-amino butyric acid. Second, this application may add new and relevant data to the 
ongoing discussion about the implementation of DBS sampling in TDM. The use of dried matrix spots for TDM 
purposes, with sampling either in the clinic or at the patient’s home, has many advantages. E.g. patients can 
easily collect their own samples at home. Since gabapentin is an anticonvulsant taken by many out-patients 
[42], DBS could be a useful tool for these patients: monitoring their gabapentin concentrations may be relevant 
to guarantee that therapeutic concentrations are reached and supratherapeutic concentrations are avoided. 
The determination of gabapentin may not only be useful for TDM (including clinical toxicology), but also for the 
determination in a forensic context. E.g. there is an increased illegal use of gabapentin in Britain’s opiate-using 
and prison populations [43]. A second aim of determining gabapentin in DBS was to evaluate the correlation 
between blood and serum concentrations (Chapter 4). This is relevant as therapeutic ranges for gabapentin 
are available in plasma or serum, but not in blood. In the context of a pharmacokinetic study for gabapentin we 
therefore conducted a so-called “bridging study”. Such studies, in which a comparison is made between 
concentrations obtained from DBS and those obtained from plasma or serum, are an essential step for the 
implementation in routine practice (Chapter 4). 
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Second, we aimed at applying the “microwave-assisted on-spot derivatization” approach for the assessment 
of BHB, a molecule of relevance in forensic toxicology (Chapter 5). BHB is an endogenous compound 
structurally related to GHB. Elevated levels of this ketone body are found in ketotic diabetics and alcoholics and 
may induce ketoacidosis (i.e. reduced blood pH caused by an increased level of the ketone bodies). Although 
ketoacidosis may contribute to the cause of death, it has not been unequivocally established what the 
relevance is of routinely determining BHB in all cases in the forensic laboratory, when already having at hand 
the results of acetone, another ketone body. To address this question, we aimed at setting up a retrospective 
analysis of a large number of biological forensic samples (Chapter 5). Importantly, as BHB can be assessed in a 
variety of matrices, we wished to extend in this context the above-described DBS approach to a “dried matrix” 
approach, wherein we also evaluated dried urine and dried vitreous samples, which were volumetrically 
applied (Chapter 5). 
 
In addition to the above-mentioned bio-analytical DBS-based applications, we also wished to set up a DBS-
based genotyping method. The haptoglobin (Hp) gene, encoding for an abundant hemoglobin-binding plasma 
protein, was chosen, as polymorphisms in this gene -with 2 common alleles, denoted 1 and 2- may have 
important biological and clinical consequences [44,45]. As there is a perfect correlation between the Hp pheno- 
and genotype, PCR-based methods have emerged as a good alternative for time-consuming protein-based 
phenotyping methods. E.g. large-scale studies have unequivocally shown that diabetics with the Hp 2-2 
phenotype have a 2-5-fold increased risk for developing micro- and macrovascular complications [46-49]. In 
Chapter 6, we wished to evaluate whether we could improve and simplify the current ‘gold standard’ of Hp 
genotyping by developing an extractionless procedure, directly starting from DBS micropunches, allowing Hp 
genotyping in a high-throughput setting. 
 
In Chapter 7 the broader international context, the relevance and the future perspectives are described. 
Chapter 8 gives a summary and a general conclusion. Box 2 outlines the aims of each Chapter in this thesis. 
 
Box 2. Overview of the aims of each Chapter. 
Chapter Aim 
1 Introductory Chapter to DBS 
2 Correlation between venous and capillary blood concentrations of GHB 
3 Set-up of a new derivatization strategy for DBS: microwave-assisted on-spot derivatization 
4 
Application of a new derivatization strategy:  
correlation between blood and serum concentrations of gabapentin (bridging study) 
5 
Application of a new derivatization strategy:  
relevance of BHB determination in routine forensic toxicology analysis 
6 DBS application: set-up of an improved Hp genotyping method 
7 Broader international context, relevance and future perspectives 
8 Conclusion and summary 
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Abstract 
During recent years dried blood spot (DBS) sampling and DBS analysis have increasingly received attention in 
various fields, amongst which in clinical, forensic and occupational toxicology. In this Chapter, we provide an 
overview of the different DBS-based methods that have been developed for detecting (markers of) abused 
substances. These include both legal and illegal drugs, belonging to different categories, amongst which 
cannabinoids, cocaine and metabolites, opioids, benzodiazepines and Z-drugs, amphetamines and analogues, 
gamma-hydroxybutyric acid, ketamine and new psychoactive substances such as cathinones. Also covered are 
markers of ethanol consumption and tobacco use. Since overall, the majority of published methods shows 
promising results, an interesting role for DBS analysis in diverse toxicological applications can be envisaged. For 
the distinct applications, we discuss the specific potential and benefits of DBS, the associated limitations and 
challenges, as well as recent developments and future perspectives. 
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1.1 Introduction  
The use of dried blood spots (DBS) and DBS sampling is not new. DBS analysis was introduced over a century 
ago by Ivar Bang [1], who used DBS for glucose monitoring in rabbits, while it was Guthrie and Susi who spread 
the applicability of DBS by demonstrating its usefulness in the newborn screening of phenylketonuria and in 
other screening programs [2,3]. In the last few years, DBS applications have grown exponentially, not only in 
newborn screening, but also for the analysis of DNA, proteins, small molecules and trace elements in animals, 
children, adults, and even post-mortem samples [4]. 
 
The use of DBS can be looked at from different perspectives. On the one hand, DBS can be considered as a 
simple and cost-effective sample preparation procedure, as the filter paper can retain several matrix 
compounds [5-8]. Consequently, the use of DBS may simplify the extraction procedure, possibly allowing 
automated online extraction (see section 1.4). Alternatively, DBS can be considered as a useful matrix in clinical 
and forensic toxicology as they can be collected in a fast, simple and economical way (in contrast to blood 
samples obtained by venipuncture) and give information on the acute state of the patient (in contrast to urine, 
oral fluid and hair) [8]. However, in emergency toxicology -in cases where diagnosis and treatment of the 
patient may depend upon toxicological information- DBS will likely have little added-value since medical 
personnel should have rapid access to toxicological information and there is no time to wait for DBS to dry for 
at least two hours. When speed is not essential, DBS -either as a sampling or sample preparation technique- 
can be useful for screening purposes as well as for quantitative analysis. In this context, it should be noted that 
DBS may readily dry during transit from the sampling site to the laboratory, so in many cases there will be no 
delay after arrival at the laboratory.  
 
The aim of this Chapter is to give an overview of applications of DBS in toxicology, more specifically for the 
analysis of abused substances (see Table 1.1 & Appendix 1). DBS sampling for therapeutic drug monitoring 
(TDM) and metabolic screening is beyond the scope of this Chapter, as is DBS sampling for the analysis of 
therapeutic drugs, environmental contaminants, toxins and (trace) elements. Abused substances include both 
legal and illegal drugs, belonging to different categories, amongst which cannabinoids, cocaine and 
metabolites, opioids, benzodiazepines and Z-drugs, amphetamines and analogues, gamma-hydroxybutyric acid 
(GHB), ketamine and new psychoactive substances such as cathinones. Also covered in this overview are 
markers of ethanol consumption and tobacco use. 
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Table 1.1 Overview of the different drug categories of abused substances determined in DBS, with referral to the utilized analytical techniques and their potential to 
measure cut-off concentrations proposed by DRUID.  
Drug category Technique References DRUID cut-off Comments 
Cannabinoids  LC-MS/MS 
GC-MS 
LC-HRMS 
[7,11,12,93]   
[26]  
[94]  
 
 
 
Only 1 method attained sufficient sensitivity, yet 
still requiring complete 20-µL DBS [94]; no 
methods for synthetic cannabinoids in DBS 
Cocaine and metabolites 
 
RIA 
LC-MS/MS 
LC-FLUO 
GC-MS 
LC-HRMS 
[19,97]  
[8,12,13,31,47,56,77,93,96,97]  
[6]  
[26]  
[63,94]  
(a) 
 
(a) 
 
(b) 
DBS need to be stored at freezing temperatures 
Opiates  
 
LC-MS/MS 
GC-MS 
[8,11-13,31,40,45,47,61,67,79,93,96,100,101,116]  
[26]  
 
 
Stabilizing effect of DBS for 6-
monoacetylmorphine 
Non-opiate opioids LC-MS/MS 
GC-MS 
LC-coulometry 
LC-MS 
[8,11-13,30,36,40,45,47,93,101,103,116]  
[26]  
[20]  
[10]  
(c) 
 
(d) 
(d) 
Analytes include methadone, buprenorphine, 
tramadol, fentanyl, pethidine and their 
metabolites 
Benzodiazepines LC-MS/MS 
GC-MS 
LC-HRMS 
[5,8,11-13,37,46,77,91,93,117-120,122]  
[26]  
[39]  
(e) 
 
(f) 
Stabilizing effect of DBS for benzodiazepines 
Z-drugs  LC-MS/MS 
GC-MS 
[5,8,9,12,13,78,91,122]  
[26]  
 
 
Stabilizing effect of DBS for zopiclone 
Amphetamine and 
analogues 
LC-MS/MS 
GC-MS 
LC-HRMS 
[8,12,13,31,41,47,79,80,91,93,121]  
[26]  
[94]  
 
 
 
 
GHB LC-MS/MS 
GC-MS 
[44]  
[23-25]  
n.a. No ex vivo formation of GHB in DBS; similar 
concentrations in cDBS and vDBS 
Ketamine and metabolite  LC-MS/MS 
LC-DAD 
[47,80,104]  
[21]  
 
 
 
New psychoactive 
substances 
LC-MS/MS [41,80]  n.a. Analytes include cathinones, piperazines and 
mephedrone; stabilizing effect of DBS on 
cathinone derivatives when stored cooled 
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Table 1.1 Continued. 
Drug category Technique References DRUID cut-off Comments 
Alcohol markers LC-MS/MS [43,51,110-114]  n.a. Analytes include ethylglucuronide, ethylsulphate 
and phosphatidylethanol; no ex vivo de novo 
formation of phosphatidylethanol 
Markers of tobacco use GC-MS 
LC-MS/MS 
Paper spray MS 
LC-HRMS/MS 
[22]  
[29,49,72]  
[35]  
[42] 
n.a. Analytes include nicotine and metabolites, 
anabasine and anatabine; primary application lies 
in newborn DBS analysis 
 
The ‘DRUID cut-off’ column indicates if the DBS methods attained sufficient sensitivity to allow detection at DRUID LLOQ levels, when starting from complete ≤ 10-µL DBS 
and/or ≤ 6.4-mm diameter DBS punches. 
 
(a) only benzoylecgonine; (b) only cocaine and benzoylecgonine; (c) only methadone and tramadol; (d) only methadone; (e) only 7-aminoclonazepam, 7-
aminoflunitrazepam, alprazolam, OH-alprazolam, clobazam, clonazepam, diazepam, desalkylflurazepam, desmethylflunitrazepam, flunitrazepam, flurazepam, 
lormetazepam, lorazepam, midazolam, nitrazepam, oxazepam, temazepam, triazolam and nordiazepam; (f) only midazolam 
cDBS: capillary dried blood spots; DAD: diode array detection; DBS: dried blood spot; DRUID: driving under the influence of drugs, alcohol and medicines; FLUO: 
fluorescence detector; GC-MS: gas chromatography coupled to mass spectrometry; GHB: gamma-hydroxybutyric acid; HRMS: high resolution mass spectrometry; LC: liquid 
chromatography; n.a.: not applicable; RIA: radioimmunoassay; vDBS: venous dried blood spots 
Chapter 1: Analysis of abused substances using dried blood spots 
 
  
16 
 
1.2 Paper used and volume spotted  
Whatman® 903 paper is the predominant filter paper used for DBS collection and is manufactured from 100% 
pure cotton fibers. Other cellulose-based papers used for determination of drugs of abuse are Ahlström 226, 
Sartorius TFN, Whatman® BFC 180 and Whatman® FTA® (see Appendix 1). The latter paper is chemically 
treated to prevent degradation of genomic DNA. Bond Elut DMS is a non-cellulose collection material which 
would reduce non-specific binding, improving mass spectrometer analyte response and increasing signal to 
noise ratios [9]. Our experience, however, learned that the reduced rigidity of this paper makes it less suitable 
for manual punching. Eibak et al. obtained higher recoveries for methadone using alginate and chitosan foams 
as sampling media, when compared with Whatman® FTA® DMPK and Bond Elut DMS filter paper [10]. Although 
these foams, which can be fully solubilized in 1 mM HCl, seem promising, further experiments are warranted to 
investigate their utility in routine applications. 
 
The volume of blood that has been used to generate DBS for detecting abused substances ranges from 5 to  
100 µL. While 5-µL spots have primarily been used in a sample preparation context [5,8,11-13], it should be 
noted that 100-µL DBS are not easily obtained by fingerprick; hence an important advantage of DBS sampling is 
lost in that case. In case of volumetric application, often the complete DBS is analyzed. However, such 
volumetric application is difficult to sustain when it is to be performed by non-trained persons -although also 
here progress is underway. E.g. Lenk et al. developed a prototype of a ‘metering chip’ [14], whereas Leuthold et 
al. evaluated a microfluidic approach which consists of a microfluidic plate with sized capillaries and a DBS card 
holding element [15]. Another recently developed approach which allows the collection of a fixed volume of 
blood from a non-volumetrically deposited sample is volumetric absorptive microsampling (VAMS) [16,17] This 
alternative collection device wicks up a fixed volume of blood, independent of hematocrit (Hct), onto a porous 
substrate. When DBS are obtained by direct application from the fingertip onto filter paper, typically a smaller 
disk (e.g. 3- or 6-mm diameter) is punched from the DBS. Analyzing a complete spot largely avoids the Hct 
effect and facilitates validation. In contrast, analysis of a partial punch further reduces the amount available for 
analysis, resulting in an even higher requirement of sensitivity, and imposing a more elaborate validation (see 
section 1.6) [18]. It also needs to be remarked that the vast majority of available publications describes the 
analysis of DBS that have been obtained by pipetting existing venous blood samples, already available in the 
lab, rather than setting up a true capillary DBS (cDBS) approach. Lastly, it has to be noted that archived 
newborn DBS, which are obtained by heel stick within the first 1-3 days of life in the context of screening for 
inborn errors of metabolism and are in general larger than DBS obtained by fingerprick (newborn DBS 
correspond to about 80 µL of blood), have also been used to assess abused substances. Since in most cases a 
substantial left-over remains after the newborn screening procedure (except in those cases where newborn 
screening was positive), the remaining material can be used for assessing exposure to abused substances at 
birth.  
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1.3 Analytical techniques 
An extra challenge associated with using small blood volumes is the requirement of highly sensitive techniques 
for identification and quantification of the compounds. The first report about the determination of abused 
substances in DBS was published by Henderson et al., who applied a modified urinary benzoylecgonine 
radioimmunoassay screening test on newborn DBS in order to assess prenatal use of cocaine by the mother 
[19]. The obtained results correlated well with gas chromatography-mass spectrometric (GC-MS) 
measurements in blood. Although immunoassays can be used for DBS analysis in some cases, they are subject 
to non-specific binding and to cross-reactivity with endogenous components and/or structurally related drugs 
and metabolites. Chromatographic techniques, either liquid or gas chromatography, have been used in later 
studies. Mostly, liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) is the most 
appropriate technique, preceded by either online or offline sample preparation (see section 1.4). Although 
MS/MS detection is usually required and preferred, also other detectors have been used for identifying and 
quantifying abused substances in DBS. Examples include spectrofluorimetric detection of natively fluorescent 
cocaine, benzoylecgonine and cocaethylene [6], and coulometric and diode array detection of methadone and 
(nor)ketamine, respectively [20,21]. Also GC-MS has been applied, more particularly for cotinine [22], GHB [23-
25], amphetamine-like drugs, cocaine, benzodiazepines, zopiclone, buprenorphine, methadone, tramadol, Δ
9
-
tetrahydrocannabinol (THC) and THC-COOH [26]. However, GC-based analyses mostly require a derivatization 
step, which can be seen as a disadvantage. 
 
1.4 Extraction 
The desorption of analytes from DBS is most often performed using organic solvents, water or a mixture of 
both. Mixtures with a water content of over 25-30% will typically yield colored extracts, indicating release from 
hemoglobin -and also other proteins- from the filter paper. In contrast, mixtures containing less water will yield 
cleaner extracts, as is also the case when using pure organic solvents, as shown by Déglon et al. [27]. The 
desorption process can be performed by mere passive infusion of the filter paper, but is most often facilitated 
by sonication, agitation or heating. To this end, Saracino et al. even used microwave-assisted extraction [20]. 
 
Another possible simplification of the pre-analytical phase is the concept of “on-spot derivatization”, developed 
by Ingels et al. for the quantitation of GHB using GC-MS [23-25]. This approach consists of adding derivatization 
reagents directly onto the filter paper, without the use of an extraction solvent, followed by drying and re-
dissolution in a suitable solvent, ensuring a minimal, less time-consuming sample pretreatment. In Chapter 3, 
we used this derivatization technique in combination with microwave-assisted derivatization for the 
determination of some polar low molecular weight compounds with clinical and forensic toxicological 
relevance [28].  
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A straightforward procedure for sample work-up consists of immediately subjecting the obtained extract to 
further analysis, either directly or following dilution. Unfortunately, depending on the elution solvent used, 
extra pre-analytical steps may be necessary for sample clean-up, such as protein precipitation, solid phase 
extraction (SPE) and/or liquid-liquid extraction. Since elaborate sample pretreatment is labor intensive and 
requires a lot of consumables, more efficient alternatives have been developed. For example, Saracino et al. 
used microextraction packed sorbent for the determination of methadone, ketamine and norketamine, 
drastically reducing the volume of solvents [20,21]. The use of automated sample preparation procedures has 
also been described: Murphy et al. performed SPE with a robotic system prior to cotinine analysis and Clavijo et 
al. and Saussereau et al. implemented online extraction for the analysis of a wide range of drugs of abuse, 
significantly reducing the number of manual steps needed [29-31]. Fully automated analysis of DBS cards has 
become possible with the development of automated DBS samplers, as described further in this section. Other 
recent developments include digital microfluidics [32] and paper spray MS [33-35]. 
 
If mere injection or dilution of the extract is not an option because of required sensitivity or because the 
extraction solvent is not compatible with the analyzing system, evaporation may be a necessary step. After this 
additional tedious step, which is often relatively time-consuming, the extract is reconstituted in a limited 
volume of a suitable solvent (e.g. the mobile phase), most often offering the advantage of concentrating the 
sample. An alternative has been proposed by Eibak et al., who used electromembrane extraction for sample 
clean-up and for enrichment of the target analyte (methadone) in an aqueous acceptor solution compatible 
with LC [10]. Important to note is that, as mentioned before, in this case DBS are not eluted from filter paper, 
but rather are dissolved, together with the matrix that consists of chitosan or alginate foam substrates. 
Electromembrane extraction was also used by Seip et al. for the analysis of methadone and pethidine [36].  
 
Apart from the automated DBS samplers referred to in the next paragraph, several methods have been 
developed to achieve higher throughput without significant investment. One example is the simple offline 
procedure employed by Déglon et al. for the analysis of benzodiazepines and Z-drugs [5]. This procedure 
consists of infusing a whole DBS directly into the extraction solvent contained in a LC vial, immediately followed 
by injection of an aliquot of the supernatant onto the chromatographic system. A similar but more automated 
approach has been developed by Versace et al. for a rapid LC–MS/MS target screening on DBS [8]. To this end, 
a quick (2 min) and automated in-well extraction was performed in the LC autosampler itself, before injecting 
part of the supernatant. Another inventive approach was proposed by Johnson et al., who used an improved 
punching device to punch DBS directly into filter tips of a liquid-handling device that was subsequently used to 
elute the analytes from the DBS [37]. This semi-automated procedure was used for the analysis of alprazolam, 
OH-alprazolam and midazolam, yielding similar results as an offline approach, whilst reducing sample 
preparation time by more than 50%. 
 
Despite efforts to increase the efficiency of DBS sample pretreatment, its manual character remains an 
important hurdle to more widespread use of DBS analysis in routine practice. However, during the last few 
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years progress has been made in automating this process, increasing the throughput and making DBS analysis 
more appealing to modern laboratories. Déglon et al. were the first to describe the concept of online 
desorption of DBS [27], while Thomas et al., from the same lab, were the first to use this concept for the 
analysis of drugs of abuse [11]. To this end, whole DBS were punched out and placed in a home-made 
desorption cell, integrating the sample directly into the LC device. Using a column switching procedure, the 
analytes were desorbed from the filter paper in the cell prior to online analysis. An improved prototype, based 
on an automated rotating plate that can host more manually punched samples, was implemented by Lauer et 
al. and Déglon et al. for the screening of a wide range of drugs in DBS, including cocaine and metabolites, 
opiates, amphetamines and benzodiazepines [12,13]. Three commercial suppliers have developed fully 
automated DBS samplers: CAMAG (DBS-MS 500), Prolab Instruments, GmbH (SCAPTM) and Spark-Holland 
(DBS
TM
 Autosampler) [38]. In the context of (potential) abused substances, the SCAP
TM
 system was used by 
Oliveira et al. for the determination of midazolam, leading to a 5-fold improvement in sensitivity when 
compared with an offline procedure [39]. Verplaetse and Henion quantified opioids and stimulants by coupling 
the Spark-Holland Autosampler to online SPE-LC-MS/MS [40,41]. Such automated system was also utilized by 
Tretzel et al. for the determination of nicotine and its major metabolites in DBS [42].  
 
1.5 Lower limit of quantification (LLOQ) 
As mentioned in section 1.3, DBS sampling has the inherent disadvantage of providing only a small amount of 
target analyte, often requiring an analytical technique such as GC-MS, LC-MS or LC-MS/MS to reach sufficient 
sensitivity. When punches are used -which often is the most feasible approach in real practice as it does not 
necessitate volumetric application- the available amount of sample decreases even further. E.g. when 
envisaging low ng/mL detection of an analyte, starting from a 3-mm punch (corresponding to approximately  
3 µL of blood), this means that only low pg amounts of analyte are available. In an attempt to increase the 
amount of starting material and hence improve the LLOQ, larger punch sizes can be used or multiple punches 
can be analyzed simultaneously [29,43-47]. As discussed above in section 1.4, the dilution introduced during 
the extraction process may require the incorporation of a concentrating step during sample pretreatment. Also 
in this respect, online extraction of DBS may be advantageous, as it allows complete transfer of the analyte of 
interest to the (LC-)MS/MS. E.g. Abu-Rabie and Spooner demonstrated a 10-fold increase in sensitivity using a 
DBS direct elution technique compared to manual DBS extraction [48].  
 
In order for DBS analysis to be implemented in routine laboratories, the obtained LLOQs have to be relevant to 
clinical/toxicological practice. Obviously, the required sensitivity depends on the compound of interest. As 
newer abused substances are often more potent, their quantitation may require very low LLOQs, making the 
analysis of such compounds challenging, especially when using DBS. Moreover, the required LLOQ is also 
determined by the intended use of the method. For example, the LLOQ of cotinine in newborn whole blood for 
the detection of maternal smoking (6 ng/mL) is higher than the one to establish newborn exposure to 
secondhand smoke (0.02 ng/mL) [49]. Furthermore, expected concentration ranges depend on the intended 
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application, e.g. TDM, toxicological analysis, pharmacokinetics (PK) and analyses in the context of driving under 
the influence of drugs (DUID). In the latter case, the required LLOQs may vary between countries as well. 
 
As DBS sampling may be an interesting alternative option in the context of DUID, we evaluated whether the 
methods that are currently present in literature are fit for this purpose, by comparing the stated LLOQs with 
the cut-offs proposed by the DRUID project [50] and the legally accepted limits in Belgium (Table 1.1 & 
Appendix 2). Especially for abused substances that can be used for therapeutic purposes as well, it is quite 
challenging to establish legal limits, as phenomena such as tolerance can occur, and, consequently, relatively 
high blood levels may not necessarily impair a person’s ability to drive. Moreover, further studies are needed to 
establish a universal cut-off for phosphatidylethanol (PEth) as well. Kummer et al. already suggested a cut-off 
value at 221 ng/mL for PEth 16:0/18:1 to distinguish between inpatients in alcohol withdrawal and control 
volunteers [51]. However, more sensitive methods are required to determine optimal cut-off values for PEth 
18:1/18:1 and PEth 16:0/16:0. When interpreting the LLOQs of the methods mentioned in Appendix 2, it is also 
important to note the different DBS sizes or volumes, ranging from a 2-mm flow-through area to complete  
100-µL DBS. In the latter cases, the mentioned LLOQs might actually be underestimated, as DBS containing 
smaller blood volumes will be available in real practice. Considering the data in Table 1.1, Appendix 1 and 
Appendix 2, for the majority of analytes of the DRUID panel, there are methods available that achieve sufficient 
sensitivity to allow detection at the required level, when starting from complete ≤ 10-µL DBS and/or ≤ 6.4-mm 
diameter DBS punches. These methods can be found in the shaded columns of Appendix 2. 
 
1.6 Validation 
The choice between a partial- and whole-cut DBS method should ideally be made before setting up a DBS-
based method, as it has important repercussions on what parameters should be included in the validation 
protocol. Validation of a DBS-based procedure using partial punches ideally encompasses extra validation 
parameters, e.g. punch location, blood volume spotted and Hct, as these factors may have an impact on the 
quantitative result [3,18,52,53]. More specifically, Hct may affect the precision, accuracy, extraction efficiency 
and the recovery of an analyte [54,55]. For instance, punches from DBS prepared from blood with a high Hct 
will contain larger volumes of blood than punches from DBS of blood with lower Hct, resulting in respectively 
an over- and underestimation when the calibration line is established in blood with intermediate Hct. 
Therefore, it is recommended to establish a calibration curve with a Hct in the middle of the range of the target 
population, to minimize the Hct effect. Sosnoff et al., for instance, prepared QCs in blood with a Hct close to 
that of newborns [56]. In conclusion, the combined effect of Hct, blood volume spotted and punch location has 
to be evaluated when using partial-cut DBS. Analyzing complete, volumetrically applied DBS, however, may 
overcome the Hct effect. Ideally, before broad implementation of the method, its validity should be tested by 
applying it on a set of real samples, thereby evaluating incurred sample reproducibility and -if applicable- the 
equivalence between capillary and venous concentrations. Relevant to mention in this context is that, for 
practical reasons, virtually all validations are performed by applying anticoagulated venous blood onto filter 
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paper. Although this blood differs from the one obtained in a real-life application by direct application after 
fingerprick, we are not aware of reports describing problems related to this inherent methodological problem. 
Furthermore, Hct needs to be taken into account when a correlation or conversion is to be made between DBS 
and plasma concentrations (see section 1.7). Additionally, a distinction has to be made between DBS analysis 
for qualitative (i.e. screening) and for quantitative purposes. Obviously, strict validation parameters are needed 
when aiming at quantitative analysis of DBS. 
 
There are various ways of introducing an internal standard (IS) during the process of DBS sampling and analysis 
[55]. Ideally, the IS should be mixed homogenously with the blood sample prior to blood spotting, enabling 
correction for any analyte loss. However, this approach is only feasible when DBS are seen as an alternative 
sample preparation strategy. Alternative approaches are spraying [57-59] or application of IS to the DBS card 
prior to spotting [57,60,61]. An example of the latter is the procedure developed by Mommers et al., who 
described two IS DBS pre-impregnation procedures, in which the DBS card is pretreated with IS (morphine-D3) 
[61]. Abu-Rabie et al. demonstrated that, when combined with accurate volume DBS sampling and whole-spot 
extraction, the IS spray technique may nullify the Hct-based assay bias [59]. However, in the vast majority of 
reports, the IS is added to the extraction solvent. As this means that there can be no compensation for varying 
recoveries, sufficient time should be spent in developing a robust extraction procedure.  
 
1.7 Comparison with other biological matrices 
The use of a DBS method as an alternative for techniques using (larger amounts of) whole blood or plasma 
requires some additional experiments, demonstrating the equivalence or correlation with results measured in 
whole blood or plasma. When analyzing cDBS, also the equivalence with concentrations in venous blood has to 
be evaluated, as mentioned above in section 1.6. However, such cross-comparison between concentrations in 
venous DBS (vDBS) and cDBS has often not been performed. Examples where this cross-comparison has been 
made include the work by de Boer et al., who compared concentrations of midazolam and its main metabolite 
1’-hydroxymidazolam in cDBS and plasma and whole blood, obtained by venipuncture [46], as well as our own 
work, in which we confirmed that capillary and venous concentrations of GHB are comparable [62 + Chapter 2]. 
The group of Huestis observed a discrepancy between cDBS and venous blood concentrations for cocaine and 
benzoylecgonine, although further studies are warranted as they also found a significant DBS variability [63]. 
Kummer et al. found a good correlation between the PEth concentrations in venous blood, vDBS and cDBS [51]. 
The agreement between DBS and other biological matrices can be evaluated by performing ordinary linear 
regression analysis. In this graphical method, the results of one method (for instance those obtained from the 
DBS method) are plotted against the results of another method (for instance those from whole blood analysis). 
However, ordinary linear regression analysis involves several assumptions which are seldomly met in practice 
and may lead to misleading results [64,65]. A better insight into the correlation between two methods can be 
obtained by Deming, Passing-Bablok and/or Bland-Altman analysis [64-66]. A Bland-Altman analysis plots the 
(percentage) differences between the results obtained by two measurement procedures (y-axis) against the 
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average of these results (x-axis). In this comparative graph the mean difference between both procedures is 
also plotted, together with its 95% confidence interval (corresponding to 2 standard deviations of the mean). 
Then, it should be evaluated whether the difference between both methods and the width of the 95% 
confidence interval are acceptable [66]. By using Bland-Altman analysis, Garcia Boy et al., for instance, found a 
mean difference between vDBS and whole blood of 0.43 ± 0.67 ng/100 µL for morphine, meaning that DBS 
values are somewhat higher than blood values, with a 95% confidence interval spanning 2.6 ng/mL in total [67]. 
In the absence of an effect of the spotting per se, equivalent concentrations should be observed in venous 
blood and in DBS derived by spotting this blood. Deviations can be present because of the Hct effect (primarily 
when analyzing partial spots) and because of capillary-venous differences. When a comparison with plasma is 
to be made, one has to take into account the blood:plasma ratio, which is determined by the Hct and by the 
red blood cell (RBC):plasma distribution of a drug. Also here, deviations may occur, e.g. in certain disease states 
where altered plasma protein levels may affect the normal RBC:plasma distribution. Additionally, there is an 
effect of the particulate fraction present in blood: even when a compound is evenly distributed throughout 
plasma and RBCs, it will be present in blood at concentrations about 85% of those found in plasma, when 
considering blood with Hct of about 0.40. Hence, also here Hct plays a role, as blood with lower Hct will have a 
reduced particulate fraction. To make a quantitative comparison between plasma and DBS concentrations 
and/or to derive plasma concentrations from DBS concentrations, the latter are mostly multiplied with a mean 
correction factor, assuming a ‘normal’ Hct. For instance, Saracino et al. multiplied the methadone levels in DBS 
with 1.79, assuming a mean Hct of 0.44 [20], whereas Mercolini et al. introduced 1.62 and 1.92 as correction 
factor for THC, THC-OH and THC-COOH in women and men, assuming a Hct of respectively 0.38 and 0.48 [7]. 
However, one has to be aware of populations with deviating Hct levels, such as newborns or patients suffering 
from anemia. Ideally, the Hct of any sample should be known to determine a correct conversion factor. In this 
context, potassium measurements of DBS could be a promising strategy, as the potassium content of DBS 
allows prediction of the approximate Hct from non-volumetrically applied DBS [68]. In fact, it has been shown 
that this approach allows to correct for the Hct effect in samples with deviating Hct [69]. Also reflectance 
spectroscopy [70] and near-infrared spectroscopy [71] have recently been shown to allow Hct prediction of 
DBS. Furthermore, an even partitioning between RBCs and plasma is assumed in many cases. However, this 
distribution has to be investigated, as demonstrated for benzoylecgonine by Henderson et al. [19] or for 
cotinine by Sosnoff and Bernert [72]. Lastly, although whole blood analyses are common in toxicology, dried 
plasma spots may also be used. These can be prepared by spotting plasma on filter paper after conventional 
plasma preparation or, alternatively, via the use of dedicated cards [73-76]. Such plasma separator devices are 
multilayered extraction cards onto which a drop of blood is applied. The multilayered polymeric filter 
membrane consists of a separation and collection membrane and a removable top layer. The upper membrane 
traps the RBCs and allows plasma to penetrate through onto the bottom collection membrane. After waiting 
for a few minutes, the top layer onto which the cellular fraction is trapped, can be peeled off and plasma spots 
are generated onto the lower membrane.  
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1.8 Stability  
In the forensic toxicology laboratory, it is not unusual that analytes need to be detected a considerable time 
after sampling. An important limitation to be considered is that only analytes which remain stable for an 
extended period of time, may be detected. The use of DBS could be an advantage here since DBS may improve 
analyte stability, as pointed out in multiple publications. Examples of unstable analytes include 
benzodiazepines, zopiclone and cocaine, which are subject to hydrolysis of the amide or ester function, 
respectively. They rapidly degrade in biological fluids, such as whole blood, whereas the degradation process is 
reduced or minimized in DBS, as demonstrated in a number of publications [19,77,78]. A stabilizing effect of 
DBS is also seen for 6-monoacetylmorphine (6-MAM), a heroin metabolite whose detection points at heroin 
use. Whereas filter paper stabilizes 6-MAM, in blood it is rapidly metabolized into morphine, which is also a 
metabolite of prescribed opiates such as codeine [67,79]. In untreated whole blood samples, cathinones are 
also prone to degradation, whereas in DBS all cathinone derivatives (with the exception of cathinone itself) are 
stable for 2 weeks when stored at 4°C [80-82]. Verplaetse and Henion observed stability problems for 
mephedrone which could be counteracted by storage of DBS under a N2 flow and/or at cooled temperature 
[41]. A second remark to be considered when analysis does not take place immediately after sampling, is the 
possibility of ex vivo formation of some compounds upon storage of biofluids. Also here, DBS may increase the 
reliability of the result: although ex vivo generation of PEth and GHB may take place in biological fluids [43,83-
86], this phenomenon is not seen in DBS [24,43].  
 
1.9 Applications 
1.9.1 Driving under the influence of drugs  
Currently, the use of on-site drug testing in oral fluid is described in the legislation of many countries, and in 
some of these, oral fluid is effectively used for DUID testing [87]. However, this matrix suffers from the 
drawback that contamination may not be excluded and is sometimes criticized as measured concentrations not 
necessarily reflect those present in blood (although this is of less relevance in per se legislation). Therefore, in 
selected cases, DBS sampling may be considered as a possible alternative. However, several factors need to be 
taken into account when considering DBS sampling in the context of DUID. First, it should be noted that cDBS 
sampling is also inherently associated with a contamination risk. For example, when a fingerprick is made from 
an individual who touched drug powder or fluid without actively ingesting the drug, traces of the substance 
may be found when analyzing DBS (if the finger is insufficiently decontaminated). As is the case for hair 
analysis, identification of metabolites could be a possible solution [88,89]. For instance, when a DBS only 
contains cocaine, and no benzoylecgonine is detected, external contamination may be likely. External 
contamination and false positive results can also arise upon incorrect handling of the filter paper. This can be 
checked for by evaluating blank paper material, adjacent to the DBS. Another point of attention is that blood 
spot on filter paper must be dried adequately. Bringing the DBS in a standardized container with desiccant may 
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be a convenient way to allow them to dry safely during street controls, as has been applied for remote 
sampling in animals [90]. While DBS prepared from authentic DUID venous blood samples have been analyzed 
[5,31,91], overall giving comparable results as those obtained by routine analytical methods (see further), we 
are not aware of reports describing the use of true cDBS for DUID roadside testing. If cDBS are to be used, 
again, it will be important to demonstrate equivalence between capillary and venous concentrations for the 
analyte of interest. Moreover, cut-offs in e.g. Belgian legislation (mentioned in Appendix 2) refer to plasma 
levels rather than to blood levels, so this is an additional aspect that needs to be taken into account. 
 
1.9.2 Cannabinoids 
Cannabinoid determination in DBS may offer a promising approach in the follow-up of drug addicts or in the 
context of DUID [7]. When considering the detection of different abused substances in DBS, cannabinoids are 
likely amongst the more challenging compounds. Analytes typically monitored are THC, as well as its 
metabolites THC-OH and THC-COOH (Figure 1.1). As THC-OH has a short half-life, it can be considered as a 
marker of recent cannabis use. In contrast, detection of THC-COOH, displaying a very long half-life, generally 
indicates past use of cannabis [92].  
 
 
Figure 1.1 Structures of THC, THC-OH and THC-COOH. 
 
Current methods describing the detection of cannabinoids in DBS require high blood volumes (100 µL of a  
5-ng/mL DBS) or have insufficient sensitivity [7,11,12,26,93]. Using a high-end MS combining a quadrupole 
mass filter, a higher energy collision dissociation cell and an Orbitrap detector, Thomas et al. succeeded in 
attaining a LOD respectively LLOQ of 0.25 respectively 1 ng/mL for THC, starting from a complete 20-µL DBS 
[94]. An enhanced sensitivity for cannabinoids (in the range of sub-ng/mL) is relevant in e.g. the context of 
DUID, where the legal cut-off in Belgium is currently set at 1 ng/mL THC in plasma.  
 
Using an online DBS extraction device coupled with a hydrophilic interaction/reversed-phase LC-MS/MS 
system, Thomas et al. were able to detect THC, the most important compound in cannabis, as well as its 
metabolites THC-OH and THC-COOH (and its glucuronide) in 5-µL DBS, albeit at very high concentrations [11]. 
The same group developed a screening method based on an automated DBS extraction for the detection of a 
wide range of abused substances, including THC (50 ng/mL in a 5-µL DBS) [12]. An UHPLC-MS/MS screening 
method developed by Kyriakou et al. [93] and a GC-MS method developed by Langel et al. [26] also had 
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insufficient sensitivity for the detection of cannabinoids (15 ng/mL in 30-µL DBS and 5 ng/mL in 100-µL DBS, 
respectively). Mercolini et al. developed a method for the quantitative analysis of THC, THC-OH and THC-COOH 
in DBS [7]. The good correlation between plasma concentrations that were calculated from DBS concentrations 
and those that were actually measured in corresponding plasma samples of 5 cannabis users was based upon 
several assumptions. First, it was assumed that a 7-mm punch corresponds to 10 µL blood; second, an even 
partitioning of the different analytes of interest between plasma and RBCs was assumed, which is actually not 
really the case [95]. Hence, although these results are promising, studies including larger groups are warranted.  
 
1.9.3 Cocaine and metabolites 
Cocaine is an illicit drug whose effects (increased self-confidence, a sense of omnipotence and sometimes a 
sensory impairment) explain its relevance in DUID studies [6]. Given the short half-life of cocaine, cocaine use is 
generally demonstrated by detecting its main metabolite benzoylecgonine (Figure 1.2). Multiple methods  
-either GC- or LC-based- have been developed for detection and quantification of cocaine and/or 
benzoylecgonine in DBS [8,12,13,26,47,56,63,77,93,94,96]. Cocaethylene, a metabolite formed after 
concomitant use of cocaine and ethanol-containing drinks, was also included in the DBS-based methods of 
Mercolini et al. and Saussereau et al. [6,31]. Saussereau et al. and Odoardi et al. were able to quantify the 
metabolite ecgonine methyl ester as well [31,47]. The metabolite norcocaine was included in the method of 
Ellefsen et al. [63]. 
 
 
Figure 1.2 Structures of cocaine and its metabolites benzoylecgonine, ecgonine methyl ester, norcocaine and 
cocaethylene.  
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Cocaine abuse among pregnant women is associated with neonatal and obstetrical complications. Therefore, 
benzoylecgonine concentrations have been measured in newborn DBS to examine the prevalence and 
demographic aspects of cocaine use during pregnancy [19,56,97]. It has to be noted that detection in newborn 
DBS will only be possible if maternal use of cocaine took place at the end of the pregnancy.  
 
As cocaine is subject to hydrolysis in whole blood samples, potential degradation needs to be taken into 
account when interpreting blood concentrations. Henderson et al., for example, detected increasing amounts 
of benzoylecgonine upon incubation of cocaine-spiked blood [19]. These authors reported that in DBS, in 
contrast, degradation was minimal: no detectable benzoylecgonine concentrations were found when cocaine-
containing DBS were incubated for 108 h at 45°C [19]. Kyriakou et al. observed no significant alteration of 
cocaine and benzoylecgonine DBS concentrations when stored at room temperature for two weeks [93]. 
Saussereau et al. evaluated long-term stability of cocaine and its metabolites in DBS and found that after a  
6-month storage at -20°C concentrations had changed less than 20%. However, after a 6-month storage of DBS 
at 4°C, cocaine concentrations had decreased by 55% and ecgonine methylester concentrations by 88% [31]. 
Therefore, DBS for cocaine analysis need to be stored at freezing temperatures. 
 
Mercolini et al. determined cocaine, benzoylecgonine and cocaethylene in cDBS obtained from cocaine and 
ethanol abusers [6]. They used an arbitrary correction factor to convert DBS concentrations to plasma 
concentrations, taking into account expected Hct levels for males and females, and reported a good 
correlation, although only documented for one case. Rather than starting from DBS prepared from spiked 
blood, these authors used blank DBS to which standards were spiked during validation. Ellefsen et al. 
investigated the correlation between cocaine and metabolite concentrations in DBS and venous blood 
following controlled intravenous cocaine administration. They observed slightly lower concentrations in DBS 
and, importantly, large intra- and inter-subject variability for both cocaine and benzoylecgonine. According to 
the authors, this variability could be attributed to nonhomogeneity of the blood spots, different blood spot 
volumes and different extraction efficiencies of the methods used for blood and DBS analysis. Since sampling 
occurred rapidly after cocaine administration, the authors also believe that the observed discrepancies 
between cDBS and venous blood concentrations may be due to inherent concentration differences between 
these two matrices [63]. Saussereau et al., utilizing a limited set of authentic samples, reported a good 
correlation between benzoylecgonine concentrations in venous blood and DBS prepared thereof, assuming 
that a 3-mm DBS contains a volume of 3 µL blood [31]. Also Antelo-Dominguez et al. and Odoardi et al., 
analyzing limited sets of authentic venous samples by a DBS-based procedure and by a routine procedure for 
blood analysis, reported a good correlation between both methods [47,96]. However, in both approaches the 
use of DBS should be considered as an alternative sample preparation procedure: whereas Odoardi et al. used 
100-µL DBS, in the approach of Antelo-Dominguez et al. the blood samples need to be diluted first with water 
before spotting them on filter paper [47,96]. Starting from 5-µL DBS and utilizing a new-generation MS, Versace 
et al. detected cocainics equally well as when using routine screening procedures which require larger amounts 
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of sample (about 1 mL) [8]. Overall, to our opinion, more studies illustrating the suitability of DBS as a valid 
alternative for routine procedures using conventional matrices, are warranted.  
 
1.9.4 Opiates 
Morphine is a metabolite of several opiates, either illicit (heroin) or licit (codeine). Consequently, detection of 
morphine alone does not allow to find out the parent molecule, whereas detection of 6-MAM indicates heroin 
use. A high prevalence of viral infections is seen in heroin abusers as this illicit drug is mainly abused 
intravenously. Consequently, special safety precautions have to be taken when handling these samples. Here, 
DBS may offer an advantage as DBS minimize the risk of transmitting blood-borne viruses since these lose their 
infectivity upon drying [98,99]. Furthermore, whereas 6-MAM degrades rapidly in whole blood at any storage 
temperature different from -20°C, Skopp reported it to be stable in DBS for at least 6 days at any storage 
temperature [79]. Kyriakou et al. also observed a decrease of less than 10% when the DBS samples were stored 
at room temperature for two weeks [93]. Garcia Boy et al. confirmed this stabilizing effect of DBS for 6-MAM: 
although the 6-MAM concentration in DBS still decreased by 50% within 5 days at 40°C, storage in whole blood 
resulted in complete disappearance of 6-MAM [67]. Clavijo et al. demonstrated increased stability of the 3- 
and 6-glucuronide metabolites of morphine in DBS [100]. Whereas in plasma, the glucuronides were stable for 
only 24 h at 4°C and for less than 8 h at room temperature, in DBS, these metabolites were stable for at least 7 
days at 4°C and for 3 days at room temperature.  
 
DBS sampling for opiate analysis may have several applications: for compliance monitoring in chronic pain 
patients, reliable quantification of opiates in the context of DUID, doping control or for the follow-up of drug 
addicts. The structures of most important opiates are given in Figure 1.3. Garcia Boy et al., using authentic 
samples, found a good correlation between morphine concentrations in 100 µL blood and 100-µL DBS, albeit 
with a somewhat positive bias for the DBS [67]. Jantos et al., also starting from complete 100-µL DBS, reported 
similar concentrations of the opiates morphine, hydromorphone, oxycodone and noroxycodone in DBS and 
whole blood [101]. Similar results were obtained by Odoardi et al. [47]. Using spiked blood samples, Goggin et 
al. determined DBS:plasma ratios for various opiates, including codeine, dihydrocodeine, morphine, 
hydrocodone, hydromorphone, oxycodone and oxymorphone in 9 samples [45]. Although not holding true for 
all analytes, the overall DBS:plasma ratios were more or less in line with expected ratios. While in only one 
sample of the report by Antelo-Dominguez et al. morphine concentrations were high enough to allow 
comparison between a DBS-based method and a GC-MS-based screening method, the results of both methods 
were essentially the same [96]. The automated DBS extraction procedure set up by Versace et al. for screening 
DBS for drugs of abuse showed limited sensitivity for opiates, as exemplified by the fact that the procedure 
frequently missed morphine and codeine in authentic samples [8]. On the other hand, the fully automated DBS-
SPE-LC-MS/MS method developed by Verplaetse and Henion, seems promising for the quantification of 
morphine, codeine, oxycodone and hydrocodone in a real setting [40].  
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Figure 1.3 Structures of heroin, 6-MAM, morphine, hydromorphone, codeine, hydrocodone, dihydrocodeine, oxymorphone, oxycodone and noroxycodone. 
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1.9.5 Non-opiate opioids 
Methadone is a long-acting synthetic µ-opioid receptor agonist used in rehabilitation programs by opiate 
addicts, in particular heroin addicts. This heroin substitute reduces craving and withdrawal symptoms, resulting 
in less tendency to use heroin. Similar to morphine, DBS sampling may facilitate compliance monitoring. 
Saracino et al. determined methadone concentrations in cDBS and in the corresponding plasma samples in 
methadone maintenance patients [20]. Bland-Altman plots showed a good correlation between both matrices, 
however, requiring the following: i) calculation of the blood volume contained within the DBS (calculated from 
the DBS surface, assuming an average Hct), ii) application of a correction factor to calculate the plasma 
concentration from the DBS concentration (again assuming an average Hct), and iii) assuming an even 
distribution of methadone between RBCs and plasma. The latter assumption in fact may not hold true, as 
methadone partitions more in plasma than in RBCs [102]. A deviating correlation was indeed observed by 
Goggin et al., who compared methadone DBS concentrations with plasma levels [45]. Odoardi et al. observed 
similar DBS and blood concentrations in an authentic post-mortem sample [47]. The structures of methadone 
as well as its metabolites 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-
diphenylpyrroline (EMDP) are given in Figure 1.4.  
 
 
Figure 1.4 Structures of methadone, EDDP and EMDP. 
 
Other synthetic opioids analyzed in DBS are the analgesics tramadol and fentanyl (also agonists) and 
buprenorphine, a partial agonist used in opioid addiction treatment (Figure 1.5). Using an online LC-MS/MS 
method, Thomas et al. were able to monitor the in vivo metabolism of buprenorphine by repeated DBS-based 
sampling following intraperitoneal injection of this molecule in a rat [11]. Verplaetse and Henion developed a 
method for the quantification of fentanyl using flow-through elution of the DBS card, followed by online-SPE 
[40]. Clavijo et al. successfully quantified fentanyl and its major metabolites, norfentanyl and 
despropionylfentanyl, in DBS of neonates for the assessment of PK [103]. Odoardi et al. used DBS as a sample 
preparation step for the determination of alfentanyl, fentanyl, norfentanyl and sufentanyl in post-mortem 
samples [47]. Jantos et al. found similar concentrations of fentanyl and norfentanyl in DBS and whole blood 
[101]. From a bridging study performed by Goggin et al., where DBS and plasma concentrations of a variety of 
opioids were compared (e.g. tramadol, fentanyl and buprenorphine), it can be concluded that, although for 
some analytes a DBS:plasma ratio conform expectations was observed, more in-depth studies are needed [45].  
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Figure 1.5 Structures of buprenorphine, tramadol, fentanyl, norfentanyl, despropionylfentanyl, sufentanyl and 
alfentanyl.  
 
1.9.6 Benzodiazepines and Z-drugs 
Benzodiazepines and Z-drugs (Figure 1.6) are prescribed for the treatment of insomnia or anxiety disorders. 
However, as these are addictive drugs and given their sleep-inducing effect, they are of interest in clinical and 
forensic toxicology and in the context of DUID. The amide in zopiclone and in most benzodiazepines renders 
these compounds subject to degradation, more particularly hydrolysis. Again, the use of DBS may offer a 
stability advantage, as has been demonstrated for zopiclone. Whereas in whole blood only 25% of the initial 
zopiclone concentrations was left after 8 days at room temperature, in low-level DBS which were stored for 30 
days at room temperature still 77% of the initial concentration could be found [78]. These findings were 
corroborated by Déglon et al., who reported stability of a multi-analyte panel after 30 days storage at room 
temperature [5]. These authors developed a simplified offline LC-MS/MS method, allowing detection of the 
major benzodiazepines (except bromazepam) and Z-drugs, along with selected metabolites, in 5-µL DBS. 
 
To investigate the equivalence of DBS methods and whole blood methods, Jantos and Skopp analyzed blood 
and 100-µL DBS from volunteers participating in driving simulation experiments and who had ingested drugs, 
amongst which alprazolam [91]. They found a mean blood/DBS ratio of 0.99 for alprazolam, which means that 
the concentrations found in DBS do not differ from those in blood. Déglon et al. applied their method on DBS 
prepared from venous blood samples that had been collected in the context of DUID [5]. Again, a good 
correlation was seen between the quantitative results obtained from DBS and those obtained from blood that 
had been analyzed by routine LC-MS, resulting in the implementation of the simplified method in routine 
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analysis. Versace et al. also found similar results between a newly developed screening method based on an 
automated extraction of 5-µL DBS and routine screening procedures starting from 1 mL [8]. With the aim of 
phenotyping the liver enzyme CYP 3A4, de Boer et al. determined the PK profile of midazolam in plasma, whole 
blood, cDBS and vDBS. Regression analyses indicated a strong correlation between the concentrations in the 
corresponding samples. However, these analyses also demonstrated that, apart from the expected difference 
in concentration between blood and plasma, there was also a difference between concentrations in venous 
blood and DBS derived thereof, as well as between concentrations in vDBS and cDBS [46]. Midazolam has also 
been measured in rat DBS, using a fully automated system, coupling online DBS extraction to 2D LC and high 
resolution MS [39]. 
 
 
 
 
Figure 1.6 Structures of benzodiazepines and Z-drugs.      
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Figure 1.6 Continued. 
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1.9.7 Amphetamine and analogues (methamphetamine, MDMA, MDA and  
  MDEA) 
Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxy-N-
ethylamphetamine (MDEA) are amphetamine-like drugs (Figure 1.7). Determination of these drugs is relevant 
in the forensic context and in cases of DUID as consumption of MDMA may affect risk assessment and may 
result in a disturbed balance and motor coordination.  
 
 
Figure 1.7 Structures of amphetamine and analogues. 
 
Déglon et al., Versace et al., Ambach et al. as well as Kyriakou et al. developed DBS-based screening methods  
-either for classic drugs of abuse or for new psychoactive substances- enabling the detection of amphetamine-
like drugs [8,12,80,93]. Thomas et al. focused on determination of prohibited drugs for doping controls [94]. 
For the quantitative analysis of amphetamine and analogues in DBS, Jantos and Skopp, Odoardi et al. as well as 
Saussereau et al., developed an LC-MS/MS method, whereas Langel et al. applied GC-MS [26,31,47,91]. Using 
an automated DBS system, Verplaetse and Henion were able to quantify amphetamine, methamphetamine and 
MDMA [41]. 
 
Jantos and Skopp and Saussereau et al. performed a cross-comparison between vDBS and whole blood and 
concluded that both methods gave similar results [31,91]. Ambach et al. and Versace et al. also did not observe 
major discrepancies between DBS-based and blood-based screening, taking into account different sensitivities 
of both methods -the DBS method starting from 50 or even 200x less material but utilizing a higher-end MS 
than the methods for routine analysis [8,80].  
 
1.9.8 Gamma-hydroxybutyric acid  
GHB is primarily notorious for its use as club and date-rape drug (Figure 1.8). Unfortunately, interpretation of 
GHB concentrations is not always straightforward. First of all, the presence of GHB in a blood sample can be 
attributed either to illicit use of this substance or to its endogenous presence. Furthermore, GHB may be 
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formed de novo post-mortem as well as ex vivo in stored samples [83,84]. This ex vivo formation, however, is 
not observed in DBS [24]. Additionally, GHB is quickly cleared from the circulation, making rapid sampling 
imperative. Here as well, DBS sampling may offer an interesting alternative since no medical staff is needed for 
the sampling procedure, hence allowing more prompt sampling. This way, GHB concentrations representative 
of the intoxication state at the moment of interest can be measured. Particularly in cases of drug-facilitated 
sexual assault (DFSA) a rapid sampling method may prove to be of crucial importance as there is most often a 
delay before the victim reports the assault. The good correlation between concentrations in venous blood, DBS 
prepared from venous blood and cDBS [24 and Chapter 2], suggests that the DBS sampling technique for GHB 
analysis in toxicological cases may be recommended in routine practice. In our laboratory, we routinely use 
dried matrix spots (DBS, but also dried plasma or dried urine spots) for GHB analysis in a forensic context. To 
this end, we prepare spots volumetrically and, after adding labeled IS, subject the complete spots to “on-spot 
derivatization” and analysis via GC-MS [23,24]. 
 
 
Figure 1.8 Structure of GHB. 
 
1.9.9 Ketamine and norketamine 
Ketamine is a popular drug for sedation and anesthesia in children which requires proper knowledge of PK and 
pharmacodynamics for choosing the right dose and dosing interval (Figure 1.9). DBS sampling is an attractive 
method for sampling blood for PK studies in neonates, as only a minimal amount of blood is needed [104]. 
Ketamine is also used as a recreational drug and in cases of DFSA. In these cases as well, DBS sampling may be a 
valuable option as sampling should be done as fast as possible (see GHB, subsection 1.9.8).  
 
 
Figure 1.9 Structures of ketamine and norketamine.  
 
With the aim to improve the understanding of PK in neonates, Moll et al. developed a method for the 
quantification of ketamine and its main metabolite norketamine in DBS [104]. Ketamine was also included in 
the multi-analyte DBS-based procedures developed by Ambach et al. and Odoardi et al. [47,80]. Furthermore, 
utilizing a microextraction packed sorbent procedure followed by HPLC-diode array detection analysis, Saracino 
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et al. could also successfully quantify ketamine and norketamine in DBS [21]. Studies are still in progress to 
investigate the equivalence with whole blood.  
 
1.9.10 New psychoactive substances  
During the last decade, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has observed 
a significant increase of new (psychoactive) substances, mainly cathinones and synthetic cannabinoids [105]. 
Mephedrone, a cathinone analogue (Figure 1.10), was successfully quantified by Verplaetse and Henion using 
an online SPE-LC-MS/MS method, following flow-through desorption [41]. Ambach et al. developed an LC-
MS/MS method for the screening of 64 established and new psychoactive substances (including e.g. 
amphetamines, cathinones, piperazines), using complete 10-µL DBS [80]. Samples that scored positive in this 
screening were quantified with a validated whole blood method used in routine analysis. As overall similar 
results were obtained with both methods and DBS may simplify sample preparation, the authors concluded 
that DBS are a useful matrix for rapid screening of new psychoactive substances. Furthermore, DBS have a 
stabilizing effect on cathinone derivatives when stored cooled [80]. Mercolini et al. demonstrated that other 
alternative matrices like hair, oral fluid, dried urine and dried plasma also have potential for the determination 
of new psychoactive substances [106,107].  
 
 
Figure 1.10 Structures of cathinone and mephedrone.  
 
1.9.11 Alcohol markers 
It has been well established that alcohol misuse has social and behavioral effects, as well as effects on mental 
and physical health. Consequently, tracing ethanol consumption or abstinence is relevant, either for clinical, 
forensic or traffic cases (e.g. in driver’s license regranting), or in the context of workplace monitoring. Assessing 
whether someone is under the influence of alcohol can be done by breath testing and by measuring blood 
alcohol concentrations. However, when the aim is to evaluate whether ethanol consumption took place in the 
recent past, the small detection window of ethanol itself may not suffice. There are several alternative markers 
available for this purpose. Examples include ethylglucuronide and ethylsulfate, which are highly sensitive and 
specific markers of either recent (blood, urine) or historic (hair, nails) intake of ethanol [108,109]. Redondo et 
al. successfully developed a method allowing detection of these biomarkers in complete 10-µl DBS [110]. As 
long-term alcohol biomarker, however, ethylglucuronide and ethylsulfate are not widespread yet. An 
alternative marker is PEth, the collective term for a group of ethanol-derived phospholipids formed from 
Chapter 1: Analysis of abused substances using dried blood spots 
 
  
36 
 
phospathidylcholine after ethanol consumption. Formation of these products is catalyzed by phospholipase D 
in the membranes of RBCs. PEth has gained popularity as biomarker of alcohol misuse during the last few years 
and should offer a wider window of detection than ethylglucuronide and ethylsulfate [43,111-114]. However, 
PEth is susceptible to post-sampling synthesis during storage of ethanol-containing samples and could generate 
false positive results [43,112]. Consequently, blood samples have to be stored at -80°C and should be analyzed 
within 30 days [111]. DBS, however, lack ex vivo de novo formation of PEth, as demonstrated by Jones et al.: 
PEth 16:0/18:1 (a specific isomer) could not be detected in DBS stored in ethanol vapor or in DBS which were 
spiked to significant ethanol concentrations [43]. According to Kummer et al., PEth 16:0/18:1 and PEth 
18:1/18:1 are stable for 6 months in DBS when stored at room temperature. They developed an UHPLC-MS/MS 
method for the quantification of PEth species (PEth 16:0/18:1, PEth 18:1/18:1 and PEth 16:0/16:0 (see Figure 
1.11)) in blood and DBS and found a good correlation between venous blood, vDBS and cDBS concentrations, 
suggesting that DBS are a valid alternative to venous blood for the detection of alcohol consumption [51].  
 
 
 
Figure 1.11 Structures of PEth 16:0/16:0, PEth 18:1/18:1 and PEth 16:0/18:1. 
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Given the risk of neurocognitive problems in children exposed to alcohol during pregnancy, attention is paid to 
screening newborns for prenatal alcohol exposure (PAE) [113]. Therefore, meconium fatty acid ethyl esters 
(FAEE) are, to date, measured to confirm PAE. However, this approach suffers from some limitations, amongst 
which low sensitivity and possibility of post-collection synthesis [43,114]. Detection of PEth in newborn DBS 
may be an interesting alternative for FAEE in meconium as post-collection synthesis does not occur on DBS 
cards [43] and no extra sampling is needed since DBS are already taken from newborns to screen for metabolic 
disorders. Although first reports confirm that accurate detection of PEth in conjunction with other biomarkers 
facilitates detection of PAE, other studies are warranted to further examine the utility of determining PEth in 
newborn DBS for identifying cases of PAE [113]. It has to be pointed out that, given the relatively short 
detection window (about 2-3 weeks), PEth in DBS is a biomarker of PAE during the last stage of pregnancy, 
whereas meconium FAEE allow detection of alcohol consumption during the 2
nd
 and 3
rd
 trimester [114]. 
However, in spite of the longer detection window of the latter biological matrix, it is still not able to identify 
maternal alcohol consumption in early pregnancy. Additionally, detection of PEth in DBS may allow more 
sensitive detection of PAE than meconium FAEE, despite the much shorter detection window [113].  
 
1.9.12. Cotinine 
The occurrence of low birth weight, childhood cancers and premature death has been associated with the 
active use of tobacco and exposure to second-hand smoke during pregnancy [22,29,49,72,115]. To assess 
exposure to tobacco or second-hand smoke, cotinine concentrations are measured as cotinine is the primary 
metabolite of nicotine. Given the good correlation between cotinine concentrations in DBS and in plasma, 
Murphy et al. proposed DBS cotinine as a reliable biomarker of tobacco metabolism [29]. Furthermore, several 
studies in newborns demonstrated that cotinine levels in newborn DBS may be used to identify maternal 
smoking at the very end of pregnancy [22,49,115]. However, several limitations have to be considered. Given 
the small sample volume, cotinine in newborn DBS could not be used as a biomarker of maternal second-hand 
smoke because of sensitivity issues [49,72]. Moreover, one has to be aware that cotinine concentrations will 
only be increased when DBS are collected within 72 h after birth and exposure was close to the time of delivery 
[22,29,49,72]. Yang et al. also found a good correlation between DBS cotinine levels and umbilical cord blood 
cotinine concentrations in a large set of samples (n = 100) from a newborn screening program, although 
concentrations in umbilical cord blood were somewhat higher [49]. Wang et al. also reported similar cotinine 
concentrations in blood and DBS from a rat that had been injected with nicotine [35]. These authors used the 
interesting approach of paper spray MS, a technique in which a spray, that is generated by applying a high 
voltage directly onto filter paper, directly enters the MS. Using a fully automated online SPE LC-HRMS/MS 
approach, Tretzel et al. were able to quantify nicotine, its major metabolites nornicotine, cotinine and trans-3’-
hydroxycotinine and the tobacco alkaloids anabasine and anatabine for sports drug testing purposes [42]. The 
structures of tobacco markers are given in Figure 1.12.  
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Figure 1.12 Structures of tobacco markers. 
 
1.10   Conclusion 
A substantial number of DBS methods is available to detect and quantify a vast array of abused substances. The 
majority of these methods shows sufficient sensitivity to be relevant in the context of DUID, despite the fact  
that some compounds (e.g. THC) are clearly more challenging than others. Moreover, DBS sampling provides 
several benefits over conventional sampling techniques that can be advantageous for the analysis of abused 
substances. First, this technique is minimally invasive and represents a fast, simple and economic way to collect 
a specimen that provides information on the acute intoxication state of a person. Second, as DBS sampling can 
be performed by non-medical personnel, the time until sample collection is minimized, which is especially of 
importance in the context of DUID and DFSA. Third, DBS offer a very stable matrix, reducing degradation and 
preventing de novo formation, often even at room temperature, thereby facilitating storage and 
transportation. As discussed above (section 1.8), benzodiazepines, cocaine, zopiclone, cathinones and 6-MAM 
are susceptible to degradation in whole blood, whereas the degradation process is reduced or minimized in 
DBS. It should be noted though, that for several analytes, storage will still require freezing at -20°C or flushing 
with N2 [41]. Furthermore, ex vivo formation of GHB or of the alcohol biomarker PEth is not seen in DBS, in 
contrast to other biological fluids. Last, but certainly not least, given the higher prevalence of viral infections in 
drug abusers, DBS sampling may provide an appealing alternative to venipuncture, as the dried matrix of DBS 
drastically reduces biohazard.  
 
Aside from quantitative applications, DBS can be used for rapid toxicological screening as well, since DBS may 
simplify sample preparation and reduce the necessary sample volume, which in (forensic) toxicological analysis 
can be limited. Additionally, DBS, which are already collected in the context of newborn screening programs for 
metabolic diseases, also provide a very interesting matrix for the assessment of newborn exposure to tobacco, 
ethanol and certain drugs during (the last part of) pregnancy. This facilitates extensive studies evaluating the 
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effect of these factors on the occurrence of e.g. premature death and childhood cancers. Moreover, these 
methods can also be used in a more clinical context, e.g. for the diagnosis of PAE.  
 
Despite the numerous advantages associated with DBS sampling and the wide range of applications, this 
approach also faces some challenges. Given the small blood volume that is available, highly sensitive detection 
techniques are often required. For instance, cannabinoid quantitation proved to be a real challenge as, to the 
best of our knowledge, only one method, using high-end equipment, attained sufficient sensitivity, yet still 
requiring complete 20-µL DBS. Other challenges associated with DBS sampling are contamination risk, the 
acquisition of correctly obtained samples, the influence of the site of punching and of the blood volume 
spotted, the chromatographic effect and the Hct effect, the most widely discussed DBS-related problem. With 
respect to the latter, several solutions have been proposed [54]. Moreover, the number of applications 
performed in a real setting and the number of applications demonstrating the equivalence with results in other 
biological fluids are limited. Based on the available data, it can be concluded that in most cases no “DBS effect” 
per se is present, meaning that equivalent concentrations are present in DBS and in whole blood. Whether this 
also holds true for cDBS and venous blood, remains to be established in most cases. Conclusively, although 
current DBS approaches for the detection of abused substances seem promising, more experiments are 
warranted for the implementation of DBS sampling in routine analysis. 
  
Chapter 1: Analysis of abused substances using dried blood spots 
 
  
40 
 
1.11   References 
1. Bang I. Der Blutzucker, Wiesbaden, Germany (1913). 
2. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations 
of newborn infants. Pediatrics 32(3), 338-343 (1963). 
3. Li W, Tse F. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small 
molecules. Biomed Chromatogr 24(1), 49-65 (2010). 
4. Stove C, Ingels A, De Kesel P, Lambert W. Dried blood spots in toxicology: from the cradle to the 
grave? Crit Rev Toxicol 42(3), 230-243 (2012). 
5. Déglon J, Versace F, Lauer E et al. Rapid LC-MS/MS quantification of the major benzodiazepines and 
their metabolites on dried blood spots using a simple and cost-effective sample pretreatment. 
Bioanalysis 4(11), 1337-1350 (2012). 
6. Mercolini L, Mandrioli R, Gerra G, Raggi M. Analysis of cocaine and two metabolites in dried blood 
spots by liquid chromatography with fluorescence detection: a novel test for cocaine and alcohol 
intake. J Chromatogr A 1217(46), 7242-7248 (2010). 
7. Mercolini L, Mandrioli R, Sorella V et al. Dried blood spots: liquid chromatography-mass spectrometry 
analysis of Delta9-tetrahydrocannabinol and its main metabolites. J Chromatogr A 1271(1), 33-40 
(2013). 
8. Versace F, Déglon J, Lauer E, Mangin P, Staub C. Automated DBS extraction prior to hilic/RP LC-MS/MS 
target screening of drugs. Chromatographia 76(19-20), 1281-1293 (2013). 
9. Hudson W, Yong B, Boguszewski P. Analysis of clozapine, nortriptyline, paroxetine and zolpidem using 
dried blood spots. Agilent Technologies. http://www.chem.agilent.com/Library/applications/5990-
8033EN.pdf.10.  
10. Eibak L, Hegge A, Rasmussen K, Pedersen-Bjergaard S, Gjelstad A. Alginate and chitosan foam 
combined with electromembrane extraction for dried blood spot analysis. Anal Chem 84(20), 8783-
8789 (2012). 
11. Thomas A, Déglon J, Steimer T, Mangin P, Daali Y, Staub C. On-line desorption of dried blood spots 
coupled to hydrophilic interaction/reversed-phase LC/MS/MS system for the simultaneous analysis of 
drugs and their polar metabolites. J Sep Sci 33(6-7), 873-879 (2010). 
12. Déglon J, Thomas A, Mangin P, Staub C. Direct analysis of dried blood spots coupled with mass 
spectrometry: concepts and biomedical applications. Anal Bioanal Chem 402(8), 2485-2498 (2012). 
13. Lauer E, Déglon J, Versace F, Thomas A, Mangin P, Staub C. Target screening of drugs from dried blood 
spot samples based on LC-MS/MS and on-line desorption. Presented at: 49th Annual Meeting of The 
International Association of Forensic Toxicologists (TIAFT). San Francisco, CA, USA, 25-30 September 
2011. 
14. Lenk G, Sandkvist S, Pohanka A, Stemme G, Beck O, Roxhed N. A disposable sampling device to collect 
volume-measured DBS directly from a fingerprick onto DBS paper. Bioanalysis 7(16), 2085-2094 
(2015). 
Chapter 1: Analysis of abused substances using dried blood spots 
 
  
41 
 
15. Leuthold LA, Heudi O, Déglon J, et al. New microfluidic-based sampling procedure for overcoming the 
hematocrit problem associated with dried blood spot analysis. Anal Chem 87(4), 2068-2071 (2015). 
16. Denniff P, Spooner N. Volumetric absorptive microsampling: a dried sample collection technique for 
quantitative bioanalysis. Anal Chem 86(16), 8489-8495 (2014). 
17. Spooner N, Denniff P, Michielsen L, et al. A device for dried blood microsampling in quantitative 
bioanalysis: overcoming the issues associated blood hematocrit. Bioanalysis 7(6), 653-659 (2015). 
18. Denniff P, Spooner N. The effect of hematocrit on assay bias when using DBS samples for the 
quantitative bioanalysis of drugs. Bioanalysis 2(8), 1385-1395 (2010). 
19. Henderson L, Powell M, Hannon W et al. Radioimmunoassay screening of dried blood spot materials 
for benzoylecgonine. J Anal Toxicol 17(1), 42-47 (1993). 
20. Saracino M, Marcheselli C, Somaini L et al. A novel test using dried blood spots for the 
chromatographic assay of methadone. Anal Bioanal Chem. 404(2), 503-511 (2012). 
21. Saracino M, Marcheselli C, Bugamelli F, Morganti E, Serpelloni G, Raggi M. Club drugs: analysis of 
ketamine and norketamine in dried blood spots by HPLC-DAD-MEPS. Presented at: 24th International 
Symposium on Pharmaceutical and Biomedical Analysis. Bologna, Italy, 30 June - 3 July 2013. 
22. Spector L, Hecht S, Ognjanovic S, Carmella S, Ross J. Detection of cotinine in newborn dried blood 
spots. Cancer Epidemiol Biomarkers Prev 16(9), 1902-1905 (2007). 
23. Ingels A, Lambert W, Stove C. Determination of gamma-hydroxybutyric acid in dried blood spots using 
a simple GC-MS method with direct "on spot" derivatization. Anal Bioanal Chem 398(5), 2173-2182 
(2010). 
24. Ingels A, De Paepe P, Anseeuw K et al. Dried blood spot punches for confirmation of suspected 
gamma-hydroxybutyric acid intoxications: validation of an optimized GC-MS procedure. Bioanalysis 
3(20), 2271-2281 (2011). 
25. Ingels A, Hertegonne K, Lambert W, Stove C. Feasibility of following up gamma-hydroxybutyric acid 
concentrations in sodium oxybate (Xyrem®)-treated narcoleptic patients using dried blood spot 
sampling at home: an exploratory study. CNS drugs 27(3), 233-237 (2013). 
26. Langel K, Uusivirta H, Ariniemi K, Lillsunde P. Analysis of drugs of abuse by GC-MS in dried blood spot 
sample matrix. Presented at: 49th Annual Meeting of The International Association of Forensic 
Toxicologists (TIAFT). San Francisco, CA, USA, 25-30 September 2011. 
27. Déglon J, Thomas A, Cataldo A, Mangin P, Staub C. On-line desorption of dried blood spot: a novel 
approach for the direct LC/MS analysis of micro-whole blood samples. J Pharm Biomed Anal 49(4), 
1034-1039 (2009). 
28. Sadones N, Van Bever E, Archer JRH, et al. Microwave-assisted on-spot derivatization for gas 
chromatography-mass spectrometry based determination of polar low molecular weight compounds 
in dried blood spots. J Chromatogr A 1465, 175-183 (2016). 
29. Murphy S, Wickham K, Lindgren B, Spector L, Joseph A. Cotinine and trans 3'-hydroxycotinine in dried 
blood spots as biomarkers of tobacco exposure and nicotine metabolism. J Expo Sci Environ Epidemiol 
23(5), 513-518 (2013). 
Chapter 1: Analysis of abused substances using dried blood spots 
 
  
42 
 
30. Clavijo C, Thomas J, Hammer G, Christians U, Galinkin J. A sensitive LC-MS/MS assay for quantification 
of methadone and its metabolites in dried blood spots. Presented at: 2010 Annual Meeting of the 
American Society of Anesthesiologists (ASA). San Diego, CA, USA, 16-20 October 2010. 
31. Saussereau E, Lacroix C, Gaulier J, Goulle J. On-line liquid chromatography/tandem mass spectrometry 
simultaneous determination of opiates, cocainics and amphetamines in dried blood spots. J 
Chromatogr B Analyt Technol Biomed Life Sci 885-886, 1-7 (2012). 
32. Lafrenière N, Shih S, Abu-Rabie P, Jebrail M, Spooner N, Wheeler A. Multiplexed extraction and 
quantitative analysis of pharmaceuticals from DBS samples using digital microfluidics. Bioanalysis 6(3), 
307-318 (2014). 
33. Liu J, Wang H, Manicke N, Lin J, Cooks R, Ouyang Z. Development, characterization, and application of 
paper spray ionization. Anal Chem 82(6), 2463-2471 (2010). 
34. Zhang Z, Xu W, Manicke N, Cooks R, Ouyang Z. Silica coated paper substrate for paper-spray analysis of 
therapeutic drugs in dried blood spots. Anal Chem 84(2), 931-938 (2012). 
35. Wang H, Ren Y, McLuckey M et al. Direct quantitative analysis of nicotine alkaloids from biofluid 
samples using paper spray mass spectrometry. Anal Chem 85(23), 11540-11544 (2013). 
36. Seip K, Gjelstad A, Pedersen-Bjergaard S. Electromembrane extraction from aqueous samples 
containing polar organic solvents. J Chromatogr A 1308, 37-44 (2013). 
37. Johnson C, Christianson C, Sheaff C, Laine D, Zimmer J, Needham S. Use of conventional bioanalytical 
devices to automate DBS extractions in liquid-handling dispensing tips. Bioanalysis 3(20), 2303-2310 
(2011). 
38. Henion J, Oliveira R, Fumin L, Foley T, Pomponio R. Dried blood spots: the future. In: Microsampling in 
Pharmaceutical Bioanalysis (ebook). Zane P, Emmons GT (Eds), Future Science Ltd, 48-66 (2013). 
39. Oliveira R, Henion J, Wickremsinhe E. Fully-automated approach for online dried blood spot extraction 
and bioanalysis by two-dimensional-liquid chromatography coupled with high-resolution quadrupole 
time-of-flight mass spectrometry. Anal Chem 86(2), 1246-1253 (2014). 
40. Verplaetse R, Henion J. Quantitative determination of opioids in whole blood using fully automated 
dried blood spot desorption coupled to on-line SPE-LC-MS/MS. Drug Test Anal 8(1), 30-38 (2016). 
41. Verplaetse R, Henion J. Hematocrit-independent quantitation of stimulants in dried blood spots: pipet 
versus microfluidic-based volumetric sampling coupled with automated flow-through desorption and 
online solid phase extraction-LC-MS/MS bioanalysis. Anal Chem 88(13), 6789-6796 (2016). 
42. Tretzel L, Thomas A, Piper T, et al. Fully automated determination of nicotine and its major 
metabolites in whole blood by means of a DBS online-SPE LC-HR-MS/MS approach for sports drug 
testing. J Pharm Biomed Anal 123, 132-140 (2016). 
43. Jones J, Jones M, Plate C, Lewis D. The detection of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanol 
in human dried blood spots. Anal Methods 3(5), 1101-1106 (2011). 
44. Forni S, Pearl P, Gibson K, Yu Y, Sweetman L. Quantitation of gamma-hydroxybutyric acid in dried 
blood spots: feasibility assessment for newborn screening of succinic semialdehyde dehydrogenase 
(SSADH) deficiency. Mol Genet Metab 109(3), 255-259 (2013). 
Chapter 1: Analysis of abused substances using dried blood spots 
 
  
43 
 
45. Goggin M, Lundberg R, Janis G. Measuring circulating levels of 13 opiate and opioid analgesics from 
dried blood spot samples. Presented at: American Association of Pharmaceutical Scientists (AAPS). 
Chicago, USA, 14-17 October 2012. 
46. de Boer T, Wieling J, Meulman E et al. Application of dried blood spot sampling combined with LC-
MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers. Biomed 
Chromatogr 25(10), 1112-1123 (2011). 
47. Odoardi S, Anzillotti L, Strano-Rossi S. Simplifying sample pretreatment: application of dried blood spot 
(DBS) method to blood samples, including postmortem, for UHPLC-MS/MS analysis of drugs of abuse. 
Forensic Sci Int 243, 61-67 (2014). 
48. Abu-Rabie P, Spooner N. Direct quantitative bioanalysis of drugs in dried blood spot samples using a 
thin-layer chromatography mass spectrometer interface. Anal Chem 81(24), 10275-10284 (2009). 
49. Yang J, Pearl M, Jacob Pr et al. Levels of cotinine in dried blood specimens from newborns as a 
biomarker of maternal smoking close to the time of delivery. Am J Epidemiol 178(11), 1648-1654 
(2013). 
50. Verstraete A, Knoche A, Jantos R, et al. DRUID, deliverable 1.4.2. per se limits- methods of defining 
cut-off values for zero tolerance (2011). 
51. Kummer N, Ingels AS, Wille SM, et al. Quantification of phosphatidylethanol 16:0/18:1, 18:1/18:1, and 
16:0/16:0 in venous blood and venous and capillary dried blood spots from patients in alcohol 
withdrawal and control volunteers. Anal Bioanal Chem 408(3), 825-838 (2016). 
52. Edelbroek P, van der Heijden J, Stolk L. Dried blood spot methods in therapeutic drug monitoring: 
methods, assays, and pitfalls. Ther Drug Monit 31(3), 327-336 (2009). 
53. O'Mara M, Hudson-Curtis B, Olson K, Yueh Y, Dunn J, Spooner N. The effect of hematocrit and punch 
location on assay bias during quantitative bioanalysis of dried blood spot samples. Bioanalysis 3(20), 
2335-2347 (2011). 
54. De Kesel P, Sadones N, Capiau S, Lambert W, Stove C. Hemato-critical issues in quantitative analysis of 
dried blood spots: challenges and solutions. Bioanalysis 5(16), 2023-2041 (2013). 
55. van Baar B, Verhaeghe T, Heudi O et al. IS addition in bioanalysis of DBS: results from the EBF DBS-
microsampling consortium. Bioanalysis 5(17), 2137-2145 (2013). 
56. Sosnoff C, Ann Q, Bernert JJ et al. Analysis of benzoylecgonine in dried blood spots by liquid 
chromatography-atmospheric pressure chemical ionization tandem mass spectrometry. J Anal Toxicol 
20(3), 179-184 (1996). 
57. Abu-Rabie P, Denniff P, Spooner N, Brynjolffssen J, Galluzzo P, Sanders G. Method of applying internal 
standard to dried matrix spot samples for use in quantitative bioanalysis. Anal Chem 83(22), 8779-
8786 (2011). 
58. Zimmer D, Hassler S, Betschart B, Sack S, Fankhauser C, Loppacher M. Internal standard application to 
dried blood spots by spraying: investigation of the internal standard distribution. Bioanalysis 5(6), 711-
719 (2013). 
Chapter 1: Analysis of abused substances using dried blood spots 
 
  
44 
 
59. Abu-Rabie P, Denniff P, Spooner N, Chowdhry BZ, Pullen FS. Investigation of different approaches to 
incorporating internal standard in DBS quantitative bioanalytical workflows and their effect on 
nullifying hematocrit-based assay bias. Anal Chem 87(9), 4996-5003 (2015). 
60. Manicke NE, Abu-Rabie P, Spooner N, Ouyang Z, Cooks RG. Quantitative analysis of therapeutic drugs 
in dried blood spot samples by paper spray mass spectrometry: an avenue to therapeutic drug 
monitoring. J Am Soc Mass Spectrom 22(9), 1501-1507 (2011). 
61. Mommers J, Mengerink Y, Ritzen E, Weusten J, van der Heijden J, van der Wal S. Quantitative analysis 
of morphine in dried blood spots by using morphine-d3 pre-impregnated dried blood spot cards. Anal 
Chim Acta 774, 26-32 (2013). 
62. Sadones N, Archer JR, Ingels AM, et al. Do capillary dried blood spot concentrations of gamma-
hydroxybutyric acid mirror those in venous blood? A comparative study. Drug Test Anal 7(4), 336-340 
(2015). 
63. Ellefsen KN, da Costa JL, Concheiro M, et al. Cocaine and metabolite concentrations in DBS and venous 
blood after controlled intravenous cocaine administration. Bioanalysis 7(16), 2041-2056 (2015). 
64. Bland J, Altman D. Stastistical methods for assessing agreement between two methods of clinical 
measurement. Lancet 1(8476), 307-310 (1986). 
65. Stockl D, Dewitte K, Thienpont L. Validity of linear regression in method comparison studies: is it 
limited by the statistical model or the quality of the analytical input data? Clin Chem 44(11), 2340-
2346 (1998). 
66. Dewitte K, Fierens C, Stockl D, Thienpont L. Application of the Bland-Altman plot for interpretation of 
method-comparison studies: A critical investigation of its practice. Clin Chem 48(5), 799-801 (2002). 
67. Garcia Boy R, Henseler J, Mattern R, Skopp G. Determination of morphine and 6-acetylmorphine in 
blood with use of dried blood spots. Ther Drug Monit 30(6), 733-739 (2008). 
68. Capiau S, Stove V, Lambert W, Stove C. Prediction of the hematocrit of dried blood spots via potassium 
measurement on a routine clinical chemistry analyzer. Anal Chem 85(1), 404-410 (2013). 
69. De Kesel PM, Capiau S, Stove VV, Lambert WE, Stove CP. Potassium-based algorithm allows correction 
for the hematocrit bias in quantitative analysis of caffeine and its major metabolite in dried blood 
spots. Anal Bioanal Chem 406(26), 6749-6755 (2014). 
70. Capiau S, Wilk LS, Aalders MC, Stove CP. A novel, nondestructive, dried blood spot-based hematocrit 
prediction method using noncontact diffuse reflectance spectroscopy. Anal Chem 88(12), 6538-6546 
(2016). 
71. Oostendorp M, El Amrani M, Diemel EC, Hekman D, van Maarseveen EM. Measurement of hematocrit 
in dried blood spots using near-infrared spectroscopy: robust, fast, and nondestructive. Clin Chem 
62(11), 1534-1536 (2016). 
72. Sosnoff C, Bernert J. Analysis of cotinine in dried blood spots by LC APCI tandem mass spectrometry. 
Clin Chim Acta 388(1-2), 228-229 (2008). 
Chapter 1: Analysis of abused substances using dried blood spots 
 
  
45 
 
73. Li Y, Henion J, Abbott R, Wang P. The use of a membrane filtration device to form dried plasma spots 
for the quantitative determination of guanfacine in whole blood. Rapid Commun Mass Spectrom 
26(10), 1208-1212 (2012). 
74. Kim JH, Woenker T, Adamec J, Regnier F. Simple, miniaturized blood plasma extraction method. Anal 
Chem 85(23), 11501-11508 (2013). 
75. Sturm R, Henion J, Abbott R, Wang P. Novel membrane devices and their potential utility in blood 
sample collection prior to analysis of dried plasma spots. Bioanalysis 7(16), 1987-2002 (2015). 
76. Ryona I, Henion J. A book-type dried plasma spot card for automated flow-through elution coupled 
with on-line SPE-LC-MS/MS bioanalysis of opioids and stimulants in blood. Anal Chem in press (2016). 
77. Alfazil A, Anderson R. Stability of benzodiazepines and cocaine in blood spots stored on filter paper. J 
Anal Toxicol 32(7), 511-515 (2008). 
78. Jantos R, Vermeeren A, Sabljic D, Ramaekers J, Skopp G. Degradation of zopiclone during storage of 
spiked and authentic whole blood and matching dried blood spots. Int J Legal Med 127(1), 69-76 
(2013). 
79. Skopp G. Blood spot analysis. Presented at: Joint Meeting of the ICADTS and TIAFT. Seattle, WA, USA, 
26-30 August 2007. 
80. Ambach L, Redondo H, Konig S, Weinmann W. Rapid and simple LC-MS/MS screening of 64 novel 
psychoactive substances using dried blood spots. Drug Test Anal 6(4), 367-375 (2013). 
81. Sorensen L. Determination of cathinones and related ephedrines in forensic whole-blood samples by 
liquid-chromatography-electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol 
Biomed Life Sci 879(11-12), 727-736 (2011). 
82. Johnson R, Botch-Jones S. The stability of four designer drugs: MDPV, mephedrone, BZP and TFMPP in 
three biological matrices under various storage conditions. J Anal Toxicol 37(2), 51-55 (2013). 
83. Berankova K, Mutnanska K, Balikova M. Gamma-hydroxybutyric acid stability and formation in blood 
and urine. Forensic Sci Int 161(2-3), 158-162 (2006). 
84. Zorntlein S, Kopp A, Becker J, Kaufmann T, Rohrich J, Urban R. In vitro production of GHB in blood and 
serum samples under various storage conditions. Forensic Sci Int 214(1-3), 113-117 (2012). 
85. Aradottir S, Seidl S, Wurst F, Jonsson B, Alling C. Phosphatidylethanol in human organs and blood: a 
study on autopsy material and influences by storage conditions. Alcohol Clin Exp Res 28(11), 1718-
1723 (2004). 
86. Helander A, Zheng Y. Molecular species of the alcohol biomarker phosphatidylethanol in human blood 
measured by LC-MS. Clin Chem 55(7), 1395-1405 (2009). 
87. Huestis M, Verstraete A, Kwong T, Morland J, Vincent M, de la Torre R. Oral fluid testing: promises and 
pitfalls. Clin Chem 57(6), 805-810 (2011). 
88. De Kesel PMM, Lambert WE, Stove CP. The role of (bio)markers in hair analysis. In: New sampling 
strategies in toxicology and therapeutic drug monitoring (ebook), Stove CP (Ed), Future Science Ltd, 
121-134 (2015). 
Chapter 1: Analysis of abused substances using dried blood spots 
 
  
46 
 
89. Cooper G, Kronstrand R, Kintz P. Society of Hair Testing guidelines for drug testing in hair. Forensic Sci 
Int 218(1-3), 20-24 (2012). 
90. Trudeau S, Mineau P, Cartier G et al. Using dried blood spots stored on filter paper to measure 
cholinesterase activity in wild avian species. Biomarkers 12(2), 145-154 (2007). 
91. Jantos R, Skopp G. Comparison of drug analysis in whole blood and dried blood spots. Toxichem 
Krimtech 78, 268-275 (2011). 
92. Huestis M, Henningfield J, Cone E. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-
THC and THCCOOH during and after smoling marijuana. J Anal Toxicol 16(5), 276-282 (1992). 
93. Kyriakou C, Marchei E, Scaravelli G, Garcia-Algar O, Supervia A, Graziano S. Identification and 
quantification of psychoactive drugs in whole blood using dried blood spot (DBS) by ultra-performance 
liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 128, 53-60 (2016). 
94. Thomas A, Geyer H, Schanzer W et al. Sensitive determination of prohibited drugs in dried blood spots 
(DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer. Anal 
Bioanal Chem 403(5), 1279-1289 (2012). 
95. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 4(8), 1770-1804 (2007). 
96. Antelo-Dominguez A, Cocho J, Tabernero M, Bermejo A, Bermejo-Barrera P, Moreda-Pineiro A. 
Simultaneous determination of cocaine and opiates in dried blood spots by electrospray ionization 
tandem mass spectrometry. Talanta 117, 235-241 (2013). 
97. Henderson L, Powell M, Hannon W et al. An evaluation of the use of dried blood spots from newborn 
screening for monitoring the prevalence of cocaine use among childbearing women. Biochem Mol 
Med 61(2), 143-151 (1997). 
98. Parker S, Cubitt W. The use of the dried blood spot sample in epidemiological studies. J Clin Pathol 
52(9), 633-639 (1999). 
99. Mei J, Alexander J, Adam B, Hannon W. Use of filter paper for the collection and analysis of human 
whole blood specimens. J Nutr 131(5), 1631S-1636S (2001). 
100. Clavijo C, Hoffman K, Thomas J et al. A sensitive assay for the quantification of morphine and its active 
metabolites in human plasma and dried blood spots using high-performance liquid chromatography-
tandem mass spectrometry. Anal Bioanal Chem 400(3), 715-728 (2011). 
101. Jantos R, Schumacher M, Skopp G. Comparison of opioid analysis in whole blood and dried blood 
spots. Presented at: 49th Annual Meeting of The International Association of Forensic Toxicologists 
(TIAFT). San Francisco, CA, USA, 25-30 September 2011. 
102. Baselt R. In: Disposition of toxic drugs and chemicals in man (9th edition) Biomedical Publications, 
Foster City, CA, USA (2011). 
103. Clavijo C, Thomas J, Cromie M et al. A low blood volume LC-MS/MS assay for the quantification of 
fentanyl and its major metabolites norfentanyl and despropionyl fentanyl in children. J Sep Sci 34(24), 
3568-3577 (2011). 
Chapter 1: Analysis of abused substances using dried blood spots 
 
  
47 
 
104. Moll V, Clavijo C, Cohen M, Christians U, Galinkin J. A analytical method to determine ketamine and 
norketamine levels in dried blood spots. Presented at: Annual Meeting of the American Society of 
Anesthesiologists (ASA). New Orleans, LA, USA, 17-21 October 2009. 
105. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report. 
http://www.emcdda.europa.eu/attachements.cfm/att_239505_EN_TDAT15001ENN.pdf 
106. Mercolini L, Protti M, Catapano MC, Rudge J, Sberna AE. LC-MS/MS and volumetric absorptive 
microsampling for quantitative bioanalysis of cathinone analogues in dried urine, plasma and oral fluid 
samples. J Pharm Biomed Anal 123, 186-194 (2016). 
107. Mercolini L, Protti M. Biosampling strategies for emerging drugs of abuse: towards the future of 
toxicological and forensic analysis. J Pharm Biomed Anal 130, 202-219 (2016). 
108. Maenhout T, De Buyzere M, Delanghe J. Non-oxidative ethanol metabolites as a measure of alcohol 
intake. Clin Chim Acta 415, 322-329 (2013). 
109. Crunelle C, Yegles M, van Nuijs A et al. Hair ethyl glucuronide levels as a marker for alcohol use and 
abuse: a review of the current state of the art. Drug Alcohol Depend 134, 1-11 (2014). 
110. Hernández Redondo A, Schroeck A, Kneubuehl B, Weinmann W. Determination of ethyl glucuronide 
and ethyl sulfate from dried blood spots. Int J Legal Med 127(4), 769-775 (2013). 
111. Faller A, Richter B, Kluge M, Koenig P, Seitz H, Skopp G. Stability of phosphatidylethanol species in 
spiked and authentic whole blood and matching dried blood spots. Int J Legal Med 127(3), 603-610 
(2013). 
112. Faller A, Richter B, Kluge M et al. LC-MS/MS analysis of phosphatidylethanol in dried blood spots 
versus conventional blood specimens. Anal Bioanal Chem 401(4), 1163-1166 (2011). 
113. Bakhireva L, Leeman L, Savich R et al. The validity of phosphatidylethanol in dried blood spots of 
newborns for the identification of prenatal alcohol exposure. Alcohol Clin Exp Res 38(4), 1078-1085 
(2014). 
114. Bakhireva L, Savich R, Raisch D et al. The feasibility and cost of neonatal screening for prenatal alcohol 
exposure by measuring phosphatidylethanol in dried blood spots. Alcohol Clin Exp Res 37(6), 1008-
1015 (2013). 
115. Searles Nielsen S, Dills R, Glass M, Mueller B. Accuracy of prenatal smoking data from Washington 
Statebirth certificates in a population-based sample with cotinine measurements. Ann Epidemiol 
24(3), 236-239 (2014). 
116. Marin LJ, Tyrrel-Pawlowic CA, Moroney EC, Coopersmith BI, Shet MS. Comparative analysis of 
buprenorpine and oxycodone in human dried blood spots (DBS) using LC-MS/MS. Presented 
at: American Association of Pharmaceutical Scientists (AAPS)- Pharmaceutical Sciences World 
Congress. New Orleans, LA, USA, 14-18 November 2010. 
117. Havard G, Théberge MC, Boudreau N, Lévesque A, Massé R. Development and validation of a  
 dried blood spot assay for the determination of midazolam in human whole blood by  
 LCMSMS. Presented at: American Association of Pharmaceutical Scientists (AAPS)- 
Pharmaceutical Sciences World Congress. New Orleans, LA, USA, 14-18 November 2010. 
Chapter 1: Analysis of abused substances using dried blood spots 
 
  
48 
 
118. Havard G, Théberge MC, Boudreau N, Lévesque A, Pellerin B. Determination of midazolam in human 
plasma and whole blood: comparison of dried blood spot and different collection procedure. 
Presented at: American Association of Pharmaceutical Scientists (AAPS). Washington, USA, 23-27 
October 2011. 
119. Lad R. Validation of individual quantitative methods for determination of cytochrome P450 probe 
substrates in human dried blood spots with HPLC-MS/MS. Bioanalysis 2(11), 1849-1861 (2010). 
120. Mather J, Rainville P, Spooner N, Evans C, Smith N, Plumb R. Rapid analysis of dried blood spot samples 
with sub-2-microm LC-MS/MS. Bioanalysis 3(4), 411-420 (2011). 
121. Jantos R, Veldstra J, Mattern R, Brookhuis K, Skopp G. Analysis of 3,4-
methylenedioxymetamphetamine: whole blood versus dried blood spots. J Anal Toxicol 35(5), 269-273 
(2011). 
122. Lee H, Park Y, Jo J, et al. Analysis of benzodiazepines and their metabolites using DBS cards and LC-
MS/MS. Forensic Sci Int 255, 137-145 (2015).  
 
  
  
49 
 
 
 
CHAPTER 2:  
CORRELATION OF GHB CONCENTRATIONS  
BETWEEN vDBS AND cDBS 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
         
 Based on 
Sadones N, Archer JR, Ingels AM, Dargan PI, Wood DM, Wood M, Neels H, Lambert WE, Stove CP. Do capillary 
dried blood spot concentrations of gamma-hydroxybutyric acid mirror those in venous blood? A comparative 
study. Drug Test Anal 7(4), 336-340 (2015).  
Chapter 2: Correlation of GHB concentrations between vDBS and cDBS 
 
  
50 
 
Abstract 
Gamma-hydroxybutyric acid (GHB) is a well-known illicit club and date-rape drug. Dried blood spot (DBS) 
sampling is a promising alternative for classical venous sampling in cases of (suspected) GHB intoxication since 
it allows rapid sampling, which is of interest for the rapidly metabolized GHB. However, there is limited data if  
-and how- capillary DBS concentrations correlate with venous concentrations. We conducted a comparative 
study in 50 patients with suspected GHB intoxication, to determine and to correlate GHB concentrations in 
venous DBS (vDBS) and capillary DBS (cDBS). This is the first study that evaluates in a large cohort the 
correlation between capillary and venous concentrations of an illicit drug in real-life samples. Of the 50 paired 
samples, 7 were excluded: the vDBS concentration was below the LLOQ of 2 µg/mL in 3 cases and 4 samples 
were excluded after visual inspection of the DBS. Bland-Altman analysis revealed a mean % difference of -2.8% 
between cDBS and vDBS concentrations, with the zero value included in the 95% confidence interval of the 
mean difference in GHB concentration. A paired sample T-test confirmed this observation (p = 0.17). Also the 
requirement for incurred sample reproducibility was fulfilled: for more than 2/3 of the samples the 
concentrations obtained in cDBS and those in vDBS were within 20% of their mean. Since equivalent 
concentrations were observed in cDBS and vDBS, blood obtained by fingerprick can be considered a valid 
alternative for venous blood for GHB determination. 
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2.1 Introduction 
Gamma-hydroxybutyric acid (GHB) and its precursor gamma-butyrolactone (GBL) are used as recreational drug 
and date-rape drug, particulary in a nightclub environment and in men having sex with men. There have been 
many cases of GHB intoxication, also in combination with other drugs of abuse [1-4]. Toxicological 
interpretation of GHB concentrations in clinical and forensic samples is impeded by its endogenous presence. 
Furthermore, given the short half-life of GHB, rapid sampling is needed [5]. Dried blood spot (DBS) sampling has 
been proposed as a possible alternative for classical venipuncture, offering several advantages, in particular 
rapid and easy collection of a representative sample and easy sample transfer and storage [6]. A number of 
studies have provided a proof-of-concept of the potential to determine abused substances, including GHB, in 
DBS samples [7]. However, these studies have generally not assessed the developed methodology in a large 
cohort of patients, comparing capillary samples with the gold standard of venous samples. In addition, in most 
reports a cross-comparison between venous DBS (vDBS) and capillary DBS (cDBS) concentrations is lacking [7]. 
Therefore, although DBS sampling is an interesting and promising alternative to classical venous sampling, it 
remains to be demonstrated if cDBS concentrations correlate with those in venous samples. While we 
previously demonstrated in our laboratory that GHB can be quantitatively determined in DBS of patients with a 
GHB/GBL intoxication and in narcoleptic patients taking the medication Xyrem® (sodium oxybate, the sodium 
salt of GHB) [8-10], the aim of this study was to compare GHB concentrations in vDBS and cDBS in a large 
cohort of patients with acute GHB intoxication. 
 
2.2 Materials and methods 
The derivatization reagents trifluoroacetic anhydride and heptafluorobutanol, as well as the sodium salt of GHB 
were purchased from Sigma-Aldrich (Diegem, Belgium). The internal standard GHB-D6 was obtained from 
Lipomed (Arlesheim, Switzerland). Suprasolve methanol and ethyl acetate were provided by Merck (Darmstadt, 
Germany). The sodium fluoride/potassium oxalate (NaF-KOx) blood collection tubes (9 mL tubes with 100 mg 
sodium fluoride and 22.50 mg potassium oxalate) were obtained from Terumo (Leuven, Belgium).   
 
2.2.1 Samples 
This study was approved by The UK National Research Ethics Service (Reference 11/LO/0976). All patients 
presenting to the emergency department at Guy’s and St Thomas’ Hospital, London between February and 
December 2013 with either a clinical diagnosis or other indications of GHB/GBL intoxication were considered 
for inclusion. cDBS were generated by non-volumetric direct application of a blood drop from the fingertip onto 
Whatman filter paper following a fingerprick. vDBS were obtained by pipetting 25 µL of venous blood from the 
NaF-KOx blood tubes in which the venous samples were collected and stored. DBS were dried for at least 2 
hours before storage at room temperature in zip-closure plastic bags with desiccant. Paired cDBS and venous 
whole blood samples were collected at the time of admission from 99 patients. As these patients were 
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generally drowsy or agitated at presentation, informed consent was not possible prior to the collection of 
samples and therefore delayed consent was employed. Of the patients sampled, 50 provided delayed consent. 
The paired samples obtained from these 50 patients were used in this study. 
 
2.2.2 Analytical procedures 
GHB concentrations in DBS were determined using a validated gas chromatography coupled to mass 
spectrometry (GC-MS)-based procedure [9]. Briefly, 6-mm partial-spot punches were taken from the DBS. After 
adding the internal standard (IS) GHB-D6, the DBS punches were subjected to “on-spot derivatization” by direct 
application of a mixture of 50 µL trifluoroacetic acid anhydride and heptafluorobutanol (2:1) and heating for 10 
min at 60°C. After evaporation under a gentle stream of nitrogen, the dried extract was re-dissolved in 100 µL 
ethyl acetate and 1 µL was injected into an Agilent 6890 GC system coupled to a 5973 MS. Of those DBS with a 
GHB concentration above 100 µg/mL, 10 µL of the final derivatized extract was diluted to 100 µL with ethyl 
acetate.  
 
Venous whole blood samples were analyzed according to the procedure of Van hee et al. [11]. Briefly, after 
adding the IS 1,3-propylene glycol and the catalyst dimethylformamide to 20 µL of whole blood, the samples 
were directly derivatized with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) at 70°C for 15 min. Following 
centrifugation, an aliquot was injected into a GC-MS sytem.  
 
2.2.3 Storage experiment 
To evaluate GHB stability in venous whole blood (collected in NaF-KOx tubes), we added two different 
concentrations (10 and 100 µg/mL) in whole blood and stored the samples at different temperatures (4°C and 
room temperature) for up to 2 weeks. At different time points, 25-µL DBS were generated from this spiked 
blood, which were analyzed using the above-mentioned DBS-based GC-MS method of Ingels et al. [9]. 
 
2.2.4 Data analysis 
To evaluate the correlation between venous and capillary concentrations, we performed a paired sample T-
test, using Microsoft Excel® 2010 (Microsoft, Redmond, WA, USA), and Bland-Altman and Passing-Bablok 
analysis, using MedCalc® (MedCalc software bvba, Ostend, Belgium). 
 
A p-value ≤ 0.05 was considered statistically significant. In the Bland-Altman plot, the differences between 
venous and capillary concentrations were plotted against the average of both measurements. Indicated in this 
plot are the mean difference between both concentrations and the limits of agreement (1.96 SD), along with 
the respective 95% confidence intervals. In the Passing-Bablok scatter plot diagram, capillary concentrations 
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were plotted against venous concentrations. If the confidence interval of the slope includes 1, there is no 
proportional difference between both measurements. When the confidence interval of the intercept value 
includes 0, it can be concluded that there is no systematic difference between both methods.  
 
2.3 Results and discussion 
Of the 50 paired samples, 7 were excluded: the venous blood concentration was below the LLOQ in 3 cases, 
while 4 samples were excluded after visual inspection of the DBS (in 3 cases cDBS samples were too small (< 6 
mm diameter) and in one case vDBS had an irregular shape). cDBS concentrations of GHB ranged from 41 to 
646 µg/mL, whereas vDBS concentrations ranged from 48 to 705 µg/mL. Clinically, all patients -apart from the 3 
patients with a venous concentration below LLOQ- had clinical symptoms consistent with acute GHB 
intoxication.  
 
In literature, a cut-off GHB concentration of 4-5 µg/mL in blood has been proposed to differentiate between 
endogenous and exogenous GHB [5,12-14]. In our study, 43 patients were screened positive for GHB: both 
venous and capillary concentrations were well above these cut-off levels. In the 3 cases of our study that did 
not have symptoms of acute GHB intoxication, venous concentrations were below the limit. However, GHB 
intake is likely as clearly higher signals were detected than those found in GHB-naïve persons (see Figure 2.1).  
 
 
Figure 2.1 Overlay of representative chromatograms obtained by analyzing (a) vDBS of a GHB-naïve person,  
(b) vDBS of a patient with assumed GHB intake (GHB concentration < 2 µg/mL), (c) vDBS with a GHB 
concentration of 2 µg/mL (LLOQ), (d) vDBS of a GHB-intoxicated person (GHB concentration of 48 µg/mL), using 
a DBS-based GC-MS method [9].  
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These cases presented to the hospital with clinical symptoms consistent with recent stimulant use or secondary 
to GHB withdrawal rather than acute intoxication. In all 3 cases, there was some evidence that GHB use may 
have taken place more than 5 hours before sampling (e.g. history of GHB abuse, declared GHB use,…). 
However, it was not possible to formally confirm GHB use in these patients, as urine samples were not 
routinely collected. As suggested by these 3 cases, rapid sampling is of utmost importance since GHB is 
metabolized rapidly, with a half-life of less than one hour, resulting in blood concentrations below proposed 
cut-off levels within a few hours after use [15,16]. Shima and colleagues proposed lowering the cut-off to  
1 µg/mL in blood in cases where in-life blood specimens can be collected aseptically and stored at 4°C or lower 
before timely analysis [17]. In legal cases, cDBS samples may provide the advantage that they may not only 
allow rapid sampling, but also stabilise the sample, allowing long-term storage at room temperature [9]. 
 
We performed Bland-Altman analysis to compare cDBS and vDBS concentrations. As can be seen in Figure 2.2a, 
we found a mean % difference of -2.8%, with the zero value included in the 95% confidence interval of the 
mean difference in GHB concentration. From this, it can be concluded that there is no significant difference 
between cDBS and vDBS concentrations. A paired sample T-test confirmed this conclusion (p = 0.17). We also 
applied the European Medicines Agency (EMA) guideline for incurred sample reanalysis in bioanalytical method 
validation [18]. These state that the concentration obtained for the initial analysis and the concentration 
obtained by reanalysis should be within 20% of their mean for at least 67% of the repeats. Although this 
requirement actually concerns reanalysis of the same samples, this condition was still fulfilled when analyzing 
different (cDBS versus vDBS) samples: in 72% of cases the concentrations obtained in cDBS and those in vDBS 
were within 20% of the mean GHB concentrations obtained with the 2 methods. As can be seen in Figure 2.2b, 
a Passing-Bablok scatter plot also demonstrated a good overall correlation between cDBS and vDBS GHB 
concentrations, although 1 was just not included in the 95% confidence interval of the slope. 
 
In addition to performing a pairwise comparison between cDBS and vDBS, we also performed reanalysis of both 
cDBS (n = 29) and vDBS (n = 28). Again, the EMA requirement for incurred sample reanalysis was fulfilled: we 
found that for more than two-thirds (i.e. 70%) of the samples the initial concentration and the concentration 
obtained by reanalysis, were within 20% of the mean of the first and repeat measurement.  
 
When comparing DBS values with those obtained from venous blood (using another procedure in another 
laboratory), the latter were significantly lower (p < 0.005) although the differences remained limited: Bland-
Altman analysis revealed a mean % difference of -9.2% and -13% between venous whole blood and respectively 
cDBS and vDBS (Figures 2.3 and 2.4). Also here, the EMA guidelines for incurred sample reanalysis were 
fulfilled: in 77% of the cases the concentrations obtained in cDBS and those in venous whole blood were within 
20% of the mean GHB concentrations; also for more than two-thirds of the samples, the vDBS concentrations 
and the concentrations obtained from venous whole blood were within 20% of their mean. It is unclear if the 
observed difference between concentrations in venous blood and in DBS prepared thereof can be ascribed to 
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the DBS approach per se or rather is the result of differences in calibration between the distinct analyzing 
laboratories.   
 
 
 
Figure 2.2 (a) Bland-Altman analysis of cDBS and vDBS, plotting the % differences between both GHB 
concentrations (y-axis) against the average of these results (x-axis). The mean difference and the limits of 
agreement (set to 1.96 SD) are also indicated with its 95% confidence interval. (b) Passing-Bablok regression 
analysis of cDBS and vDBS, plotting the concentrations in both matrices against each other. The solid line 
illustrates the regression line, the dashed lines indicate the confidence interval for the regression line and the 
dotted line corresponds to the identity line.  
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Figure 2.3 (a) Bland-Altman analysis of cDBS and venous whole blood, plotting the % differences between both 
GHB concentrations (y-axis) against the average of these results (x-axis). The mean difference and the limits of 
agreement (set to 1.96 SD) are also indicated with its 95% confidence interval. (b) Passing-Bablok regression 
analysis of cDBS and venous whole blood, plotting the concentrations in both matrices against each other. The 
solid line illustrates the regression line, the dashed lines indicate the confidence interval for the regression line 
and the dotted line corresponds to the identity line.  
 
It should be noted that, while cDBS and venous blood were sampled at almost the same time point, in some 
cases, there was a delay of several days before vDBS were prepared from the venous blood. To exclude that 
this may have an effect on our results, we evaluated GHB stability in spiked venous whole blood collected in 
NaF-KOx tubes that were stored for up to two weeks at 4°C and at room temperature before DBS preparation. 
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The bias from nominal concentrations (10 or 100 µg/mL) did not exceed 11%. This suggests that no substantial 
alteration takes place in GHB concentration if venous blood, collected in NaF-KOx tubes, is stored under these 
conditions. Although this finding is consistent with previously published data [19-21], it should be noted that in 
incurred (real-life) samples a contribution from e.g. hydrolysis of GHB glucuronide might not be excluded. 
However, such contribution is expected to be limited [22]. 
 
 
 
Figure 2.4 (a) Bland-Altman analysis of vDBS and venous whole blood, plotting the % differences between both 
GHB concentrations (y-axis) against the average of these results (x-axis). The mean difference and the limits of 
agreement (set to 1.96 SD) are also indicated with its 95% confidence interval. (b) Passing-Bablok regression 
analysis of vDBS and venous whole blood, plotting the concentrations in both matrices against each other. The 
solid line illustrates the regression line, the dashed lines indicate the confidence interval for the regression line 
and the dotted line corresponds to the identity line.  
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2.4 Conclusion 
DBS sampling is a promising alternative for classical venous sampling in cases of (suspected) GHB intoxication: 
the DBS sampling technique allows rapid sampling -which is of interest for the rapidly metabolized GHB- and 
DBS are also easier to store and transport than venous samples. The study reported here is the largest 
comparative study to date evaluating capillary and venous concentrations of an illicit drug. In a large cohort of 
patients with acute GHB intoxication we observed equivalent GHB concentrations and an excellent correlation 
between cDBS and vDBS. In conclusion, blood obtained by fingerprick is a valid alternative for venous blood for 
GHB determination. 
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Abstract 
Dried blood spot (DBS) sampling and analysis is increasingly being applied in bioanalysis. Although the use of 
DBS has many advantages, it is also associated with some challenges. E.g. given the limited amount of available 
material, highly sensitive detection techniques are often required to attain sufficient sensitivity. In gas 
chromatography coupled to mass spectrometry (GC-MS), derivatization can be helpful to achieve adequate 
sensitivity. Because this additional sample preparation step is considered as time-consuming, we introduce a 
new derivatization procedure, i.e. “microwave-assisted on-spot derivatization”, to minimize sample 
preparation of DBS. In this approach the derivatization reagents are directly applied onto the DBS and 
derivatization takes place in a microwave instead of via conventional heating. In this Chapter we evaluated the 
applicability of this new concept of derivatization for the determination of two polar low molecular weight 
molecules, gamma-hydroxybutyric acid (GHB) and gabapentin, in DBS using a standard GC-MS configuration. 
The method was successfully validated for both compounds, with imprecision and bias values within 
acceptance criteria (< 20% at LLOQ, < 15% at 3 other QC levels). Calibration lines were linear over the 10-100 
µg/mL and 1-30 µg/mL range for GHB and gabapentin, respectively. Stability studies revealed no significant 
decrease of gabapentin and GHB in DBS upon storage at room temperature for at least 84 days. Furthermore, 
DBS-specific parameters, including hematocrit and volume spotted, were evaluated. As demonstrated by the 
analysis of GHB and gabapentin positive samples, “microwave-assisted on-spot derivatization” proved to be 
reliable, fast and applicable in routine toxicology. Moreover, other polar low molecular weight compounds of 
interest in clinical and/or forensic toxicology, including vigabatrin, beta-hydroxybutyric acid, propylene glycol, 
diethylene glycol, 1,4-butanediol and 1,2-butanediol, can also be detected using this method.  
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3.1 Introduction  
Dried blood spot (DBS) sampling has been associated with many advantages. It is a minimally invasive sampling 
technique enabling rapid (home-)sampling and convenient transport and storage of samples [1,2]. Moreover, it 
offers a reduced risk of infection and in many instances leads to improved compound stability. Furthermore, 
DBS are a convenient sample preparation strategy: they may simplify sample preparation procedures and they 
are suitable for automation of sample processing and analysis [3,4]. Consequently, DBS analysis is an increasing 
field of research, which can be deduced from the rapidly increasing number of published studies on DBS in the 
last decade [2,3].  
 
DBS have been applied in many disciplines such as preclinical and clinical studies, epidemiological research, 
phenotyping, therapeutic drug monitoring and toxicology [3,5-8]. In these applications, mostly liquid 
chromatography coupled to tandem mass spectrometry (LC-MS/MS) has been used [9-11]. Adequate sensitivity 
has also been achieved with other analytical methods, such as direct MS/MS, LC coupled to fluorescence 
detection, LC with ultraviolet detection or gas chromatography coupled to (tandem) mass spectrometry (GC-
MS(/MS)) [10].  
 
GC-MS based analysis of DBS has been described for metabolomic profiling as well as for the detection of a 
wide range of analytes, amongst which pesticides, drugs of abuse, anti-epileptic and antidepressant drugs [11-
16]. GC-MS also still has its place in many forensic toxicology laboratories, for a variety of reasons. First, GC-MS 
remains an important confirmation method in systematic toxicological analysis, complementing LC-MS/MS 
results [17-19]. Second, one single configuration can be used for a variety of compounds with widely varying 
polarity, not requiring a dedicated configuration for determination of a given compound. E.g. while LC-MS/MS 
procedures for the determination of gamma-hydroxybutyric acid (GHB) have been described, these typically 
require the use of hydrophilic interaction liquid chromatography, although reversed phase C18 columns with 
acidified mobile phases have been used as well. However, the latter poses limitations with respect to method 
sensitivity and selectivity [20]. Third, the use of a standard GC-MS configuration also offers the advantage that 
it is a robust and highly selective technique which is widely available at reasonable prices, requiring less 
specialized handling than LC-MS. Additionally, in emerging countries, some laboratories cannot afford buying 
or maintaining expensive LC-MS equipment but do often have a GC-MS system at their disposal. 
 
In many GC-MS based procedures (including those starting from DBS), a derivatization reaction is needed to 
improve the chromatographic properties of the analytes of interest and to achieve adequate method sensitivity 
[10,21]. Although the integration of derivatization techniques may offer several advantages -higher molecular 
weight compounds can more easily be discerned from interfering signals and the chromatographic and/or mass 
spectrometric properties of the target analyte may be improved- this additional sample preparation step is 
often experienced as laborious and tedious. In order to overcome this rate limiting step, we further simplified 
the concept of “on-spot derivatization” that we introduced in Chapter 2 [22]. In this concept, we add the 
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derivatization reagents directly to a DBS, without the use of a separate extraction step. Here, we extend this 
concept towards “microwave-assisted on-spot derivatization”. Microwave derivatization is increasingly being 
applied in a toxicological context [23-30]. To the best of our knowledge, we are the first to combine microwave 
derivatization with “on-spot derivatization”. By doing so, the derivatization step should no longer be 
experienced as a rate-limiting step of the sample workup protocol. An approach bearing some resemblance to 
the “microwave-assisted on-spot derivatization” used here is actually already being applied in proteomics, 
where DBS are subjected to a direct enzymatic digestion in a microwave, allowing quantification of therapeutic 
proteins [31] .  
 
We evaluated the validity of “microwave-assisted on-spot derivatization” in a real setting for the GC-MS based 
determination of two distinct polar low molecular weight compounds, GHB and gabapentin, in DBS (Figure 3.1). 
GHB and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are well-known illicit club and 
date-rape drugs which are often abused in combination with other drugs of abuse [32-35]. Consequently, 
quantification of GHB is important in forensic and clinical toxicology. While determination of the anti-epileptic 
drug gabapentin may be done in the context of therapeutic drug monitoring, this drug is also increasingly 
encountered in the forensic lab, given the increased illegal use of gabapentin [36]. Additionally, to demonstrate 
that our methodology is not limited to these two compounds, we also assessed the applicability of our method 
for the determination of some other polar low molecular weight molecules with relevance in forensic and 
clinical toxicology, including the ketone body beta-hydroxybutyric acid (BHB), the GHB precursor 1,4-BD and its 
isomer 1,2-butanediol (1,2-BD), as well as the glycols propylene glycol (PG) and diethylene glycol (DEG) and the 
anti-epileptic vigabatrin, which is often prescribed together with gabapentin (Figure 3.1).  
 
 
Figure 3.1 Structures of 1,2-BD, 1,4-BD, BHB, DEG, gabapentin, GBL, GHB, PG and vigabatrin. 
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3.2 Materials and methods 
3.2.1 Chemicals and reagents 
1,4-BD, 1,2-BD, DEG, PG, vigababatrin, gabapentin, the sodium salt of BHB and GHB, as well as the 
derivatization reagents (trifluoroacetic anhydride (TFAA), acetic anhydride, pyridine and heptafluorobutanol 
(HFB)) were purchased from Sigma-Aldrich (Diegem, Belgium). Suprasolve methanol, ethyl acetate, toluene and 
hexane were provided by Merck (Darmstadt, Germany). The internal standards (IS) GHB-D6 and gabapentin-
D10 were obtained from Lipomed (Arlesheim, Switzerland) and Sigma-Aldrich (Diegem, Belgium), respectively.  
 
3.2.2 Preparation of calibrators and quality control samples 
Stock solutions were prepared by dissolving respectively 50 mg of BHB, 10 mg of GHB and 10 mg of gabapentin 
in one mL of methanol. For DEG, PG, 1,2-BD and 1,4-BD, we prepared 100 mg/mL stock solutions in methanol. 
Vigabatrin was available as a 1 mg/mL solution in methanol. Quality control samples (QCs) were prepared from 
independent stock solutions. All these stock solutions were stored at -20°C. At the day of analysis, working 
solutions were prepared by dilution of the stock solutions with methanol. These working solutions were used 
to prepare a multi-analyte mix, i.e. a mix containing all of the above-mentioned analytes, being PG, DEG, 1,2-
BD, 1,4-BD, GHB, BHB, vigabatrin and gabapentin. Using this mix, 6 calibration standards (5, 20, 50, 100, 150 
and 200 µg/mL for PG, 1,2-BD and 1,4-BD; 2.5, 10, 20, 40, 75 and 100 µg/mL for DEG; 5, 15, 20, 50, 100 and 300 
µg/mL for BHB; 10, 15, 25, 50, 75 and 100 µg/mL for GHB; 1, 5, 10, 17.5, 22.5 and 30 µg/mL for gabapentin; 5, 
10, 12.5, 17.5, 20 and 30 µg/mL for vigabatrin) and 4 QCs (5, 15, 85 and 175 µg/mL for PG, 1,2-BD and 1,4-BD; 
2.5, 7.5, 50 and 90 µg/mL for DEG; 5, 10, 125 and 250 µg/mL for BHB; 10, 12.5, 30 and 85 µg/mL for GHB; 1, 
2.5, 15 and 25 µg/mL for gabapentin; 5, 7.5, 15 and 25 µg/mL for vigabatrin) were prepared in blood. The 
percentage organic solvent used to prepare calibrators and QCs did not exceed 5%. Finally, DBS were prepared 
by spotting 25 µL of venous whole blood, which was spiked with the above-mentioned polar low molecular 
weight molecules, onto filter paper. For quantification of GHB and gabapentin, we used the IS GHB-D6 and 
gabapentin-D10, which were mixed to obtain final concentrations of 60 and 12 µg/mL, respectively. For the 
quantification of BHB, GHB-D6 was used as IS, whereas for PG, DEG, 1,2- and 1,4-BD and vigabatrin we used 
gabapentin-D10. 
 
3.2.3 Instrumentation 
Analytical standards and QCs were prepared using an AT261 DeltaRange balance of Mettler Toledo (Zaventem, 
Belgium). Three different filter papers, being Whatman 903, Munktell 2460 and Ahlstrom 237, were evaluated. 
Microwave-assisted derivatization was performed in a Samsung ME711K household microwave. Samples were 
centrifuged at room temperature and at 4°C in respectively a MSE Mistral 2000 (Anderlecht, Belgium) and a 
5804R Eppendorf centrifuge (Hamburg, Germany). A Branson 1510 ultrasonic bath (Danbury, Connecticut, USA) 
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was used for sonication of the samples. Evaporation under nitrogen took place at 25°C in a TurboVap LC 
evaporator of Zymark (Hopkinton, Massachusetts, USA). Chromatographic separation was achieved on a 30 m x 
0.25 mm i.d. x 0.25 µm Agilent HP-5MS column in an Agilent 6890-5973 GC-MS system. 
 
3.2.4 Sample preparation  
First, a 6-mm disc was punched out of a 25-µL DBS spot. To this punch, 5 µL IS-mix was added, followed by 
evaporation under nitrogen at 25°C for 10 min. Then, the punches were subjected to “microwave-assisted on-
spot derivatization” by direct application of the derivatization reagents onto the spot. We varied the amount of 
derivatization reagent and the time of heating to evaluate which parameters gave the best results (see 
subsection 3.3.1.1). After the derivatization step, samples were subjected to a short-spin centrifugation at 4°C. 
The excess derivatization reagent was removed by evaporation under nitrogen. Subsequently, 100 µL of 
injection solvent were added to the sample (hexane, toluene and ethyl acetate were tested as injection 
solvent, as described in subsection 3.3.2.1), followed by centrifugation at room temperature for 5 min. Finally, 
one µL of the supernatant of this derivatized extract was injected into the GC-MS system. 
 
3.2.5 Analytical parameters 
Optimization of the analytical parameters was performed as described in subsection 3.3.2. Helium was used as 
carrier gas for the chromatography. We utilized a non-pulsed splitless injection (see subsection 3.3.2.5). In the 
optimized procedure, the flow rate was set at 1.1 mL/min and the injection temperature at 250°C, as described 
in subsections 3.3.2.3 and 3.3.2.2, respectively. The initial oven temperature was 60°C, which was held for 2 
minutes. Then, the temperature ramped at 8°C/min to 110°C, raised 30°C/min until 230°C, followed by an 
increase of 50°C/min to 300°C, which was held for 2 minutes. The transfer line temperature, MS ion source 
temperature and MS quadrupole temperature were set at 300, 230 and 150°C, respectively. The MS was used 
in the electron impact mode. First, the MS was operated in full-SCAN mode to obtain the mass spectrum of the 
derivatized analytes (Figure 3.2). Then, quantifier and qualifier ions were selected for each analyte, allowing to 
use the MS in SIM mode. Quantification was performed in SIM mode using m/z 87, 100 and 116 for PG, 227, 
268 and 285 for BHB, 72, 86, 101 and 117 for 1,2-BD, 227, 240, 268 and 285 for GHB, 231, 245, 273 and 291 for 
GHB-D6, 86, 101 and 114 for 1,4-BD, 84, 111, 125 and 153 for vigabatrin, 87, 117 and 182 for DEG, 153, 167 
and 195 for gabapentin and 163, 177 and 205 for gabapentin-D10. Quantifier ions are underscored.  
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Figure 3.2 Full scan mass spectrum of (a) PG, (b) BHB, (c) 1,2-BD, (d) GHB, (e) 1,4-BD, (f) vigabatrin,  
(g) DEG and (h) gabapentin derivatized with acetic anhydride, pyridine and heptafluorobutanol.   
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Figure 3.2 Continued. 
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Figure 3.2 Continued. 
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Figure 3.2 Continued. 
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3.2.6 Validation 
3.2.6.1 Microwave calibration 
A calorimetric methodology was used to calibrate the microwave (see subsection 3.3.3.1) [37]. To this end, we 
measured the temperature rise of 1 L water after heating for 90 s at 800W (maximum power) for 14 days. 
Then, the power of the microwave required for heating the water was calculated using the following formula:  
∆𝑇 =
𝑃 × 𝑡
𝑉 × Cp ×  𝜌
 
with ∆𝑇 = temperature rise after heating (K); P = microwave power (W); V = volume of water which is heated 
(m3); Cp = heat capacity (J/(kg K)); 𝜌 = density (kg/m3); t = time of heating (s). 
 
In this Chapter, we refer to the effective absorbed power, i.e. 602 ± 15W, when the microwave was set at 
maximum power (see subsection 3.3.3.1).  
 
3.2.6.2 Analytical evaluation 
We validated our newly developed method based upon the Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) guidelines for bioanalytical method validation [38,39]. For that purpose, we evaluated 
linearity, accuracy, precision, selectivity, carry-over, dilution integrity and stability, as well as two DBS-specific 
parameters, i.e. hematocrit (Hct) and volume effect [2,40]. For GHB and gabapentin, our method was 
performed in a real setting and labeled IS were used. Validation parameters were also evaluated for the other 
polar low molecular weight molecules, however, the use of labeled IS is recommended for quantification in a 
real-life application.  
 
To evaluate linearity, six-point calibration lines were constructed in duplicate on three non-consecutive days. 
These calibration lines were prepared by spotting 25 µL of venous whole blood (Hct 0.4) which was spiked with 
our multi-analyte mix. Of these DBS, 6-mm discs were analyzed. The best fitting calibration model was 
evaluated by statistical analysis. Therefore, the ratio of the peak area of the analyte to the peak area of the IS 
was plotted versus the concentration. Then, the slopes and intercepts of the calibration curves were calculated 
using weighted and unweighted linear regression. As described by Almeida et al. [41], a test of 
homoscedasticity should be performed in linear regression analysis. Therefore, we plotted the residuals versus 
the nominal concentrations and performed an F-test at the 99% confidence level. To select the most 
appropriate calibration model, we calculated the sum % residual errors (% RE) and plotted the % RE versus the 
concentration. The % RE was obtained by dividing the difference between found and nominal concentrations 
by the nominal concentration and multiplying by 100%. Linearity was assessed by performing the Fisher’s test. 
 
Samples were considered positive based on retention time and the ratio of the ion fragments. For the 
evaluation of sensitivity, we defined the lower limits of quantification (LLOQs) as the lowest concentrations 
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with an acceptable accuracy and precision. Accuracy, expressed as % bias, was calculated as % deviation from 
the nominal value. Within-day and between-day precision are expressed as % relative standard deviation and 
were calculated using one-way ANOVA, as described by Wille et al. and Peters et al. [42,43]. To this end, QCs 
were prepared at four levels (i.e. LLOQ, low, medium and high level) in duplicate on 3 separate days. Accuracy 
and precision should be within 15%, except for LLOQ where it should be within 20%. The limits of detection 
(LODs) have not been studied. For GHB, a LOD is not so relevant, given the endogenous nature of this 
compound. For gabapentin, the aim was to demonstrate the potential of using capillary DBS (cDBS) in a 
pharmacokinetic study, so also here, demonstrating its presence (far) below the therapeutic range was not 
considered relevant. 
 
To assess selectivity, we evaluated if interfering peaks were seen after analysis of DBS from six different 
sources. Carry-over was evaluated by injecting 3 blank (ethyl acetate) samples following injection of the highest 
concentration of the calibration curve. According to the EMA guidelines, carry-over in the blank sample 
following the high concentration standard should not exceed 20% of the LLOQ and 5% for the IS [39].  
 
We also evaluated dilution integrity by diluting the final derivatized extract instead of diluting the original 
sample as in case of DBS, especially cDBS, the sample cannot be diluted with blank matrix. To this end, we 
spiked blood with an analyte concentration 2x higher than the upper limit of quantification (ULOQ) and 
prepared 25-µL DBS. Of these DBS, a 1:4 dilution of the final derivatized ethyl acetate extract was made. 
Precision and accuracy of these diluted samples should be within 15%, taking the dilution factor into account.  
 
Stock solution stability was evaluated by analyzing low and high QCs (n = 3) after three freeze-thaw cycles and 
after storage for one week at -20°C. Long-term stability in DBS was assessed by analyzing these spots 
immediately after drying and after storage at room temperature for a longer period of time in a zip-closure 
plastic bag with desiccant. All stability studies were analyzed using a freshly prepared calibration curve.  
 
We also assessed the impact of DBS-specific parameters, like Hct and volume effect, on the analytical results. 
This was evaluated by analyzing DBS prepared from blood samples with different Hct values (0.30, 0.40 and 
0.49), of which different volumes of blood (i.e. 25, 35 and 50 µL) were spotted onto the filter paper.  
 
3.2.7 Application 
The applicability of our new approach was demonstrated using DBS obtained from patients and volunteers. For 
GHB, DBS were obtained from patients presenting at the emergency department of the Guy’s and St Thomas’ 
hospital in London with a suspected GHB/GBL intoxication (see subsection 2.2.1). From those patients who had 
a history of GHB abuse or declared GHB use, both venous DBS (vDBS) (prepared by spotting 25 µL of venous 
blood on filter paper) and cDBS (direct application on filter paper following fingerprick) were analyzed. This 
study was approved by the UK National Research Ethics Service (Reference 11/LO/0976). Additionally, our 
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method was applied on cDBS obtained from healthy volunteers participating in a cross-over study investigating 
the bioequivalence of two commercial gabapentin preparations (see subsection 4.2.2). This study was 
approved by the Ethics Committee of Ghent University Hospital (NCT01821235).  
 
3.3 Results and discussion 
3.3.1 Sample preparation 
3.3.1.1 Optimization of the sample preparation 
Microwave-assisted derivatization is increasingly being applied in bioanalysis, including forensic and clinical 
toxicology, to drastically reduce the derivatization time. E.g. Meyer et al. successfully quantified glycols and 
GHB in emergency toxicology using microwave-assisted trimethylsilylation [23]. Microwave-asssisted 
derivatization procedures have also been used for the determination of amphetamines, codeine, morphine, 
tetrahydrocannabinol and new psychoactive substances [24-28, 30]. 
 
For the derivatization of our DBS samples, we combined microwave-assisted derivatization, which results in an 
accelerated time of derivatization and an increased sample throughput, with the approach of “on-spot 
derivatization”, allowing minimization of the DBS sample preparation. The latter concept was previously 
developed in our lab for the GC-MS based determination of the party drug GHB in DBS and is currently applied 
in our routine forensic toxicology cases [44]. Generally, in DBS methods utilizing derivatization, analytes are 
first eluted from the DBS. After evaporation under nitrogen, the extract is then derivatized. Subsequently, the 
excess of derivatization reagent is removed by evaporation, followed by reconstitution of the sample. The “on-
spot derivatization” is a modification to this general procedure. It is a direct derivatization technique in which 
an excess of derivatization reagent is added directly to the matrix (i.e. the DBS), without the use of an 
additional extraction step: the reagent acts both as extracting and derivatizing reagent [10]. Mess et al. also 
utilized “on-spot derivatization” by the pre-treatment of DBS cards with the derivatization reagent prior to 
blood spotting [45]. 
 
When setting up a DBS based method involving “on-spot derivatization”, it needs to be taken into account that 
the filter paper is derivatized as well. We therefore evaluated different blank filter papers to check which filter 
paper showed the lowest number of interferences and found that Whatman 903 filter paper scored best. We 
also opted to use a domestic microwave as we wished to set up a method that would be applicable in a routine 
toxicological laboratory without the use of expensive, dedicated instruments.  
 
Based on Ingels et al. [22] and Damm et al. [24], combinations of TFAA, HFB, acetic anhydride and/or pyridine 
were evaluated to derivatize as many as possible of the above-mentioned polar low molecular weight 
molecules with toxicological relevance (Table 3.1).  
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Table 3.1 Evaluation of different derivatization reagents for the derivatization of various polar low molecular 
weight compounds.  
   GHB Gabapentin BHB 1,4-BD 1,2-BD DEG PG Vigabatrin 
d
er
iv
at
iz
a
ti
o
n
 r
ea
ge
n
ts
 
[TFAA + HFB] + + + - - + - + 
[(AcO)
2
O + pyridine] - - - + + + + - 
[TFAA + HFB + 
(AcO)
2
O + pyridine] 
NA NA NA NA NA NA NA NA 
[(AcO)
2
O + pyridine] & 
[HFB] 
+ + + + + + + + 
[(AcO)
2
O + HFB] - - - - - - - - 
-: not detected  +: detected  NA: not analyzed (not injected)  
 
Whereas a mix of TFAA and HFB could be used for the derivatization of DEG and analogues of gamma-
aminobutyric acid (including GHB, BHB, gabapentin and vigabatrin), acetic anhydride and pyridine could be 
used for the derivatization of the glycols. The simultaneous addition of TFAA, HFB, acetic anhydride and 
pyridine generated a product which could not be injected because of the generation of a dark clot (TFAA being 
the cause). Theoretically, a first derivatization with TFAA and HFB, followed by evaporation and then a second 
derivatization with acetic anhydride and pyridine, seems to be the best choice. However, since this would 
render the method more time-consuming and would be at the expense of the advantages of fast microwave-
assisted derivatization, we did not consider this as an option. Consequently, best results were obtained when 
first an acetylation reaction was performed using acetic anhydride and pyridine, followed by an alkylation step 
with HFB. Two separate reactions were needed as no adequate sensitivity was achieved when acetic anhydride, 
pyridine and HFB were simultaneously added. Although a silylation derivatization could be used as well, this 
derivatization reaction was not chosen as the injection of the excess of derivatization product contaminates the 
whole system and leads to in-situ derivatization of all injected compounds [46,47].  
 
We optimized the main parameters for derivatization, i.e. the time of derivatization and the amount of 
derivatization reagent. To this end, we derivatized our analytes with a derivatization mixture consisting of 
different amounts of acetic anhydride and pyridine. All these combinations were evaluated at different lenghts 
of derivatization time (60, 90, 120 and 180 s), as can be seen in Figure 3.3. Since no significant differences were 
observed between 50 and 60 µL of a mix of acetic anhydride and pyridine (1:1 ratio, i.e. 25 or 30 µL of each 
reagent), we selected the lowest amount (i.e. 50 µL). When comparing a 3:2 with a 1:1 ratio of acetic anhydride 
and pyridine, also here, no significant differences were observed. Finally, we chose an equal amount of both 
reagents. Although longer derivatization times led to higher signals, results became less reproducible as  
-because of pressure build-up- the plugs closing the test tubes tended to come off. 
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Figure 3.3 Influence of different derivatization times and different amounts of acetic anhydride and pyridine on 
the peak area of each analyte (n = 3). Data are presented as percentage of peak area of samples which were 
derivatized for 90 s with 25 µL of acetic anhydride and pyridine, followed by a second derivatization with 25 µL 
of heptafluorobutanol for 90 s. The condition finally chosen is highlighted in red. (A, E, I = 2 x 60 s; B, F, J = 2 x 
90 s; C, G, K = 2 x 120 s; D, H, L = 1 x 180 s, 1x 120 s; A, B, C, D = 30 µL acetic anhydride + 30 µL pyridine + 25 µL 
HFB; E, F, G, H = 25 µL acetic anhydride + 25 µL pyridine + 25 µL HFB; I, J, K, L = 30 µL acetic anhydride + 20 µL 
pyridine + 25 µL HFB) 
 
We also evaluated the influence of the amount of HFB, a derivatization reagent which is added to derivatize 
GHB, BHB, vigabatrin and gabapentin (Figure 3.4).  
 
 
Figure 3.4 Influence of four different amounts of heptafluorobutanol (A = 10 µL, B = 15 µL, C = 20 µL and D =  
25 µL) on the peak area of each analyte. Data are presented as percentage of normalized samples which are 
derivatized with 25 µL of heptafluorobutanol (n = 3). The condition finally chosen is highlighted in red. 
Chapter 3: Microwave-assisted on-spot derivatization of polar low molecular weight compounds 
 
  
76 
 
For the anti-epileptics, no significant differences were observed between the largest amount of HFB, i.e. 25 µL, 
and the smallest amount of derivatization reagent, i.e. 10 µL. However, for BHB and especially for GHB, best 
results were obtained with 25 µL of HFB. Consequently, in our optimized procedure, the same amount of acetic 
anhydride, pyridine and HFB, i.e. 25 µL of each reagent, is added. It is worth noting that diols only had to be 
acetylated to improve their volatility. Consequently, the second derivatization step in our protocol is no added-
value for the glycols. Therefore, if one is not interested in GHB, BHB, vigabatrin or gabapentin, the second 
derivatization could be omitted. In that case, the sample preparation is even faster and also allows the 
detection of other glycols, like ethylene glycol. 
 
3.3.1.2 Final sample preparation 
The final optimized protocol is as follows: first a 6-mm disc is punched out of a 25-µL DBS. To this punch, 5 µL IS 
mix, containing 60 µg/mL GHB-D6 and 12 µg/mL gabapentin-D10, is added, followed by evaporation under 
nitrogen at 25°C for 10 min. Then, the punches are subjected to “microwave-assisted on-spot derivatization” by 
direct application of 25 µL acetic anhydride and 25 µL pyridine to the punches and microwave heating for 90 s, 
followed by a short-spin centrifugation at 4°C. Subsequently, a second microwave derivatization is performed 
for 90 s by adding 25 µL HFB, after which the samples are subjected to a short-spin centrifugation at 4°C. After 
evaporation under nitrogen, the spots are reconstituted in 100 µL ethyl acetate and centrifuged at room 
temperature for 5 min. Finally, one µL of the supernatant of this derivatized extract is injected into the GC-MS 
system.  
 
Noteworthy is that our derivatization step only takes 3 min (2 x 90 s), twice followed by a short-spin 
centrifugation step, whereas, without microwave assistance, derivatization times of 30 min are not unusual. 
Following the removal of the excess of derivatization reagent by evaporation, ethyl acetate was added to the 
samples. The latter sample preparation step takes about 10 min (5 min sonication + 5 min centrifugation). 
Conclusively, we have developed a fast sample preparation method for DBS (estimated time of sample 
preparation is about 15 min (time of evaporation not included)). 
 
3.3.2 Analytical parameters 
3.3.2.1 Optimization of injection solvent 
Ethyl acetate, hexane and toluene were tested as injection solvent. However, it has to be noted that the choice 
of injection solvent may have an influence on the GC temperature program as the start temperature should be 
20°C lower than the boiling point of the injection solvent. Consequently, the higher the boiling point, the higher 
the start temperature, the shorter the total run time. More specifically, the temperature program should start 
at 45, 60 and 90°C with respectively hexane, ethyl acetate and toluene. We observed that only ethyl acetate 
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could be used as injection solvent as GHB and vigabatrin could not be detected when using hexane as injection 
solvent, whereas PG was not detectable if toluene was used. 
 
3.3.2.2 Optimization of injection temperature 
The injection temperature should allow vaporization of the analytes and avoid degradation of the compounds 
and/or tailing peaks. Therefore, injection temperatures of 200, 250 and 300°C were evaluated. As can be seen 
in Figure 3.5, similar results were obtained with an injection temperature of 200, 250 and 300°C. Eventually, we 
opted for an injection temperature of 250°C.  
 
 
Figure 3.5 Influence of three different injection temperatures (A = 200°C, B = 250°C and C = 300°C) on the peak 
area of each analyte. Data are presented as percentage of normalized samples which are injected with an 
injection temperature of 250°C (n = 3). The condition finally chosen is highlighted in red. 
 
3.3.2.3 Optimization of flow rate 
The flow rate corresponds to the speed of the carrier gas (i.e. helium) through the column and this may 
influence the resolution. Since different flow rates had no influence on the baseline separation, peak areas 
were compared to each other (Figure 3.6). Data are presented as percentage of peak areas obtained for 
samples analyzed at a flow rate of 1.1 mL/min. Flow rates of 1, 1.3 and 1.5 mL/min resulted in lower peak areas 
for GHB, whereas a flow rate of 1.3 mL/min resulted in lower peak areas for 1,4-BD. For PG and DEG, the higher 
the flow rate, the higher the peak areas. Finally, we chose a flow rate of 1.1 mL/min, although the differences 
with other flow rates were minimal.  
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Figure 3.6 Influence of different flow rates (A = 0.7 mL/min, B = 0.9 mL/min, C = 1 mL/min, D = 1.1 mL/min,  
E = 1.3 mL/min and F = 1.5 mL/min) on the peak area of each analyte. Data are presented as percentage of 
normalized samples with a flow rate of 1.1 mL/min (n = 3). The condition finally chosen is highlighted in red. 
 
3.3.2.4 Optimization of purge activation time 
The purge activation time is the time that the split line opens when using a splitless injection. Best results were 
obtained with a purge activation time of 120 s (Figure 3.7).  
 
 
Figure 3.7 Influence of different purge activation times (A = 45 s, B = 60 s, C = 75 s, D = 90 s and E = 120 s) on 
the peak area of each analyte. Data are presented as percentage of normalized samples with a purge activation 
time of 120 s (n = 3). The condition finally chosen is highlighted in red. 
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3.3.2.5 Optimization of pulsed splitless injection and pulse time 
We also evaluated the influence of an elevated pressure on the top of the column and the resulting sample 
transfer. We concluded that a higher increase of the pressure results in a shorter run. However, this gain in 
time is outweighted by the higher abundances obtained with a non-pulsed splitless injection, as can be seen in 
Figure 3.8.  
 
 
Figure 3.8 Influence of pulsed splitless injection and pulse time. (inset exemplifies the observed elution order, 
with respectively pulsed splitless injection (30 psi) (black color); pulsed splitless injection (25 psi) (red color); 
pulsed splitless injection (20 psi) (green color); non-pulsed splitless injection (blue color)) 
 
3.3.3 Validation 
3.3.3.1 Microwave calibration  
When monitoring the power of the microwave through time, a mean power of 602 ± 15 W was observed. The 
obtained values were plotted in a Shewhart graph (Figure 3.9) and the Westgard rules were applied. These 
rules were not broken. Consequently, the performance of the microwave was considered to be in-control.  
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Figure 3.9 Shewhart graph obtained when plotting the obtained values of the microwave power through time. 
The mean power ± SD (     ), the mean power ± 2 SD (     ) and the mean power ± 3 SD (     ) are displayed.  
 
3.3.3.2 Linearity, precision and accuracy  
Linearity was determined by constructing six-point calibration curves in duplicate on three non-consecutive 
days. In addition, blank and zero samples (blank samples spiked with IS) were injected. A representative 
chromatogram of a spiked blood sample at LLOQ level is given in Figure 3.10.  
 
Table 3.2 summarizes calibration and sensitivity data. Although the R2 values were in some cases below the 
preferred value of 0.99, a lack-of-fit test to evaluate the goodness of fit demonstrated that the calibration 
curves were linear. Additionally, we also applied the EMA guidelines for the evaluation of the calibration curve. 
These state that the target back-calculated concentrations of the calibration standards should be within 15% of 
the nominal value (20% at LLOQ and ULOQ) for at least 75% of calibration standards. This criterion was fulfilled 
for all compounds. The LLOQ of 10 µg/mL for GHB can be considered as a limitation of our procedure as the 
cut-off levels in ante-mortem blood are set at 10, 5 or 4 µg/mL, the lower values being applied most for 
samples taken from living subjects [48-51]. In case of doubt, i.e. GHB concentrations around the LLOQ, the 
original “on-spot derivatization” with TFAA and HFB using conventional heating, which offers a somewhat 
higher sensitivity with an LLOQ at 2 µg/mL, could be performed on a replicate DBS. For the anti-epileptics, our 
calibration ranges cover the therapeutic intervals of 2-20 and 5-25 µg/mL for gabapentin and vigabatrin, 
respectively. BHB concentrations lower than 50 µg/mL are considered as normal, whereas BHB concentrations 
higher than 250 µg/mL are considered as high and pathologically significant [52]. Our concentration range 
covers these cut-off levels. Also concerning 1,4-BD, our concentration range is in line with other quantification 
methods [53,54]. Our method is also appropriate in case of intoxications with DEG and PG since intoxications 
with these glycols are in the high-µg/mL range.  
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Figure 3.10 Representative chromatogram of (a) a DBS spiked with IS and (b) a DBS spiked with all studied 
compounds at LLOQ level.  
 
An overview of accuracy, within-day and between-day precision data is given in Table 3.3. For the analytes for 
which deuterated analogues were used, being GHB and gabapentin, accuracy and precision criteria were met 
for all QC levels. For the other analytes, accuracy and precision were also evaluated although the use of stable 
labeled analogues as IS is recommended for quantification in real practice. While within-day precision criteria 
were met in all instances, slight exceedances of between-day precision criteria (> 15% but still below 20%) were 
seen for 1,4- and 1,2-BD, DEG, PG and vigabatrin. For both BHB and DEG, the bias was slightly above the 
acceptance criteria for two QC levels. For 1,4- and 1,2-BD, as well as for PG, the bias exceeded 20%. Hence, we 
consider the procedure semi-quantitative for these analytes.  
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Table 3.2 Calibration and sensitivity data for the determination of GHB, gabapentin, BHB, 1,4-BD, 1,2-BD, DEG, 
PG and vigabatrin in DBS using GC-MS (n = 3x2). 
 Slope 
mean ± SD 
[95% CI] 
Intercept 
mean ± SD 
[95% CI] 
R2 
Range 
(µg/mL) 
LLOQ 
(µg/mL) 
Weighting  
factor 
GHB 0.033 ± 0.002 
[0.032-0.035] 
0.067 ± 0.058 
[0.020-0.113] 
0.993 10-100 10 1/x 
Gabapentin 0.226 ± 0.008 
[0.220-0.232] 
0.009 ± 0.024 
[-0.010-0.028] 
0.981 1-30 1 1/x 
BHB 0.074 ± 0.004 
[0.071-0.078] 
-0.018 ± 0.075 
[-0.078-0.042] 
0.993 5-300 5 1/x 
1,4-BD 0.065 ± 0.005 
[0.060-0.069] 
-0.011 ± 0.096 
[-0.088-0.066] 
0.986 5-200 5 1/x 
1,2-BD 0.112 ± 0.010 
[0.104-0.120] 
-0.074 ± 0.103 
[-0.156-0.008] 
0.986 5-200 5 1/x 
 
DEG 2.212 ± 0.148 
[2.093-2.330] 
-1.921 ± 1.584 
[-3.188- -0.654] 
0.988 2.5-100 2.5 1/x 
PG 
 
0.068 ± 0.006 
[0.063-0.073] 
-0.100 ± 0.055 
[-0.144- -0.056] 
0.979 5-200 5 1/x 
Vigabatrin 0.062 ± 0.006 
[0.058-0.067] 
-0.029 ± 0.036 
[-0.058- -0.000] 
0.984 5-30 5 1/x 
 
Table 3.3 Accuracy, intra- and interbatch precision for QCs at four concentration levels (n = 3x2). Exceedances 
of the criteria are set in italic. 
 
 GHB Gabapentin BHB 1,4-BD 1,2-BD DEG PG Vigabatrin 
 
 1/x 1/x 1/x 1/x 1/x 1/x 1/x 1/x 
W
it
h
in
-d
ay
 
p
re
ci
si
o
n
 (
%
R
SD
) LLOQ 4.45 10.20 19.30 5.47 0.16 11.52 6.63 13.47 
L QC 7.22 4.88 6.79 11.06 5.22 8.04 5.25 5.50 
M QC 4.59 4.99 8.10 8.03 11.16 5.97 12.19 9.31 
H QC 8.93 9.95 11.58 3.46 5.88 4.11 5.97 12.33 
B
et
w
ee
n
- 
d
ay
 
p
re
ci
si
o
n
 (
%
R
SD
) LLOQ 15.71 11.88 19.30 15.69 0.74 15.97 6.63 13.47 
L QC 12.53 6.88 9.00 14.40 16.53 16.83 18.46 16.11 
M QC 4.93 6.93 9.92 16.77 11.16 14.67 12.19 9.31 
H QC 8.93 8.86 11.58 10.01 7.95 9.05 8.09 12.33 
A
cc
u
ra
cy
 
(%
 b
ia
s)
 
LLOQ 19.44 -6.94 2.25 15.96 15.37 20.58 19.89 -8.19 
L QC 2.04 -6.02 18.41 22.49 32.14 0.33 25.95 -5.05 
M QC 5.88 7.99 6.54 9.50 16.40 18.40 10.13 -5.32 
H QC 6.41 3.73 16.36 14.71 17.86 9.18 13.21 -9.81 
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3.3.3.3 Selectivity, carry-over and dilution integrity 
No interfering peaks or carry-over were observed. For the evaluation of the dilution integrity, we analyzed 6 
DBS which were prepared from 25 µL venous blood which was spiked with analyte concentrations at twice the 
ULOQ level. For all analytes, accuracy and precision were within the acceptance criteria of 15%, as can be seen 
in Table 3.4.  
Table 3.4 Accuracy and precision of samples which were diluted 4-fold. 
 Dilution integrity (n = 6) 
 Accuracy  
(% bias) 
Precision  
(% CV) 
GHB *  12.29 3.64 
Gabapentin -4.93 4.88 
BHB 8.18 9.00 
1,4-BD -6.79 6.63 
1,2-BD -3.35 9.96 
DEG 10.26 13.74 
PG 9.69 7.51 
Vigabatrin 9.02 14.59 
* n = 5 
 
3.3.3.4 Stability 
Stock solutions were stable for at least one week at -20°C. Three freeze-thaw cycles did also not affect the 
stock solution. GHB and gabapentin were found to be stable in DBS stored at room temperature for at least 84 
days, with measured concentrations not deviating more than 7.4 and 4.9% of the concentrations measured at 
time point zero for GHB and gabapentin, respectively. The other analytes were also found to be stable for an 
extended period of time in DBS stored at room temperature.  
 
3.3.3.5 DBS-specific parameters 
For the evaluation of the Hct effect, we prepared blood samples with a low (0.30), medium (0.40) and high Hct 
(0.49). To evaluate the volume effect, different volumes of blood (25, 35 and 50 µL) were spotted onto the 
Whatman filter paper. For the effect of both Hct and volume, the results obtained from 25-µL DBS with a Hct of 
0.40 were taken as a reference. For gabapentin, both a Hct and volume effect were observed, i.e. we observed 
lower concentrations at the low Hct level and higher concentrations at the higher Hct and a trend of increasing 
concentrations with increased blood volumes (Figure 3.11). For GHB, a volume effect was seen for the low QC 
levels at the high Hct level, whereas the Hct effect was less pronounced (Figure 3.11). These results are in line 
with the experiments performed during the validation of our original GHB method utilizing “on-spot 
derivatization”, i.e. in that method, we observed little or no influence in the Hct range of 0.39 to 0.51 and we 
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concluded that the best blood volume spotted was between 20 and 35 µL since higher blood volumes result in 
an overload of the filter paper when using a calibration line based upon 25-µL DBS [44]. The influence of 
volume and Hct did not show a pronounced trend for the other analytes (see Figure 3.11). The impact of the 
punch location, also a DBS-specific parameter, was not evaluated since there is no true peripheral localization 
when taking a 6-mm disc from a 25-µL DBS.  
 
3.3.4 Application  
In a first application, retrospective analysis of DBS from patients with a suspected GHB/GBL intoxication was 
performed. These DBS samples (both vDBS and cDBS) were collected to evaluate the correlation between 
venous and capillary GHB concentrations [55 and Chapter 2], using a validated GC-MS method for the 
quantification of GHB in DBS [44]. When analyzing a subset of these samples (n = 10) with our new method, we 
obtained similar GHB concentrations, with a mean difference of 1.21%. Table 3.5 gives an overview of the GHB 
concentrations measured in the DBS following the method of Ingels et al. [44] (“on-spot derivatization”) and 
those obtained using “microwave-assisted on-spot derivatization”. This observation confirms the applicability 
of our method in cases of (suspected) GHB intoxication. Our method is even faster than the original “on-spot 
derivatization” method by utilizing a microwave instead of a ‘classic’ heating block. In addition, our method 
also allows the simultaneous detection of other polar low molecular weight molecules.  
 
In a second application, gabapentin concentrations were measured in treated volunteers. Of these volunteers, 
paired cDBS and serum samples were obtained at different time points. We quantified these cDBS 
concentrations, whereas the obtained serum concentrations were measured using an independent method 
[56]. The pharmacokinetic profile obtained from both fingerprick blood and serum of one volunteer is given in 
Figure 3.12. These measurements served as the basis for a larger study evaluating the correlation between 
serum and blood concentrations and to investigate the correlation between our method and an independent 
method (see Chapter 4). Our observation that DBS concentrations are somewhat lower than those in serum is 
in line with the expectation: although gabapentin is assumed to be evenly distributed between plasma/serum 
and blood, the blood-to-plasma(serum) ratio is slightly lower than 1 due to the presence of solid constituents in 
blood. Additionally, this study demonstrated the ease of DBS sampling: whereas a phlebotomist was needed to 
obtain serum samples, DBS sampling does not require trained staff and can be performed by the patient 
himself, even at home.  
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Figure 3.11 Influence of both the Hct and the blood volume spotted on GHB, gabapentin, BHB, 1,4-BD, 1,2-BD, 
DEG, PG and vigabatrin concentrations. Data are presented as percentage of normalized samples with a Hct of 
0.40 and a spotted blood volume of 25 µL. The ± 15% deviation limits are indicated by dotted lines.  
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Table 3.5 GHB concentrations measured in cDBS and vDBS of patients with a suspected GHB intoxication using 
our method versus the concentrations obtained following the method of Ingels et al. [44]. 
  GHB concentration (µg/mL) 
  “microwave-assisted on-spot derivatization” “on-spot derivatization” 
1 vDBS 186.0 167.5 
2 vDBS 67.1 75.2 
3 vDBS 272.6 271.4 
4 vDBS 43.6 48.1 
5 vDBS 229.2 191.6 
6 cDBS 242.2 233.7 
7 cDBS 162.8 151.4 
8 cDBS 41.1 41.4 
9 cDBS 172.0 187.1 
10 cDBS 206.1 200.3 
 
 
 
Figure 3.12 Pharmacokinetic profile of a volunteer who was administered gabapentin. This profile was obtained 
by analyzing cDBS and serum samples which were collected at different time points. 
 
3.4 Conclusion 
We have developed and validated a GC-MS method for the determination of GHB and gabapentin in DBS, 
utilizing “microwave-assisted on-spot derivatization”. This approach combines microwave derivatization with 
direct application of the derivatization reagents onto the DBS (“on-spot derivatization”). Consequently, the 
derivatization step should no longer be experienced as a laborious and time-consuming sample preparation 
step. To the best of our knowledge, we are the first using this direct derivatization technique.  
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In our method, the use of DBS could be considered as a sample preparation strategy. However, many other 
advantages have been associated with DBS, amongst which convenient storage and transport, reduced risk of 
infection, easy sampling, and so on. Another non-negligible advantage of our method is that no dedicated 
equipment is needed as the standard GC-MS configuration utilized in routine forensic toxicology, could be 
used. 
 
Our method proved to be reliable, fast and applicable in routine toxicology, as exemplified by the analysis of 
gabapentin- and GHB-positive samples. Additionally, our method also allows the detection of other polar low 
molecular weight compounds with relevance in the forensic and clinical toxicological context, including 
vigabatrin, 1,4-BD, BHB, DEG, PG and 1,2-BD. 
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Abstract 
We evaluated the applicability of a validated GC-MS method for the determination of gabapentin in dried 
blood spots (DBS). Important for the acceptance of DBS sampling as an alternative sampling strategy is the 
possibility to base solid conclusions on the quantification. Therefore, bridging studies -studies in which the 
correlation between both DBS and a reference matrix (e.g. serum) is evaluated statistically- need to be 
conducted. To this end, a comparative study was set up to quantify gabapentin in both blood (DBS) and serum 
samples. Statistically significant differences between DBS and serum concentrations were found (p < 0.001). A 
mean blood-to-serum ratio of 0.85 was observed, which is in line with expectations. Calculated serum 
concentrations (obtained by dividing the DBS concentrations by 0.85) demonstrated a good correlation with 
measured serum concentrations, with 87% of samples fulfilling the criterion for incurred sample reanalysis. 
Furthermore, our data indicate a good correlation between capillary and venous concentrations. Conclusively, 
this study demonstrated that DBS are a valid alternative to serum for the determination of gabapentin.  
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4.1 Introduction 
Gabapentin, an anticonvulsant structurally related to the inhibitory neurotransmitter gamma-amino butyric 
acid, is used for the treatment of epilepsy and neuropathic pain. Monitoring gabapentin blood concentrations 
may be relevant in assessing compliance and in avoiding potential toxicity. Furthermore, the illicit use of 
gabapentin as street drug also increases. E.g. in the UK, there is a significant rise in prescribing of gabapentin, 
especially among opiate users and prisoners [1]. These populations often mix gabapentin with other 
depressants, resulting in life-threatening effects.  
 
Since its introduction in neonatal screening in the 1960s by Guthrie and Susi [2], dried blood spot (DBS) 
sampling has increasingly received interest as an alternative sampling strategy and has been applied in various 
disciplines, including toxicology, phenotyping and therapeutic drug monitoring [3-7]. Many advantages have 
been associated with this minimally invasive sampling technique, amongst which easy transport and storage of 
the samples, simplification of sample preparation procedures and automation of sample processing. Moreover, 
the dried matrix may improve compound stability and reduce the risk of infection [3,8-11]. Other biological 
matrices have also been collected as a spot on (cellulose) filter paper, e.g. urine and plasma. The latter has 
already been used for the quantification of gabapentin [12,13]. However, these dried plasma spots were 
generated by pipetting plasma which was prepared by centrifugation of whole blood, obtained via 
venipuncture. Consequently, these methods are less feasible for sampling at home. Fingerprick sampling is a 
more convenient technique in a real-life setting and can be performed by non-experienced individuals. To the 
best of our knowledge, we are the first to describe the application of a procedure to quantify gabapentin in 
DBS obtained by fingerprick sampling. In this method, we applied gas chromatography coupled to mass 
spectrometry (GC-MS), following “microwave-assisted on-spot derivatization”. This new derivatization strategy 
simplifies and minimizes sample preparation by combining fast microwave-assisted derivatization with direct 
“on-spot derivatization”. Additionally, no dedicated equipment is needed since a standard GC-MS 
configuration, present in most routine toxicological and clinical laboratories, is used. We also opted for a GC-
MS system since some laboratories in emerging countries cannot afford buying or maintaining expensive LC-MS 
equipment whereas they may have a GC-MS system at their disposal.  
 
When setting up a DBS-based method, several parameters may complicate the interpretation of DBS results. 
Besides analytical issues like the impact of hematocrit (Hct) on DBS-based quantitation, an important factor 
that needs to be taken into consideration is the fact that therapeutic ranges for drugs are mostly based on 
plasma and serum concentrations. Consequently, a conversion factor is needed for the adequate interpretation 
of these blood concentrations, and thus also of gabapentin. Furthermore, for the acceptance and 
implementation of capillary DBS (cDBS) as an alternative (minimally invasive) sampling strategy in a routine 
laboratory, the execution of bridging studies is essential [10,14-16]. Bridging studies are studies in which 
concentrations determined in DBS are compared to those obtained in a reference matrix, e.g. serum. To this 
end, we set up a comparative study to investigate how serum and blood (DBS) concentrations are correlated.  
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4.2 Experimental 
4.2.1 Chemical reagents and stock solutions 
Gabapentin and its deuterated analogue gabapentin-D10 (available as a 100 µg/mL solution in methanol) were 
purchased from Sigma-Aldrich (Diegem, Belgium), as well as the derivatization reagents acetic anhydride, 
pyridine and heptafluorobutanol. Suprasolve ethyl acetate was delivered by Merck (Darmstadt, Germany).  
 
A 10 mg/mL gabapentin stock solution in methanol was used to prepare calibration standards of 1, 5, 10, 17.5, 
22.5 and 30 µg/mL in venous whole blood. DBS were prepared by spotting 25 µL of this spiked blood onto 
Whatman 903 filter paper (GE Healthcare, Dassel, Germany). Quality control samples (QCs) were prepared in a 
similar way from an independent stock solution.  
 
4.2.2 Study set-up and sample collection 
A comparative study was set up to determine gabapentin concentrations in both cDBS and serum samples. This 
study was approved by the Ethics Committee of Ghent University Hospital (NCT01821235). Samples from 15 
healthy volunteers aged between 18 and 55 years and with a Hct between 0.37 and 0.48 were included. These 
subjects received either a single oral dose of 800 mg Neurontin® (Pfizer, Freiburg, Germany) or 800 mg 
Gabasandoz® (Salutas Pharma GmbH, Barleben, Germany). Patients were hospitalized up to 12 hours after 
administration, followed by a visit to the clinical research unit 24 hours after dosing. Prior to sampling, all 
volunteers provided informed consent. At 7 time points (predose, 2, 4, 6, 8, 12 and 24 hours postdose), paired 
serum samples and cDBS were collected. cDBS were generated by (non-volumetric) application of a drop of 
blood onto Whatman 903 filter paper following a fingerprick with an automated lancet. These spots were then 
dried for at least 2 hours before storage at room temperature in a plastic bag with desiccant until analysis. 
Assistance was provided during DBS sampling to ensure correct sampling (e.g. the first drop of blood was wiped 
off (because of the presence of tissue fluid), only one drop of blood was used for every spot and direct contact 
between the fingertip and the DBS card was avoided). Furthermore, some volunteers were drowsy after 
gabapentin administration and were not in a condition to prepare DBS themselves. At the same time, blood 
was taken via a cannula and serum was prepared within 1 hour after blood sampling. Serum samples were 
stored at -80°C and quantified in the Department of Clinical Pharmacology and Pharmacy of the VU University 
Medical Center (Amsterdam, The Netherlands) according to a validated UPLC-MS/MS method [17]. 
 
4.2.3 DBS analysis 
The DBS were analyzed utilizing the validated GC-MS procedure described in Chapter 3 [18]. This method can 
be summarized as follows: first, a central 6-mm disc was taken from the dried spot. Then, after adding the 
internal standard (5 µL of 12 µg/mL gabapentin-D10), the punches were subjected to “microwave-assisted on-
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spot derivatization” by direct application of 25 µL acetic anhydride and 25 µL pyridine and microwave heating 
at maximum power for 90 s, followed by a second microwave-assisted derivatization for 90 s with 25 µL 
heptafluorobutanol. After every derivatization step, the samples were subjected to a short-spin centrifugation 
step at 4°C. Following evaporation under nitrogen at 25°C, 100 µL ethyl acetate was added to the samples. 
Finally, one µL of this derivatized extract was injected into an Agilent 6890 GC system coupled to a 5973 MS 
(Agilent Technologies, Avondale, PA, USA). Chromatographic separation was achieved on a 30 m x 0.25 mm i.d. 
x 0.25 µm Agilent HP-5MS column. The injection temperature was set at 250°C, and a splitless injection was 
performed with a purge activation time of 120 s. The initial oven temperature was set at 60°C, which was held 
for 2 minutes. Then, the temperature was ramped at 8°C/min to 110°C, raised 30°C/min until 230°C, followed 
by an increase of 50°C/min to 300°C, which was held for 2 minutes. High-purity helium was used as the carrier 
gas with a constant flow rate of 1.1 mL/min. The transfer line temperature, ion source temperature and MS 
quadrupole temperature were set at 300, 230 and 150°C, respectively. Quantification of gabapentin and 
gabapentin-D10 was performed in SIM mode using m/z 153, 167 and 195 for derivatized gabapentin and 163, 
177 and 205 for derivatized gabapentin-D10. Quantifier ions are underscored.  
 
This method was validated based upon the Food and Drug Administration (FDA) and European Medicines 
Agency (EMA) guidelines for bioanalytical method validation as described in subsection 3.2.6.2 [19,20]. 
Calibration lines were linear between 1 and 30 µg/mL, applying 1/x weighted linear regression. Within-day and 
between-day precision (% RSD) and accuracy (% bias), evaluated at 4 different QC levels (LLOQ, low, medium 
and high level), were below 11, 12 and 8%, respectively, thereby meeting pre-set acceptance criteria. No 
interferences or carry-over were observed. Gabapentin was found to be stable in the DBS stored for at least 84 
days at room temperature. Matrix effects and recovery could not be assessed, given the nature of the utilized 
approach (“on-spot derivatization”). The use of a stable labeled internal standard prior to derivatization allows 
to compensate for variations that may occur throughout the procedure. DBS-specific parameters may also have 
an impact on the analytical DBS result when starting from partial-spot punches [9]. Therefore, the impact of the 
Hct in a range which covers the Hct values of our study population was evaluated. Although a Hct effect was 
observed in the 0.30-0.49 Hct range, % bias remained within ± 15% of the concentrations of the normalized 
sample for the low QC level, a concentration close to the concentrations measured in the participants of this 
study. When evaluating the impact of different spotted blood volumes (i.e. 25, 35 vs. 50 µL), increased 
concentrations with increasing blood volumes were observed. The influence of even smaller blood volumes 
was not evaluated as these spots are too small to obtain a 6-mm punch [18]. For the evaluation of incurred 
sample reanalysis, 66 cDBS were re-analyzed after a storage of 141 days at room temperature. The EMA 
criterion for incurred sample reanalysis, which states that the percent difference between the initial 
concentration and the concentration measured during the repeat analysis should not be greater than 20% of 
their mean for at least 67% of the repeats, was fulfilled as for 80% of the re-analyzed cDBS, the initial analysis 
and the concentration obtained by reanalysis were within 20% of their mean. 
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4.2.4 Data analysis 
To evaluate the correlation between gabapentin concentrations in different biological matrices, a paired 
sample T-test was performed using Microsoft Excel® 2010 (Microsoft, Redmond, WA, USA). MedCalc® 
(MedCalc software bvba, Ostend, Belgium) was used to calculate the Pearson’s correlation coefficient (with p-
value), and to perform Passing-Bablok and Bland-Altman analyses. 
 
The correlation coefficient measures the strength and direction of a relationship between two variables. A p-
value ≤ 0.05 is considered statistically significant. Passing-Bablok and Bland-Altman analyses were performed to 
evaluate the correlation between the gabapentin concentrations in both matrices (i.e. blood vs. serum 
concentrations).  
 
4.3 Results and discussion 
Of the 105 paired samples, 38 cDBS were excluded: 3 cDBS were too small (< 6-mm diameter), while the other 
spots were excluded because their gabapentin concentration was below the LLOQ (i.e. < 1 µg/mL). A detailed 
overview of the obtained DBS concentrations is given in Table 4.1. 
 
Table 4.1 Overview of the DBS concentrations at different time points. 
 
When plotting the DBS vs. the serum concentrations (Figure 4.1), the blood (DBS) concentrations were found to 
be significantly lower than the serum concentrations (p < 0.001). This was in line with our expectation: 
gabapentin has been reported to freely enter red blood cells without binding to cellular or plasma proteins. 
Consequently, an equal blood-to-plasma ratio is expected [21]. However, when taking into account the fraction 
of the solid constituents in blood, the blood concentration is expected to lie approximately 15% lower than the 
plasma/serum concentrations [7,22,23]. We indeed found a mean blood-to-serum ratio of 0.85 ± 0.12, meaning 
that concentrations in DBS are about 85% of those found in serum. Consequently, serum concentrations can be 
calculated from DBS concentrations as follows: [serum] = [DBS]/0.85.  
 
 Pre-
dose 
2 h post-
dose 
4 h post-
dose 
6 h post-
dose 
8 h post-
dose 
12 h post-
dose 
24 h post-
dose 
Number of samples 
included 
 
0 
 
14 
 
15 
 
13 
 
15 
 
10 
 
0 
Number of samples 
excluded: 
< LLOQ 
< 6-mm 
 
 
14 
1 
 
 
0 
1 
 
 
0 
0 
 
 
1 
1 
 
 
0 
0 
 
 
5 
0 
 
 
15 
0 
Concentration range 
(µg/mL) 
 
/ 
 
2.30-6.10 
 
1.84-5.52 
 
1.92-4.19 
 
1.52-4.38 
 
1.49-2.97 
 
/ 
Median concentration 
(µg/mL) 
 
/ 
 
3.50 
 
3.49 
 
3.02 
 
2.38 
 
1.88 
 
/ 
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Figure 4.1 Passing-Bablok regression analysis plotting the DBS concentrations against the serum 
concentrations. The slope and intercept of the regression line (solid line) are calculated with their 95% 
confidence interval (dashed line). The dotted line corresponds to the identity line. 
 
Figure 4.2 shows a Passing-Bablok scatter plot in which the serum concentrations calculated from DBS analysis 
are plotted vs. measured serum concentrations. A good overall correlation was observed, although 1 was just 
not included in the 95% confidence interval of the slope. Bland-Altman analysis revealed a mean difference of 
only 0.12 µg/mL, with the 0 value included in the 95% confidence interval (Figure 4.3). This observation was 
confirmed by the Pearson’s correlation coefficient (r = 0.9353; p < 0.0001), demonstrating a strong correlation 
between the measured serum concentrations and the serum concentrations based on DBS results.  
 
Importantly, these differences may also be dependent on the sampling time, as exemplified for acetaminophen 
by Mohammed et al. [24]. We therefore plotted the % difference between the calculated and measured serum 
concentrations vs. the sampling time (Figure 4.4). This revealed that the differences between both 
concentrations were randomly distributed around 0, with no indication of a time-dependent effect.  
 
Another important factor that needs to be kept in mind is that the serum samples were obtained following 
traditional blood sampling by venipuncture, whereas the blood samples were collected by a capillary sampling 
technique using an automated lancet. cDBS-blood differences have been described for e.g. caffeine, 
acetaminophen, artemesinin, ethanol, lignocaine,… [7,24-26]. Although the set-up of this study did not really 
intend to compare venous and capillary blood concentrations, the data do suggest that -given the good 
correlation between the measured serum concentrations (obtained by venous sampling) and the calculated 
serum concentrations (from DBS obtained by capillary sampling)- there are no considerable capillary-venous 
differences.  
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Figure 4.2 Passing-Bablok regression analysis plotting the serum concentrations calculated from the blood 
concentrations against the measured serum concentrations. The slope and intercept of the regression line 
(solid line) are calculated with their 95% confidence interval (dashed line). The dotted line corresponds to the 
identity line. 
 
 
Figure 4.3 Bland-Altman analysis plotting the differences between the serum concentrations calculated from 
the blood concentrations and the measured concentrations (y-axis) against the average of both measurements 
(x-axis). The mean difference and the limits of agreements (set to 1.96 SD) are also indicated with its 95% 
confidence interval. 
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Figure 4.4 % difference between the calculated and measured serum concentrations vs. the time of sampling. 
 
As described in subsection 4.2.3, the EMA guidelines for incurred sample reanalysis were fulfilled [20]. 
Although these criteria are actually intended for reanalysis of the same samples, this guideline was also applied 
for the evaluation of the measured and the calculated serum concentrations. Again, this criterion was fulfilled 
as for more than two-thirds (i.e. 87%) of the samples the two results lay within 20% of their mean. This 
requirement was also fulfilled when comparing serum concentrations obtained with both the LC- and the GC-
method, excluding that the observed differences between blood and serum concentrations are caused by a 
bias between both methods. 
 
4.4 Conclusion 
We successfully applied a validated GC-MS method for the determination of gabapentin in DBS in a real-life 
setting. Based upon the observation that a mean blood-to-serum ratio of 0.85 was obtained, we established a 
conversion factor to allow interpretation of gabapentin blood concentrations since reference intervals 
concerning therapeutic and toxic gabapentin concentrations are only available in plasma/serum. Taking this 
conversion factor into consideration, serum concentrations could be calculated from DBS concentrations. By 
doing so, a good correlation was found between measured serum concentrations and serum concentrations 
calculated from DBS concentrations. Additionally, our data suggest that there is a good correlation between 
capillary and venous gabapentin concentrations. 
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Abstract  
Beta-hydroxybutyric acid (BHB) is a ketone body which is generated from fatty acids as an alternative energy 
source when glucose is not available. Determination of this compound may be relevant in the forensic 
laboratory as ketoacidosis -an elevated level of ketone bodies- may contribute to the cause of death. In this 
study, we aimed at determining the relevance of routinely implementing BHB analysis in the forensic 
toxicological laboratory, as BHB analysis typically requires an additional workload. We therefore performed an 
unbiased retrospective analysis of BHB in 599 cases, comprising 553 blood, 232 urine and 62 vitreous humour 
samples. Cases with BHB concentrations above 100 µg/mL (in blood, urine and/or vitreous humour) were 
invariably associated with elevated levels of acetone, another ketone body, the detection of which is already 
implemented in most forensic laboratories using the gas chromatographic procedure for ethanol 
quantification. Our retrospective analysis did not reveal any positive case that had been missed initially and 
confirms that BHB analysis can be limited to acetone positive cases.  
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5.1 Introduction  
Ketoacidosis is a metabolic disturbance caused by an elevated blood level of the ketone bodies acetoacetate, 
acetone and beta-hydroxybutyric acid (BHB). These compounds are generated by the liver when there is 
insufficient glucose available. Under these circumstances, lipids -stored as triglycerides in fatty tissue- are an 
alternative energy source. During lipolysis, triglycerides are degraded into fatty acids, resulting in the 
generation of acetyl-CoA. This co-enzyme is converted into acetoacetate, a precursor molecule of BHB and 
acetone. The latter compound is generated by decarboxylation of acetoacetate and is eliminated by urine and 
breath, resulting in a typical sweet odor of breath and urine. Since acetone may be reduced to isopropanol, the 
latter may also be found in case of ketoacidosis. On the other hand, acetoacetate may also be converted 
enzymatically into BHB. This small low molecular weight compound is readily water-soluble and can easily cross 
the blood brain barrier. There, BHB is converted into acetyl-CoA, which is via the Krebs cycle converted to ATP, 
an energy-carrying molecule. Consequently, high levels of ketone bodies indicate deficient sugar metabolism 
which may be caused by uncontrolled diabetes. The use of atypical antipsychotics may also induce 
ketoacidosis. Other sources of ketoacidosis are chronic alcoholism, starvation, hypothermia or infection [1]. In 
conclusion, determination of ketone bodies is relevant in a forensic context as they may elucidate pathological 
findings or the cause of death. Yet, there remains a lot of uncertainty about the interpretation of 
(concentrations of) ketone bodies. E.g. it is unclear if ketone bodies (i.e. acetone, acetoacetate and/or BHB) 
should routinely be measured in all cases or if measurement can be limited to some specific cases. It is also 
unclear if all ketone bodies should be measured or if the determination of one ketone body suffices. Up till 
now, acetone is already co-detected routinely in blood and/or urine using a standard ethanol quantification 
procedure via headspace sampling-gas chromatography-flame ionization detection (HS-GC-FID). Even a simple 
dipstick test readily sheds some light on the extent of positivity of acetone and acetoacetate in urine. On the 
other hand, BHB analysis is not performed routinely. Mostly, BHB is determined when there is a suspicion of 
ketoacidosis, based on background information. However, sometimes there is no access to background 
information. Additionally, the presence of alcoholism and/or diabetes -two important factors causing 
ketoacidosis- is not always known. There is also some controversy about the preferred biological matrix. E.g. 
can vitreous humour be considered as an alternative for blood? 
 
In this Chapter, we evaluate the relevance of routine implementation of BHB analysis in a forensic toxicological 
laboratory, taking into account that a dedicated analysis is required for the quantification of this ketone body, 
as this analyte is typically not covered by other routinely applied liquid chromatography (LC) or GC-based 
general screening procedures. To this end, we applied a recently developed dried spot-based method to 
perform retrospective BHB analysis of a large number of samples which were received for forensic toxicological 
analysis. Noteworthy is that in this retrospective analysis we did not select samples based upon background 
information (e.g. known diabetic or alcoholic) and earlier obtained toxicological results.  
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5.2 Materials and methods 
5.2.1 Chemicals and stock solutions 
Heptafluorobutanol, acetic anhydride, pyridine and the sodium salt of BHB were provided by Sigma-Aldrich 
(Diegem, Belgium). Suprasolve ethyl acetate and methanol were obtained from Merck (Darmstadt, Germany). 
Deuterated GHB (GHB-D6) was used as internal standard (IS) and provided by Lipomed (Arlesheim, 
Switzerland). 
 
A BHB stock solution was prepared by dissolving 50 mg BHB in one mL of methanol. This stock solution was 
diluted and used to prepare calibration standards of 5, 15, 25, 50, 100 and 300 µg/mL. Quality control samples 
(QCs) of 65, 125 and 250 µg/mL were prepared from an independent stock solution. For the IS, we made a  
50 µg/mL GHB-D6 solution in methanol. All solutions were stored at -20°C.  
 
5.2.2 Samples 
We performed retrospective BHB analysis of routine samples -mostly post-mortem samples- which were 
received for forensic toxicological analysis in the Laboratory of Toxicology of Ghent University and stored at  
-20°C. Since BHB has been found to be stable in post-mortem samples [2], the age of the samples was not an 
issue. All available samples were analyzed, irrespective of background information and earlier obtained 
(toxicological) results. Finally, we had access to 599 cases, comprising 553 blood samples, 232 urine samples 
and 62 vitreous humour samples. Of these samples, dried matrix spots were prepared by pipetting 15 µL of 
biofluid onto a 7-mm pre-punched disc of Whatman 903 filter paper. These spots were dried for at least 2 
hours and stored at room temperature in a zip-closure plastic bag with desiccant before analysis. Acetone and 
isopropanol were qualitatively assessed in the procedure for routine ethanol quantification (ISO/IEC 17025 
accredited), applied at the day of arrival using HS-GC-FID. 
 
5.2.3 BHB analysis 
For the quantification of BHB, the GC coupled to mass spectrometry (GC-MS) method described in Chapter 3 
was slightly adapted [3]. This adaptation consisted of using 7-mm pre-punched discs, onto which a fixed 
volume of 15 µL biofluid was applied, rather than using 6-mm partial punches from a dried blood spot (DBS). 
The protocol used can be summarized as follows: first, a fixed volume of 15 µL of blood, urine or vitreous 
humour is spotted onto a 7-mm pre-punched disc of Whatman 903 filter paper. After adding 5 µL IS (50 µg/mL 
GHB-D6 in methanol) to the dried spots, the punches are subjected to “microwave-assisted on-spot 
derivatization”, as described in subsection 3.3.1.2 [3]. Briefly, derivatization is achieved by direct application of 
25 µL acetic anhydride and 25 µL pyridine onto the spots and microwave heating for 90 s at maximum power, 
followed by a second derivatization for 90 s at maximum power with 25 µL heptafluorobutanol. Following 
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evaporation under nitrogen, 100 µL of ethyl acetate was added to the samples. Finally, one µL of the 
derivatized extract is injected into an Agilent 6890 GC coupled to a 5973 MS system. Chromatographic 
separation is achieved on a 30 m x 0.25 mm i.d. x 0.25 µm Agilent HP-5MS column. Helium is used as carrier gas 
with a flow rate of 1.1 mL/min. A splitless injection is chosen. The injection temperature is set at 250°C. The 
initial oven temperature is 60°C, which is held for 2 minutes. Then, the temperature ramped at 8°C/min to 
110°C, raised 30°C/min until 230°C, followed by an increase of 50°C/min to 300°C, which is held for 2 minutes. 
The transfer line temperature, MS ion source temperature and MS quadrupole temperature are set at 300, 230 
and 150°C, respectively. Quantification of BHB and GHB-D6 is performed in SIM mode using m/z 227, 268 and 
285 for BHB and 231, 245, 273 and 291 for GHB-D6. Quantifier ions are underscored.  
 
Validation of the procedure starting from a 6-mm disc of a 25-µL DBS prepared from fresh whole blood [3] 
encompassed the following (see subsections 3.3.3.2, 3.3.3.3 and 3.3.3.4): calibration lines were linear over the 
5-300 µg/mL concentration range, applying a 1/x weighted linear regression. Within-day and between-day 
precision criteria (< 20% at LLOQ, < 15% at 3 other QC levels) were fulfilled for all QC levels, whereas accuracy 
was slightly above the acceptance criterion for two QC levels, i.e. > 15% but still below 20%. No carry-over was 
observed following injection of the highest concentration of the calibration curve. Samples could be diluted  
4-fold without influencing precision and accuracy. Stability studies revealed no significant alteration of BHB 
concentration in DBS which were stored in a zip-closure plastic bag with desiccant for 84 days at room 
temperature [3]. 
 
5.3 Results and discussion 
BHB analysis was based on the GC-MS method for the detection of several polar low molecular weight 
compounds with relevance in forensic and clinical toxicology described in Chapter 3 [3]. This validated 
procedure (with punching a 6-mm disc from a 25-µL DBS) was slightly modified in our application as we wished 
to apply the method on a divergent set of matrices (urine, vitreous humour, post-mortem blood,…) which have 
a different spreading on the filter paper. To this end, a whole-cut approach with application of a fixed volume 
of 15 µL of biofluid onto a 7-mm pre-punched disc was utilized instead of using partial punches. To ensure the 
validity of the slightly adapted method we applied, a calibration line and QC samples were run every day of 
analysis. % CV was below 20% and % bias below 13% for 3 QC levels (65, 125 and 250 µg/mL). These QC 
concentrations were based on proposed cut-off levels (see next paragraph).  
 
The BHB concentrations obtained in blood, vitreous humour and urine were arbitrarily grouped in different 
classes (Figure 5.1): BHB concentrations below 50 µg/mL were considered as ‘low’, concentrations between 50 
and 100 µg/mL as ‘slightly elevated’, concentrations between 100 and 250 µg/mL as ‘moderately elevated’, and 
concentrations above 250 µg/L as ‘high and pathologically significant’. Although this classification is rather 
based on decision levels for BHB in blood and vitreous humour, we also applied these ranges for urine, as 
suggested by Elliott et al. [4]. 
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As can be seen in Figure 5.1a, a ‘slightly or moderately elevated’ BHB blood level was found in 28 cases (5%) 
and a ‘high’ BHB level in 5 (0.9%) blood samples. Most vitreous humour samples (89%) also had a ‘low’ BHB 
concentration (Figure 5.1b). There were no vitreous humour samples with a BHB concentration higher than  
250 µg/mL, while 7 (11%) had a ‘slightly or moderately elevated’ BHB concentration. Of the 232 analyzed urine 
samples, 8 (3.5%) had a ‘slightly or moderately elevated’ urinary BHB concentration and 6 (2.5%) had a urinary 
concentration above 250 µg/mL (Figure 5.1c). The slightly higher percentage of vitreous humour samples with 
an elevated BHB concentration may be owing to the fact that, while vitreous humour is not always routinely 
collected by the forensic pathologist, it is likely to be sampled if there is a suspicion of an electrolyte imbalance 
or ketoacidosis. Despite this inherent bias during sample collection, only three cases in which we could perform 
the retrospective BHB analysis in vitreous humour yielded a concentration near or above 100 µg/mL. For these 
samples, the sum of glucose and lactate, as a measure of antemortem glycemia [5], was within the normal 
range.  
 
Figure 5.1 BHB concentrations obtained in (a) blood, (b) vitreous humour and (c) urine, respectively. 
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Table 5.1 gives an overview of the cases with a BHB concentration above 100 µg/mL (25 cases, numbered from 
1 to 25, encompassing samples considered as ‘moderately elevated’ and ‘high and pathologically significant’) in 
blood, vitreous and/or urine. Cases with the highest BHB blood levels are first reported, followed by the cases 
with the highest BHB urine concentrations. Semi-quantitative acetone results as well as some additional 
information which may be relevant for the interpretation are also given for each case.  
 
Table 5.1 Overview of the cases with a BHB concentration above 100 µg/mL. 
Case n° 
BHB concentration (µg/mL) Acetone 
Remarks 
Blood Vitreous Urine Blood Urine 
1 1466 NA NA +++ NA Post-mortem 
Diabetic; known alcohol abuse 
[Lactate + glucose] = 990 mg/dL in 
vitreous humour 
2 848 NA NA ++ NA Post-mortem 
Diabetic; known alcohol abuse  
3 600 NA NA ++ NA Post-mortem 
Alcoholic  
4 306 NA NA ++ NA Non-fatal  
5 282 NA NA ++ NA Non-fatal   
6 247 NA NA ++ NA Post-mortem 
Alcoholic  
7 206 NA NA + NA Post-mortem 
Neurotrauma; lactic acidosis  
8 185 NA NA + NA Non-fatal  
Olanzapine  
9 177 NA NA ++ NA Post-mortem 
Anorexia  
10 171 NA 1194 + +++ Non-fatal   
11 168 NA NA NA NA Non-fatal 
Quetiapine  
12 153 157 1074 + +++ Post-mortem 
Alcohol intoxication  
[Lactate + glucose] = 292 mg/dL in 
vitreous humour 
13 131 NA NA + NA Non-fatal 
Morphine intoxication  
14 129 NA NA + NA Non-fatal   
15 117 NA 1053 + +++ Post-mortem 
Meningitis 
16 110 NA <LLOQ NA + Post-mortem 
Quetiapine  
17 109 NA NA + NA Non-fatal   
18 103 94 NA + NA Post-mortem 
Alcoholic 
[Lactate + glucose] = 220 mg/dL in 
vitreous humour 
19 102 NA 29 + + Post-mortem 
Suicide: zopiclone + alprazolam + 
alcohol  
NA: not analyzed/not available; +++: acetone concentration > 20 mg/dL; 
++: acetone concentration > 3 mg/dL; +: acetone concentration < 3 mg/dL 
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Table 5.1 Continued. 
Case n° 
BHB concentration (µg/mL) Acetone 
Remarks 
Blood Vitreous  Urine Blood Urine 
20 13 NA 347 + +++ Non-fatal   
21 80 191 333 ++ ++ Post-mortem  
[Lactate + glucose] = 194 mg/dL in 
vitreous humour 
22 14 NA 285 + ++ Post-mortem  
23 55 NA 136 + + Non-fatal 
Methadon intoxication (coma); 
Hyperglycemia (prolonged stress)  
24 93 NA 119 + + Post-mortem  
25 22 NA 110 + ++ Post-mortem (suicide)  
NA: not analyzed/not available; +++: acetone concentration > 20 mg/dL; 
++: acetone concentration > 3 mg/dL; +: acetone concentration < 3 mg/dL 
 
Of the 553 analyzed blood samples, five had a ‘high and pathologically significant’ BHB blood concentration (i.e. 
> 250 µg/mL). Two of these were non-fatal cases (cases n° 4 and 5) and three were fatalities, the latter 
encompassing one known alcoholic (case n° 3) and two diabetics with a known alcohol abuse (cases n° 1 and 2) 
(see below).  
 
The highest BHB concentration (i.e. 1466 µg/mL) was found in blood from a diabetic with known alcohol abuse 
(case n° 1). Also in the headspace chromatogram, a very pronounced peak was observed for acetone in blood. 
Semi-quantitative analysis revealed an acetone concentration higher than 20 mg/dL. Vitreous humour analysis 
had revealed a pronounced hyperglycemia ([glucose + lactate] = 990 mg/dL) and confirmed the diagnosis of 
diabetic ketoacidosis. Unfortunately, there was no vitreous humour left for this retrospective BHB study. 
 
At least three fatalities could be associated with alcoholic ketoacidosis (case n° 2 with a BHB blood 
concentration of 848 µg/mL, case n° 3 with a BHB blood concentration of 600 µg/mL and case n° 6 with a BHB 
blood concentration of 247 µg/mL, i.e. only marginally below the 250 µg/mL cut-off). Not only a ‘high and 
pathologically significant’ BHB blood concentration, but also a clear acetone peak, corresponding with an 
acetone concentration between 3 and 20 mg/dL, was observed in blood of these three alcoholics who had 
suddenly died. In case n° 2, ethanol and isopropanol were detected as well. Unfortunately, also here, no 
vitreous humour was available for BHB, glucose and lactate determination. Cases n° 4 and 5 clearly illustrate 
that the interpretation of BHB concentrations may not always be straightforward in forensic cases. In these 
cases ‘high and pathologically significant’ BHB concentrations were found, although these were not associated 
with fatalities but were linked to a theft and a drug control, respectively. Whether in these cases the 
ketoacidosis was stress-related or whether these individuals were diabetics is not known (no availability of 
background information or urine for e.g. glucose testing).   
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In the 14 cases with a BHB blood concentration between 100 and 250 µg/mL, there were eight post-mortem 
samples. In four out of these post-mortem cases an alternative cause of death (i.e. suicide (case n° 19), 
neurotrauma (case n° 7), meningitis (case n° 15) or acute alcohol intoxication (case n° 12)) was found, whereas 
two samples were from known alcoholics who had suddenly died (cases n° 6 (described in the previous 
paragraph) and 18). In case n° 18, BHB concentrations were moderately elevated in blood and vitreous humour 
and, also here, acetone was detected, albeit at a lower concentration than in the cases with the highest BHB 
concentrations. In this case, the available results do not allow to firmly conclude that this is a fatal alcoholic 
ketoacidosis. Ketoacidosis may be a contributing factor to the cause of death, but since no autopsy has been 
performed, we could not conclusively determine the cause of death. Also in cases n° 9 and 16 the cause of 
death remained unexplained although malnutrition and the use of quetiapine (an atypical antipsychotic drug) 
may have contributed to the increased BHB levels in these cases. Two out of the six non-fatal cases could be 
associated with the use of atypical antipsychotics (cases n° 8 and 11). The other non-fatal cases were related to 
a morphine intoxication (case n° 13), a theft (case n° 17), a fight (case n° 10) and an assassination attempt (case 
n° 14). Traces of isopropanol were found in cases n° 7, 9, 12 and 15, whereas acetone was detected in blood of 
all of the 14 cases with a BHB blood concentration between 100 and 250 µg/mL. Noteworthy is that, whereas in 
the cases with a BHB concentration between 100 and 250 µg/mL, acetone was invariably present, it was mostly 
only present to a limited extent in the blood. In contrast, a clear acetone peak (> 3 mg/dL) was observed in the 
blood from all cases with a BHB concentration above 250 µg/mL. Therefore, we consider acetone as a good 
initial marker to decide if BHB analysis should be performed. This finding is in line with the observation of 
Hockenhull et al. [6]. These authors reported the presence of acetone (> 2 mg/dL) in all cases with a 
‘significant’ BHB concentration (> 250 µg/mL) and readily suggested that acetone analysis is a good screening 
procedure to identify alcoholic and diabetic ketoacidosis. Acetone analysis is preferred as screening procedure 
as this analyte is easily detected using a procedure (HS-GC-FID) which is already performed routinely in every 
case. However, as readily pointed out by Hockenhull et al. [6], acetone analysis is not enough to justify the 
contribution of ketoacidosis to the cause of death. In the acetone positive samples, the measurement of BHB is 
advised to obtain a complete metabolic overview and to exclude acetone and/or isopropanol intoxications. 
Furthermore, these results should ideally be combined with autopsy findings, other toxicological results, the 
person’s background, as well as with the circumstances in which the deceased was found -if these data are 
available to the toxicologist. Since we analyzed all available forensic samples without taking into consideration 
any background information, our retrospective BHB study also included some non-fatal cases, in which there 
was no reason at all to expect elevated BHB levels. These cases demonstrate that in a forensic context ‘high 
and pathologically significant’ BHB concentrations and strongly elevated acetone concentrations are not always 
associated with fatalities and that other situations may also involve ketoacidosis. 
 
We also agree with Hockenhull et al. [6] that acetone analysis should be performed in all cases and not only in 
those cases with a (suspected) history of alcoholism or diabetes. One should also pay attention to the presence 
of isopropanol, as this compound can be generated from acetone via alcohol dehydrogenase. However, the 
absence of isopropanol does not preclude ketoacidosis. If diabetic ketoacidosis is suspected, it is also 
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recommended to estimate antemortem hyperglycemia by biochemical analysis of vitreous for glucose and/or 
lactate. While vitreous glucose may be the most reliable marker to diagnose hyperglycemia in fresh corpses, 
the use of the sum of glucose and lactate (also known as the Traub formula) has also been used in cases where 
there is a prolonged interval between death and sampling (as in several of our cases) [7-9]. Indeed, in our 
experience, in many of these cases even no or only very low glucose remains detectable.  
 
Teresinski et al. observed that elevated BHB levels are not always associated with elevated acetone 
concentrations [10]. In hypothermia cases, for instance, ketoacidosis appears to be characterized by less 
important levels of blood ketones. Both Palmiere et al. and Teresinski et al. observed an inverse relationship 
between blood acetone and ethanol levels in hypothermia cases [10-13]. Therefore, these authors questioned 
whether acetone may be a suitable marker for ketoacidosis in hypothermia cases with a high blood alcohol 
concentration. However, it is unclear to what extent ketoacidosis did play a contributing role to the cause of 
death in these hypothermia cases. Additionally, as we did not find any cases in our large-scale study with 
elevated BHB levels without elevated acetone concentrations, we believe that an additional BHB analysis 
should only be performed if acetone is detected. 
 
Of the 54 cases in which corresponding blood and vitreous humour samples were available, vitreous humour 
BHB concentrations exceeded or approached 100 µg/mL in only 3 cases. As suggested by Elliott et al. [4], the 
same ranges can be used for vitreous humour as for blood. Although the number of vitreous humour samples 
was limited, our data do support an overall good accordance between BHB concentrations in blood and the 
corresponding vitreous humour. This is in line with the conclusions of Elliott et al. [4], Kadis et al. [14], Felby et 
al. [15], Osuna et al. [16] and Pounder et al. [17]. On the other hand, Teresinski et al. and Palmiere et al. argued 
that the vitreous humour concentration may not be a true reflection of the blood concentration since the 
equilibrium between both matrices may not have been attained in case of rapidly occurring ketonemia [10,18]. 
 
When comparing urinary and blood concentrations, we observed that the blood concentration was below  
100 µg/mL for the three samples with a urinary concentration between 100 and 250 µg/mL (cases n° 23, 24 and 
25). Also in the three cases with a urinary BHB concentration between 250 and 1000 µg/mL, the corresponding 
BHB blood concentration did not exceed 100 µg/mL (cases n° 20, 21 and 22). Only in the three cases with a very 
high urinary BHB concentration, i.e. above 1000 µg/mL (cases n° 10, 12 and 15), a blood concentration 
between 100 and 250 µg/mL was observed. Conclusively, unless in more extreme cases (urinary BHB above 
1000 µg/mL), elevated or high urinary concentrations are not necessarily reflected by elevated or high blood 
concentrations. Conversely, elevated blood concentrations are neither always reflected by elevated urinary 
concentrations: in two out of the five cases with a BHB blood concentration higher than 100 µg/mL, the 
corresponding urinary BHB concentration was not elevated (cases n° 16 and 19). As already mentioned, the 
other three cases had a very high urinary concentration (> 1000 µg/mL) (cases n° 10, 12 and 15). These findings 
confirm the conclusion of Elliott et al. that a urinary BHB concentration cannot be solely used to diagnose 
pathologically significant ketoacidosis [4]. We also agree with Teresinski et al. and Palmiere et al. that the 
Chapter 5: Relevance of BHB analysis in forensic toxicology 
 
  
115 
 
interpretation of ketone body concentrations in urine is not straightforward and that blood is the most 
appropriate matrix for the determination of ketone bodies [10,18]. Not only in a forensic setting, but also in a 
clinical context (i.e. for the evaluation of the metabolic status of the patient in the treatment of diabetic 
ketoacidosis), blood levels are more reliable than urinary concentrations [19].  
 
5.4 Conclusion 
An elevated level of the ketone bodies is called ketoacidosis and may be a contributing factor to the cause of 
death. Therefore, determination of the ketone bodies may be helpful to explain pathological and/or 
toxicological findings. Qualitative acetone analysis is already implemented in most routine laboratories using a 
HS-GC-FID method, as routinely applied for ethanol quantification. Quantification of acetoacetate is less useful 
as this molecule is rapidly converted into BHB or acetone. One of the aims of this study was to evaluate 
whether BHB analysis should be implemented in routine analysis in all cases or could be limited to those cases 
where, based upon acetone analysis or background information (e.g. diabetic or alcoholic), there was a reason 
to specifically test for BHB. This is relevant when considering a limitation of the workload, without risking to 
miss positive cases (i.e. avoid false negatives).  
 
Retrospective BHB analysis of blood, urine and vitreous humour samples which were received for forensic 
toxicological analysis demonstrated that the BHB concentrations measured in vitreous humour are overall 
comparable to the concentrations obtained in blood, suggesting that vitreous humour is a good alternative for 
blood. Urinary concentrations, on the other hand, show a lower correlation with blood levels. We also 
observed that acetone was found in all cases with a BHB concentration higher than 100 µg/mL. Consequently, 
our findings confirm that acetone is a good initial marker for ketoacidosis and our findings support the 
recommendation by Elliott et al. that first a HS-GC-FID analysis should be performed to detect acetone (and 
isopropanol) [4,6]. This analysis does not impose an additional workload and is already performed for every 
forensic case. If acetone is detected, we advise to perform BHB analysis, even if no ketoacidosis is suspected 
based on background information received at case submission. Conclusively, our data suggest that if one limits 
BHB analysis to acetone positive samples, no cases with ketoacidosis will be missed.  
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CHAPTER 6:  
HAPTOGLOBIN GENOTYPING  
BY DIRECT PCR ON DRIED BLOOD SPOTS 
 
 
 
 
 
 
 
 
 
 
           
 
 
 
 
 Based on 
Sadones N, Onderbeke L, Cannaert A, De Kesel PMM, Delanghe JR, Lambert WE, Stove CP. Development of a 
new haptoglobin genotyping method by direct PCR on dried blood spots. In preparation  
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Abstract  
Haptoglobin (Hp) is a glycoprotein which prevents iron loss and renal damage by binding free hemoglobin 
which is released during hemolysis. It is synthesized by the liver and is encoded by two alleles, resulting in two 
homozygous genotypes (Hp 1-1 and Hp 2-2), and one heterozygous genotype (Hp 2-1). Hp genotyping may help 
in preventing fatal anaphylactic reactions and in establishing the relationships between the Hp genotypes and 
diseases. Current ‘gold standard’ methods for Hp genotyping suffer from the drawback that mostly two PCR 
reactions are needed to score the Hp genotype. Mostly a second PCR reaction is also required in cases of 
extensively degraded DNA or small amounts of DNA. Therefore, we aimed to set up an improved PCR-based 
assay for Hp genotyping, directly starting from a dried blood spot (DBS). To this end, we carefully selected our 
primers, allowing selective amplification of each Hp allele, resulting in a 2100 and 1800 bp fragment for Hp 1 
and 2, respectively. Using a Phusion Blood Direct PCR kit, our method is directly applicable to (dried) whole 
blood without the need for a separate DNA extraction step. Hp genotyping of 221 DBS samples demonstrated 
that the genotypes obtained with our method were fully consistent with the genotypes obtained using a 
reference method for Hp genotyping. Moreover, we are also able to detect simultaneously the single 
nucleotide Hp A-61C polymorphism in the promoter region by amplification of a 1200 bp fragment, followed by 
restriction enzyme analysis with BpmI. We found 3 heterozygotes for the Hp A-61C polymorphism, which was 
confirmed by DNA sequencing.  
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6.1  Introduction 
Haptoglobin (Hp) is a glycoprotein with an anti-oxidative capacity by binding free hemoglobin and by reducing 
iron loss following hemolysis. The Hp gene locus is located on chromosome 16, the two alleles giving rise to the 
Hp 1-1, Hp 2-2 and Hp 2-1 genotypes. This polymorphism has been associated with (increased risk of 
developing) distinct diseases, as demonstrated in Table 6.1 [1-3]. E.g. the Hp phenotype is an independent risk 
factor for complications in diabetes, via a mechanism involving oxidative stress.  
 
Table 6.1 Examples of diseases associated with the Hp polymorphism [2,3]. 
Hp 1-1 Overrepresented in breast cancer and cervix carcinoma 
Hp 2-2 Diabetics have an increased risk for developing micro- and macrovascular complications 
Hp 2-1 Excess in patients with family history of ovarian carcinoma 
 
Although historically, phenotyping by gel electrophoresis was the gold standard, this method requires fresh 
serum samples and trained staff for the interpretation. Given the perfect correlation between geno- and 
phenotype, PCR-based methods have emerged as a good alternative. To date, the method of Koch et al. [4] is 
considered the gold standard for Hp genotyping. However, different intensities of different bands, provoked by 
the large difference in band size, may lead to the false homozygous scoring of a heterozygote, which is the 
major drawback of this method. Accordingly, two PCR reactions are often needed to conclusively determine 
the Hp genotype. Furthermore, the method starts from DNA extracts, rather than directly from raw biological 
material. Therefore, we have set up an improved (conventional) PCR-based method, directly starting from a 
micropunch from a dried blood spot (DBS), allowing to discriminate between both Hp alleles. In addition, our 
method is also suitable for the simultaneous detection of the Hp A-61C polymorphism, a single nucleotide 
polymorphism in the promoter region of the Hp gene that has been associated with ahaptoglobinaemia [5]. 
 
6.2  Materials and methods 
6.2.1 Samples 
A study was set up to evaluate the applicability of our newly developed Hp genotyping method. This study was 
approved by the Ethics Committee of Ghent University Hospital (B670201317381). Written informed consent 
was obtained from all participants. Capillary DBS were generated on Whatman 903 filter paper following a 
fingerprick using an automatic lancet (Becton Dickinson ref no VAC366594, Franklin Lakes, NJ, USA). Venous DBS 
were prepared by spotting 25 µL of venous blood (obtained from left-over samples) onto the filter paper.  
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6.2.2 Hp genotyping 
6.2.2.1 Primers 
The sequences of the newly designed primers for Hp genotyping are listed in Table 6.2. We combined the 
forward primer of the method of Koch et al. [4] with two carefully selected reverse primers. Combination with 
the first reverse primer results in the amplification of a Hp 1-specific sequence of ± 2100 bp and a Hp 2-specific 
fragment of ± 3500 bp. However, the latter is too large to be easily amplified. The second reverse primer in the 
reaction generates a Hp 2-specific sequence of 1800 bp. All primers were provided by Eurofins Genomics 
(Ebersberg, Germany). 
 
Table 6.2 Overview of the primers used for Hp genotyping. 
Forward primer (F) 5’-GAGGGGAGCTTGCCTTTCCATTG-3’ 
Reverse primer 1 (R1) 5’-GAGATTATGGTGGGAAACCATCTTAGC-3’ 
Reverse primer 2 (R2) 5’-CCGAATAGAAGCTCGCGAACTG-3’ 
 
6.2.2.2 PCR reaction 
We utilized a Phusion Blood Direct PCR Kit obtained from Thermo Fisher Scientific (Erembodegem, Belgium). 
This kit contains a Phusion Blood II DNA Polymerase which exhibits high resistance to inhibitors present in 
blood and eliminates the need for a separate DNA extraction step prior to the PCR reaction. 
 
Our 20-µL PCR reaction contained a 0.5 mm DBS punch, 0.4 µL Phusion Blood DNA II Polymerase, 10 µL Phusion 
Blood PCR Buffer, and our three primers for Hp genotyping (see Table 6.2), which had a final concentration of 
0.5 µM. After an initial denaturation -allowing lysis of leukocytes and thus release of DNA- of 5 min at 98°C, 
denaturation and annealing/elongation were performed for 1 s at 98°C and 30 s at 72°C, respectively. These 
steps were repeated for 35 cycles. The final elongation step took 1 min at 72°C. This PCR reaction was 
performed in a Mastercycler® Nexus Thermal Cycler (Eppendorf, Hamburg, Germany). 
 
6.2.2.3 Gel electrophoresis and visualization 
The PCR products were separated using agarose gel electrophoresis. Therefore, we prepared a 1.5% agarose 
(Sigma Aldrich, Diegem, Belgium) gel in 50x Tris-acetate-ethylenediaminetetra-acetic acid (TAE) buffer (Thermo 
Fisher Scientific, Erembodegem, Belgium). Following the addition of 6x DNA loading dye (Thermo Fisher 
Scientific, Erembodegem, Belgium), a GeneRuler DNA ladder mix (Thermo Fisher Scientific, Erembodegem, 
Belgium) and 10 µL of each sample were loaded. Finally, the DNA fragments were visualized under UV light 
using a GelRedTM staining solution (Biotium, Hayward, CA, USA).  
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6.2.3 Determination of the Hp A-61C polymorphism 
Using restriction enzyme analysis, we are also able to detect the Hp A-61C polymorphism. To this end, a PCR-
product of ± 1200 bp which encloses position -61 in the Hp gene was amplified using the forward primer  
5’-CTCCTGTTGATGGGCATTTGTCTTG-3’ and the reverse primer 5’-GGAGCTGATGACATACCCTATAAAGTC-3’ (with 
a final concentration of 1.125 µM), followed by a restriction digest with 0.5 µL BpmI (Thermo Fisher Scientific, 
Erembodegem, Belgium) for 15 min at 30°C.  
 
6.3  Results and discussion 
As discussed by Ko et al. [6] current Hp genotyping methods utilizing conventional PCR methods suffer from the 
drawback that more than one PCR reaction is needed. Therefore, we have selected our primers so that one PCR 
reaction suffices in all cases. Our first reverse primer allows amplification of a Hp 1-specific fragment, whereas 
our second reverse primer binds to the unique part between exon 4 and exon 5 of Hp allele 2, resulting in a  
Hp 2-specific sequence of 1800 bp (see Figure 6.1).  
 
 
Figure 6.1 Scheme of the primers in the new Hp genotyping method. 
 
The similar lengths of the Hp allele-specific sequences, combined with similar efficiencies of both PCR 
reactions, results in heterozygotes in bands with similar intensities, irrespective of the amount of DNA. 
Consequently, one PCR reaction suffices in all cases in our method, in contrast to other genotyping methods, 
which are characterized by large-sized products which may be difficult to amplify and to detect. E.g. using the 
method of Koch et al. [4], it is easier to amplify the Hp 1-specific band of 1700 bp than the Hp 2-specific band of 
3400 bp in heterozygotes. Consequently, the smallest band is considerably more intense than the larger band, 
which may hamper Hp genotyping of heterozygotes (i.e. heterozygotes could be falsely scored as Hp 1-1), as 
demonstrated in Figure 6.2. Therefore, a second PCR reaction which generates a Hp 2-specific PCR product of 
about 350 bp, is warranted when using the method of Koch et al. [4].  
 
Another advantage of our assay is that it is directly applicable to a 0.5 mm punch from a DBS, without prior 
DNA extraction. We only need a limited amount of starting material (one drop of blood suffices) and sampling 
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can be performed at home without dedicated staff. Furthermore, we demonstrated that our method is also 
applicable to dried oral fluid or lyzed blood (direct PCR on 1 µL) and that hemoglobin and anticoagulants do not 
hamper the PCR reaction (see Figure 6.3).  
 
To ensure the validity of our new Hp genotyping method, we performed Hp genotyping of 221 DBS using both 
the method of Koch et al. [4] and our new method. We found a 100% correlation between the genotypes 
obtained with both methods.  
 
 
Figure 6.2 Genotyping of DBS samples using the reference method of Koch et al. [4] and our new method. 
 
 
 
Figure 6.3 Influence of hematocrit (Hct) and anticoagulants on our newly developed Hp genotyping method. 
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Using restriction enzyme analysis, we are also able to detect Hp A-61C polymorphism. To this end, we 
generated a 1200 bp-fragment, enclosing position -61, followed by a restriction enzyme digestion with BpmI. In 
absence of this Hp promoter polymorphism, BpmI will recognize one cleavage site, whereas in the presence of 
this polymorphism, two cleavage sites will be recognized (see Figure 6.4). Finally, we found 3 heterozygotes. 
This observation was confirmed by DNA sequencing.  
 
 
Figure 6.4 Hp A-61C polymorphism. 
 
What can be considered a disadvantage of our method (and other conventional PCR methods for Hp 
genotyping) is the need for a laborious and time-consuming post-amplification step (i.e. running a gel). 
Although the use of labeled probes and real-time PCR may overcome this issue, this may be at the expense of 
the simplicity of our assay, which is important for high-throughput analyses. 
  
We believe that it would be useful to determine the Hp genotype for every person. Since the Hp genotype has 
been associated with various infections and diseases, Hp genotyping may increase life expectancy and reduce 
health care costs by preventing complications. As the genotype always remains the same, this determination 
only needs to be done once per patient.  
 
6.4  Conclusion 
In conclusion, a new, simple and rapid (45 min) PCR method, allowing Hp genotyping in a high-throughput 
setting was developed. There is no need for a time-consuming and expensive DNA extraction and only a limited 
amount of biological material is required, resulting in a minimal contamination risk. Furthermore, sampling can 
be done by the patient himself. Additionally, in contrast to other genotyping methods, only one PCR reaction is 
needed to come to a conclusive result in all instances, the length of the fragments allowing simple amplification 
and detection. Using the restriction fragment length polymorphism technique, we are also able to detect 
simultaneously the Hp A-61C polymorphism in the same reaction.   
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The use of dried blood spots (DBS) as an alternative sampling strategy has gained popularity during the last 
several years. This can be deduced from the increasing number of papers dealing with DBS (see Figure 7.1) and 
from the many fields in which DBS have been implemented, covering the analysis of DNA, proteins, small 
molecules (endogenous compounds, therapeutic drugs and drugs of abuse) as well as trace elements.  
 
 
Figure 7.1 Overview of the number of publications dealing with DBS in Pubmed during the last 40 years. 
 
Several committees have focused on the potential and limitations of DBS and have provided recommendations 
for the validation of bioanalytical methods for DBS with the aim to contribute to the harmonization and 
standardization of alternative matrix analysis. E.g. the European Bioanalysis Forum (EBF), which brings together 
different pharmaceutical companies and contract research organizations, with the aim to share, discuss and 
optimize different bioanalytical topics, has a topic team formed for blood microsampling and DBS approaches: 
different subteams have evaluated DBS-related issues like hematocrit (Hct), stability, dilution and the use of 
internal standard (IS). Also in the USA, there is a microsampling working group within The International 
Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium). Such cross-company 
consortia increase the understanding and improve the processes concerning DBS sampling.  
 
In this thesis, we also gave some recommendations and/or points of attention when setting up a DBS-based 
method. Although promising results have been obtained with DBS, its widespread use, application and 
acceptance in practice is limited. This is due to some practical hurdles, technical challenges and inherent 
disadvantages which have been associated with DBS sampling (see Chapter 1). From Chapter 2 till Chapter 5, 
we tackled some of these DBS-related issues. The choice of the analytes which were used for this purpose, has 
been discussed in Chapter 3. In addition to tackling DBS-related issues, each Chapter in this thesis also 
demonstrated the advantages of DBS sampling. E.g. in Chapter 5 we demonstrated the potential of DBS in post-
mortem forensic toxicology as a convenient sample preparation strategy. 
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The Hct problem is a generally acknowledged theme in DBS analysis. The effect of the Hct on quantification of 
an analyte in DBS samples is a compound-dependent matter and is influenced by many factors. It is primarily 
an issue when dealing with non-volumetrically applied spots, where discs are punched from the DBS. In 
Chapter 3, we also evaluated the influence of the Hct on the analytical results obtained with our GC-MS 
method, following “microwave-assisted on-spot derivatization”. This DBS-specific parameter should be part of 
the validation procedure for any DBS-based procedure using partial-spot approaches. However, this requires 
some additional validation work and novel and/or improved strategies to cope with the Hct effect will be 
required to support the growing and widespread use of DBS in bioanalysis. Therefore, continuous efforts to 
further understand and tackle this issue will likely be made in the future. Recently, new approaches have been 
developed to overcome the Hct problem by allowing the collection of a fixed volume of blood from a non-
volumetrically applied sample. E.g. Lenk et al. and Leuthold et al. investigated the usefulness of microfluidic-
based sampling procedures [1,2]. The first developed a ‘disposable metering device’ prototype [1], whereas the 
latter utilize a microfluidic device which consists of a foldable support system. After applying a blood of drop 
onto the inlet of a microfluidic channel, the channel is filled by capillary force. Then the support system is 
closed, allowing contact between the outlet of the channel and a DBS card. Using this microfluidic-based 
sampling procedure, no Hct effect was observed within the Hct range 0.26-0.62 for the test compound 
Mavoglurant [2]. Verplaetse and Henion confirmed that this device is an easy-to-operate instrument for 
acquiring volumetrically applied spots and considered it as a promising tool for point-of-care patient self 
sampling, doping control, workplace drug testing and in the context of driving under the influence of drugs 
(DUID) [3]. HemaSpotTM-HF (Spot-On Sciences) is another recently developed volumetric blood sampling device 
in which one drop of blood suffices. Other interesting new approaches that overcome area bias and 
homogeneity issues associated with analyzing subpunches from DBS samples are volumetric absorptive 
microsampling (VAMS) devices. These allow the collection of a fixed volume of blood from a non-volumetrically 
deposited sample onto a porous substrate, independent of the Hct. These devices are on the march and can be 
used for other biological matrices as well. Mercolini et al., for instance, quantified cathinone analogues in dried 
urine, plasma and oral fluid using VAMS [4]. Many research groups are also developing different kinds of 
devices to generate dried plasma spots following non-volumetric application of whole blood since the use of 
dried plasma spots are another way to avoid the Hct problem. Additionally, the pharmaceutical industry prefers 
microsampling of plasma rather than DBS samples for pharmacokinetic and pharmacodynamic studies. Spot-
On-Sciences, for instance, designed the HemaSpotTM-SE device that allows the separation of serum/plasma 
from blood cells. Lenk et al. also developed a microfluidic device to collect a specific volume of plasma from an 
unknown blood volume [5]. Another focus to cope with the Hct problem may lie in the exploration of the 
potential of various endogenous compounds to function as surrogate Hct markers. These compounds allow to 
estimate or predict the Hct of a DBS and allows one to determine which analytical results are reliable and 
which analyte concentrations might need a correction. E.g. in our laboratory potassium was demonstrated to 
be a good reliable marker for Hct prediction: application of a potassium-based algorithm for the quantification 
of caffeine and paraxanthine allows correction for the Hct bias [6]. Other laboratories are using this strategy as 
well, e.g. den Burger et al. performed Hct corrected analysis of creatinine in DBS through potassium 
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measurement [7]. Recently, another new interesting approach has been developed in our laboratory to predict 
the Hct from a DBS. It concerns a nondestructive method in which the total hemoglobin content is measured 
via noncontact diffuse reflectance spectroscopy [8]. The use of near-infrared spectroscopy also allows a fast, 
robust and nondestructive quantification of the Hct [9]. Development of innovative materials/substrates that 
are less affected by Hct-dependent spreading of blood and allow more homogenous distribution across spots 
will also contribute to the widespread use and acceptance of DBS. E.g. Mengerink et al. demonstrated that new 
DBS cards which consist of hydrophilically coated woven polyester fibers give spot sizes independent of the Hct 
[10]. Conclusively, this is a highly dynamic field in which various groups are busy with the development of new 
approaches to solve or to minimize the Hct issue. Pricing may be an important determinant factor when 
considering which of the proposed approaches will eventually turn out to be competitive.   
 
The addition of IS in DBS analysis is also challenging. Also here, new IS addition techniques have been 
developed. As recently studied by Abu-Rabie et al. [11], an interesting approach is spraying the IS onto the DBS 
card. They investigated different approaches to incorporate the IS in the DBS quantitative bioanalytical 
workflow and evaluated their influence on the Hct-based assay bias. They observed that when the IS spray 
addition technique is coupled with accurate volume sampling and whole spot extraction, the Hct-based assay 
bias is nullified.  
 
In order for DBS methods to become integrated in routine toxicological practice, efforts have also been made 
to automate DBS procedures, allowing high throughput analysis. E.g. Spark-Holland developed the DBSTM 
Autosampler which enables automation of the entire workflow for DBS analysis without any manual 
intervention. First a digital picture is taken from the DBS card to detect the spot and to clamp the card. Then, 
the compounds are desorbed using automated flow-through elution, followed by online solid phase extraction. 
Verplaetse and Henion nicely demonstrated that the direct coupling of automated online DBS samplers with 
new generation LC-MS/MS equipment may prove valuable to obtain sufficient sensitivity with limited amount 
of starting material [3]. Furthermore, they opted for whole spot analysis of blood samples which were obtained 
using a microfluidic-based volumetric sampling approach, resulting in a Hct-independent fully automated 
analysis.  
 
Automation in DBS bioanalysis, however, mostly requires an investment in dedicated equipment, which may 
not be considered feasible by an average laboratory. E.g. only large, well-funded laboratories will have access 
to such automated DBS systems or robotic systems. Digital microfluidic systems, on the other hand, are more 
accessible while they also reduce extraction time and the amount of solvents. Other devices/approaches which 
minimize sample preparation have been developed as well. E.g. different suppliers developed instruments to 
automate the punching of DBS samples. Perkin Elmer, for instance, developed the DBS Puncher® device which 
automatically punches dried blood samples into microtitration plates. Manicke et al. demonstrated that paper 
spray MS may also be useful to detect drugs directly from DBS without sample preparation [12]. As time 
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management is of utmost importance in any laboratory, automation and DBS direct elution techniques will 
continue to be an important part of future DBS research. 
 
Another challenge associated with DBS sampling is to obtain sufficient sensitivity since only a limited sample 
volume is available. This is relevant in e.g. the context of DUID where the lower limit of quantification (LLOQ) of 
the method should be below proposed cut-off levels or legal limits. DBS-based methods for quantification of 
cannabinoids, for instance, may be promising in the context of DUID. However, up till now, there is only one 
method attaining sufficient sensitivity to measure cut-off levels proposed by DRUID. As newer drugs (e.g. 
synthetic cannabinoids) tend to be more potent, even higher sensitivity will be required. Up till now, no DBS 
methods for synthetic cannabinoids are available. Here as well, the direct coupling of automated online DBS 
samplers with new generation LC-MS/MS equipment may prove valuable. Also other innovative approaches, 
such as the use of alginate or chitosan foam substrates, which may allow higher recoveries, may aid to achieve 
the necessary sensitivity [13]. There will be continuous improvements in analytical equipment and efforts to 
render DBS analysis high-throughput-capable.  
 
Other difficulties may lie in establishing legal limits, e.g. in driver’s licence regranting processes. Currently, 
indirect alcohol biomarkers are used to monitor the abstinence period in case of fitness to drive decisions. 
These analyses, however, have a low sensitivity and specificity. Therefore, Kummer et al. demonstrated that 
the use of direct ethanol markers obtained by non- or minimally invasive sampling techniques has potential to 
assess the alcohol consumption in cases of fitness to drive assessment [14]. They suggest to quantify 
ethylglucuronide and ethylsulfate in urine, ethylglucuronide in hair and phosphatidylethanol in capillary DBS 
(cDBS) to give an insight into the evolution of the alcohol consumption prior to sampling.  
 
An important limitation of most DBS studies is the fact that, while they demonstrated the proof-of-principle, 
the developed methods have often not yet been applied on (true patient) capillary samples or only a limited 
number of samples was included in these studies, with often no cross-comparison between venous DBS and 
cDBS. In Chapter 2, we coped with this DBS-associated issue by setting up a comparative study in which 
capillary gamma-hydroxybutyric acid concentrations were correlated to venous concentrations. To the best of 
our knowledge, this was the first study evaluating at a large scale the correlation between venous and capillary 
concentrations for a drug of abuse. This study served as the basis for similar studies which have been set up for 
other drugs of abuse. Ellefsen et al., for instance, compared capillary and venous concentrations for cocaine 
and metabolites [15], whereas Kummer et al. evaluated venous-capillary concentrations for alcohol markers 
[16].  
 
In addition, before the use of DBS as a sampling technique can move to a next stage, more bridging studies, 
comparing concentrations in cDBS with those in venous blood or plasma, need to be conducted. In Chapter 4 
such a bridging study was set up for gabapentin. Our study was the first to evaluate the use of DBS sampling for 
gabapentin monitoring and has the potential to contribute to the acceptance of DBS as a valid alternative for 
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current quantification methods. Furthermore, it adds new and relevant data to the ongoing discussion about 
the implementation of DBS sampling in therapeutic drug monitoring (TDM). Currently, serum/plasma is the 
most common matrix in routine TDM and reference intervals are based on serum/plasma levels. However, the 
use of DBS for TDM may have many advantages: 1) sampling can be performed at home without the need for 
skilled personnel, 2) sampling can be performed at any desired time, 3) monitoring results are available when 
the patient goes to the clinician for routine control, 4) samples can be easily sent by post without any biohazard 
risk, and 5) there in an increased stability of analytes in dried spots. Therefore, bridging studies are gaining 
more and more interest as they allow to convert DBS concentrations into interpretative serum/plasma values.  
 
Given the many advantages which have been associated with DBS, there will also be an increased use of other 
dried biological matrices such as urine, vitreous humour, synovial and oral fluid. We already use dried blood 
and urine spots in a routine forensic toxicological context to quantify gamma-hydroxybuytric acid and beta-
hydroxybutyric acid using GC-MS and we aim to use dried matrix spots for the detection of other compounds as 
well, e.g. for the quantification of anti-epileptics, cocaine (and metabolites),… In the future, the use of 
“microwave-assisted on-spot derivatization” could be extended to more compounds and other derivatization 
reagents could be tested as well. Multi-analyte procedures such as our newly developed GC-MS method are 
also suitable in a routine laboratory since they increase throughput by the simultaneous detection of multiple 
compounds in a single run. The use of VAMS as well as fully automated DBS analyses will also be encouraged. 
 
Not only DBS sampling, but also other microsampling techniques, in which small amounts of blood are 
collected, are gaining interest as alternative for classical venous blood sampling. E.g. in an acute setting where 
feedback on sample concentration is urgent, whole wet blood liquid microsampling is more feasible than DBS 
sampling. Liquid microsampling techniques may also play an important role in the pharmaceutical industry. 
Therefore, there will be continuous improvements and new ways to collect small amounts of blood. E.g. 
Theranos designed a Sample Collection Device (SCD) to collect blood from a fingerprick into NanotainerTM 
tubes, which are about 1.29 cm. Liquid microsamples have the advantage that they do not differ from 
traditional liquid samples, although also here this needs to be evaluated on a case-by-case basis, as differences 
have been reported for various analytes [17]. Other alternative sampling strategies, such as the sampling of 
oral fluid, hair, meconium, interstitial fluid, sweat, exhaled breath condensate and sputum, offer interesting 
opportunities as well. It has to be noted that in the latter sampling approaches, “alternative” samples are 
collected, whereas in DBS sampling, a traditional matrix (i.e. blood) is collected in an alternative way. Analysis 
of alternative biological matrices may be a good complement to blood and urine analysis, but cannot be 
considered as an alternative for blood and urine analysis. Although alternative sampling strategies (including 
DBS sampling) will never replace traditional sampling approaches, we do believe that there is a widely 
underexplored potential for these alternative sampling strategies, either in medicine, health management or in 
(forensic) toxicology.  
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In this work we focus on dried blood spots (DBS). During the last few years, there is an increased interest in the 
use of DBS, with different kinds of applications in various fields. E.g. DBS have been applied for the analysis of 
DNA, proteins, small molecules and trace elements, with applications situated in the field of epidemiology, 
therapeutic drug monitoring (TDM), toxicology, phenotyping, and so on [1]. This variety in DBS applications is 
also reflected in this work. On the one hand, we used DBS in an analytical context, on the other hand, we 
developed a DBS-based genotyping method.  
 
DBS sampling is a microsampling strategy in which the sample (i.e. ≤ 100 µL of whole blood obtained via a heel- 
or fingerprick) is collected as a spot on a (cellulose) filter paper. Many advantages have been associated with 
this alternative sampling technique [2]. First, DBS sampling is a minimally invasive sampling technique, enabling 
collection of a representative sample from animals, newborns, children and adults with minimal discomfort. 
Furthermore, it facilitates sampling at home and in remote areas as there is no need for dedicated medical staff 
[3-5]. Secondly, the dried matrix reduces the risk of infection and improves compound stability [6-10]. Third, 
DBS samples can easily be transported and stored [5,11]. In addition, DBS may simplify sample preparation 
procedures (e.g. via “on-spot derivatization”) and they are suitable for automation of sample processing and 
analysis, which renders DBS analysis high-throughput-capable [12-19]. Consequently, there has been a growing 
interest in the use of DBS applications for a variety of purposes (e.g. in a pharmaceutical, clinical or 
toxicological context), which, on its turn, has been a driving force for moving the field forward.  
 
In Chapter 1 an overview of the DBS applications in toxicology, more specifically for the analysis of abused 
substances, is given. These include therapeutic drugs which are often abused, illegal drugs and markers for 
alcohol and tobacco use. Benefits as well as limitations and challenges which have been associated with these 
diverse toxicological applications are discussed in that Chapter. In the following Chapters, we tackled several of 
the limitations which have been associated with DBS sampling.  
 
An important limitation for the implementation of DBS sampling in the industry and in routine analysis is the 
fact that a cross-comparison between capillary and venous samples is often lacking. Such studies are essential 
for the acceptance of DBS as a valid alternative for classical venous sampling. In addition, although a large 
number of studies have demonstrated the theoretical potential of DBS applications (not using true capillary 
DBS (cDBS) samples), the developed methodologies often have not been applied on a large cohort of real-life 
samples [20]. To this end, we have set up a large-scale comparative study for gamma-hydroxybutyric acid 
(GHB) (Chapter 2). We evaluated in 50 patients with a suspected GHB intoxication how capillary GHB 
concentrations (obtained by fingerprick) were correlated with venous concentrations (obtained by 
venipuncture). DBS sampling is a promising alternative for classical venous sampling in cases of (suspected) 
GHB intoxication since it allows rapid sampling, which is of interest for the rapidly metabolized GHB. However, 
as a cross-comparison between venous DBS (vDBS) and cDBS concentrations is lacking, paired cDBS and venous 
whole blood samples -of which vDBS were prepared- were collected from patients presenting at the emergency 
department of the Guy’s and St Thomas’ Hospital in London with a suspected GHB intoxication. cDBS were 
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generated by non-volumetric direct application of a drop of blood onto Whatman 903 filter paper following a 
fingerprick, whereas vDBS were prepared by pipetting 25 µL of venous blood onto the filter paper. Following a 
drying period of at least 2 hours, the DBS samples were transported to our lab in zip-closure plastic bags with 
desiccant. GHB concentrations were determined using a validated gas chromatography coupled to mass 
spectrometry (GC-MS)-based procedure previously developed in our lab [21]. The results of this study indicated 
that GHB concentrations in cDBS and vDBS are equivalent. From this, we concluded that fingerprick blood can 
be considered as a valid alternative for venous blood for GHB determination.  
 
Given the small blood volume, there are also some sensitivity issues associated with DBS analysis. Continuous 
improvements and advancements in analytical equipment and sample preparation technology, however, allow 
quantitative determination of most analytes at low ng/mL level, starting from ± 3 µL blood. To this end, liquid 
chromatography coupled to (tandem) mass spectrometry (LC-MS(/MS)) is mostly preferred, although GC 
methods also have their place [20,22-23]. To achieve sufficient sensitivity, the latter technique, however, often 
involves the introduction of a derivatization step, an additional sample preparation step which is considered as 
laborious and time-consuming. Therefore, we introduced a new derivatization strategy by combining “on-spot 
derivatization” (in which derivatization reagents are directly applied to DBS) with “microwave derivatization”, 
thereby ensuring a minimal, economic and fast sample workup and high sample throughput.   
 
In Chapter 3, we successfully validated and evaluated the applicability of this newly developed method for GHB 
and the anti-epileptic drug gabapentin. During validation, we evaluated classical parameters like linearity, 
precision, accuracy, selectivity, carry-over, dilution integrity and stability as well as DBS-specific parameters like 
the influence of the hematocrit and spotted blood volume, which may have an impact on the analytical results. 
In many cases, the benefits of DBS sampling outweigh this additional validation work. The calibration lines were 
linear between 10 and 100 µg/mL for GHB and from 1 to 30 µg/mL for gabapentin, applying a 1/x weighing 
factor. Accuracy and precision criteria were fulfilled for both compounds. Stability studies revealed that GHB 
and gabapentin were stable in DBS when stored at room temperature for 84 days. Analysis of patient samples 
demonstrated the applicability of “microwave-assisted on-spot derivatization”, followed by GC-MS analysis, in 
a routine setting. Furthermore, this newly developed GC-MS method also allows the detection of other polar 
low molecular weight molecules with clinical and/or forensic toxicological relevance, amongst which vigabatrin, 
beta-hydroxybutyric acid (BHB), 1,4- and 1,2-butanediol, propylene glycol and diethylene glycol.  
 
In many cases, there is also a need for studies evaluating the correlation between blood concentrations and 
plasma/serum concentrations, as reference intervals are typically only available for plasma (or serum). Such 
studies are coined “bridging studies”. We have set up a study like this for the anti-epileptic drug gabapentin by 
collecting paired cDBS and serum samples from gabapentin-positive patients, in the framework of a 
pharmacokinetic study (Chapter 4). For the quantification of gabapentin in DBS, our newly developed GC-MS 
procedure following “microwave-assisted on-spot derivatization” was used, whereas serum concentrations 
were determined using an independent validated LC-MS/MS method developed by Chahbouni et al. [24]. We 
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observed a mean blood-to-serum ratio of 0.85. Taking this conversion factor into account, a good correlation 
was found between measured serum concentrations and serum concentrations calculated from DBS results. 
Consequently, our data lend support to the potential of DBS for deriving plasma concentrations of this 
compound, rendering DBS-based TDM for gabapentin a feasible option, using plasma reference values as a 
guide. 
 
Our “microwave-assisted on-spot derivatization” approach is also suitable for BHB analysis. Elevated levels of 
this ketone body are found in ketotic diabetics and alcoholics and may be a contributing factor to the cause of 
death [25]. However, the sense of routinely analyzing BHB in a forensic toxicological context is unclear. 
Therefore, we performed retrospective BHB analysis of 553 blood samples, 232 urine samples and 62 vitreous 
humour samples (Chapter 5). In this unbiased study, we observed that cases with BHB concentrations above 
100 µg/mL are invariably associated with elevated levels of acetone. Analysis of the latter ketone body is 
already implemented in most routine laboratories using a headspace GC configuration for ethanol 
quantification and does not require an additional workload. Therefore, we concluded that acetone is a good 
initial marker for ketoacidosis and that BHB analysis can be limited to acetone-positive cases. We also observed 
that vitreous humour is a good alternative for blood for BHB analysis and that the interpretation of urinary BHB 
concentrations is not straightforward. The suitability of dried matrix samples for BHB analysis was also 
demonstrated with this study.   
 
The above-mentioned DBS applications concern the analysis of small polar molecules, including illegal drugs 
(such as GHB), therapeutic drugs (like gabapentin) and endogenous molecules (BHB). However, not only small 
molecules, but also trace elements, proteins, mRNA and DNA can be analyzed using DBS. The latter was 
demonstrated in Chapter 6, by setting up a DBS-based genotyping method for haptoglobin (Hp).    
 
Hp is an abundant hemoglobin-binding plasma protein, encoded by 2 common alleles, denoted 1 and 2. This Hp 
polymorphism has been reported to have important biological and clinical consequences [26]. In this respect, 
Chapter 6 can somewhat be linked to Chapter 5, as both are related to diabetes. E.g. large-scale studies have 
unequivocally shown that diabetics with the Hp 2-2 phenotype have a 2-5-fold increased risk for developing 
micro- and macrovascular complications. Since there is a perfect correlation between the Hp pheno- and 
genotype, PCR-based methods have emerged as a good alternative for time-consuming phenotyping methods. 
We therefore set up an improved PCR-based strategy, directly starting from DBS micropunches, allowing Hp 
genotyping in a high-throughput setting. Current Hp genotyping methods utilizing conventional PCR reactions 
suffer from the drawback that in most cases more than one PCR reaction is needed to conclusively determine 
the Hp genotype [27]. To this end, we have developed a genotyping method in which one PCR reaction suffices 
in all cases. Furthermore, our method is directly applicable to DBS and does not require a separate time-
consuming and expensive DNA extraction step. In addition, our method also allows the simultaneous detection 
of the Hp A-61C polymorphism, a polymorphism in the promoter region of the Hp gene which has been 
associated with ahaptoglobinemia [28].  
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Conclusively, there are numerous new developments which are rejuvenating the “old technique” of DBS 
sampling and which support the increased use of DBS. However, one should always bear in mind that, despite 
great progress which has been made in the context of DBS sampling, there will always be some limitations and 
disadvantages associated with DBS (sampling). E.g. in some circumstances rapid access to analytical results is 
required and there is no time to wait until the sample is dry. In these cases, the use of wet (micro)sampling 
techniques is still recommended. The use of DBS sampling could be encouraged for home monitoring, in 
remote areas,… The encouraging results that have been obtained with DBS, combined with the particular 
advantages of DBS (sampling), such as the possibility of prompt and convenient sampling and the increased 
stability of DBS -both of which can be of key importance in driving under the influence of drugs cases- suggest 
that DBS analysis could also play a role in e.g. future road-side drug testing. Furthermore, a wide range of other 
toxicological applications can be envisaged for DBS analysis as well, such as analyses in the context of drug-
facilitated sexual assault, the follow-up of drug or alcohol addicts, workplace monitoring, TDM and toxicological 
analysis of post-mortem samples.  
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Gedroogde bloedspots vormen de rode draad doorheen dit werk. Ze kennen de laatste jaren een enorme 
opmars en bieden tal van mogelijkheden. Zo kunnen ze gebruikt worden voor het opsporen van heel wat 
verschillende stoffen, gaande van kleine exogene (lichaamsvreemde) tot grote endogene (lichaamseigen) 
substanties. Ook is er een toegenomen interesse vanuit diverse disciplines. De verscheidenheid aan 
toepassingen waarvoor gedroogde bloedspots gebruikt kunnen worden, wordt eveneens gereflecteerd in dit 
werk. Enerzijds zullen wij gedroogde bloedspots gebruiken voor het ontwikkelen van analytische methodes in 
een toxicologische context. Anderzijds tonen wij aan dat gedroogde bloedspots eveneens gebruikt kunnen 
worden voor genotypering. Genotypering is een proces waarbij de genetische samenstelling van een individu 
bepaald wordt door een bepaalde DNA sequentie te onderzoeken.  
 
Gedroogde bloedspots worden gevormd door capillair bloed, verkregen via een vinger- of hielprik, op te 
vangen op een filterpapier. Deze manier van staalafname werd in de jaren ’60 geïntroduceerd voor neonatale 
screeningsdoeleinden, meer bepaald voor het opsporen van zeldzame metabole stoornissen in pasgeborenen 
via een hielprik. Nadien won deze alternatieve staalafname aan populariteit en werd deze techniek ook 
gebruikt in o.a. (pre-)klinische studies, farmacokinetiek, toxicologie,… De toegenomen interesse in deze 
alternatieve staalafname is te danken aan de vele voordelen van gedroogde bloedspots. De staalafname is 
namelijk weinig invasief en kan gemakkelijk worden uitgevoerd in afwezigheid van medisch personeel. 
Bovendien zorgt de gedroogde matrix voor een verhoogde stabiliteit en een verminderd risico op infectie. Het 
vergemakkelijkt eveneens de staalvoorbereiding, de bewaring en het transport. Vermits slechts een kleine 
hoeveelheid bloed wordt afgenomen, zijn gedroogde bloedspots ook erg geschikt voor het uitvoeren van 
studies op proefdieren en/of kinderen.  
 
In hoofdstuk 1 wordt een gedetailleerd overzicht gegeven van het gebruik van gedroogde bloedspots voor het 
opsporen van drugs, cotinine (afbraakproduct van nicotine), alcoholmerkers en geneesmiddelen die vaak 
misbruikt worden. Naast de vele voordelen worden ook de beperkingen, tekortkomingen en uitdagingen die 
gepaard gaan met deze diverse toxicologische toepassingen besproken. In de daaropvolgende hoofdstukken 
zullen we deze limitaties ook aanpakken.  
 
Een eerste beperking is dat heel wat methodes niet worden toegepast op reële patiëntenstalen en dat er ook 
vaak niet wordt nagegaan of er een verschil is tussen de concentraties bekomen in capillair bloed (i.e. bloed 
bekomen via een vinger- of hielprik) en deze in veneus bloed (i.e. bloed afkomstig van een klassieke 
bloedafname via de ader). Hoofdstuk 2 beschrijft een studie die werd opgezet om na te gaan of dergelijke 
capillaire-veneuze verschillen konden worden waargenomen voor de drug gamma-hydroxyboterzuur (GHB). 
Hiervoor werkten we samen met het St Thomas ziekenhuis in Londen aangezien ze daar op de spoedafdeling 
vaak geconfronteerd worden met GHB-geïntoxiceerde personen. Er werden van 50 patiënten met een 
vermoedelijke GHB-intoxicatie zowel veneuze als capillaire bloedspots aangemaakt. De capillaire spots werden 
bekomen door een druppel bloed bekomen via een vingerprik op te vangen op filterpapier. De veneuze spots 
werden bereid door 25 µL bloed, bekomen via een klassieke bloedafname, aan te brengen op filterpapier. 
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Zowel de capillaire als de veneuze bloedspots werden nadien minstens 2 uur gedroogd vooraleer ze in een 
plastiek zakje met droogstof bewaard werden en opgestuurd werden naar het laboratorium. Wij analyseerden 
deze bloedspots dan m.b.v. een accurate en gevoelige methode voor de bepaling van GHB. Hierbij maakten wij 
gebruik van “on-spot derivatisatie”, een techniek die resulteert in een snelle en efficiënte staalvoorbereiding, 
gevolgd door analyse m.b.v. gaschromatografie gekoppeld aan massaspectrometrie (GC-MS). Deze studie 
toonde aan dat er voor GHB een goede correlatie kan worden gevonden tussen de veneuze en de capillaire 
concentraties. Bijgevolg kan worden geconcludeerd dat, in het geval van GHB, capillair bloed een volwaardig 
alternatief is voor veneus bloed.  
 
Één van de voordelen van gedroogde bloedspots is dat er slechts een kleine hoeveelheid bloed wordt 
afgenomen. Dit leidt echter ook tot een bijkomende uitdaging bij het ontwikkelen van analytische methodes, 
nl. het bereiken van voldoende gevoeligheid (i.e. de mogelijkheid om lage concentraties op te sporen). 
Bijgevolg is erg gevoelige apparatuur nodig. Alhoewel de voorkeur meestal gegeven wordt aan 
vloeistofchromatografie gekoppeld aan (tandem) massaspectrometrie, kan in bepaalde gevallen de gewenste 
gevoeligheid ook bereikt worden m.b.v. GC. Hiervoor dient echter wel een derivatisatiestap geïntroduceerd te 
worden tijdens de staalvoorbereiding. Aangezien deze extra staalvoorbereidingsstap als tijdrovend beschouwd 
wordt, introduceerden we in hoofdstuk 3 een nieuwe derivatisatiestrategie. Hierbij combineerden we “on-spot 
derivatisatie” met “microgolf-geassisteerde derivatisatie”. In dit concept worden de derivatisatiereagentia 
rechtstreeks toegevoegd aan de gedroogde bloedspots en wordt de derivatisatietijd, i.e. de tijd die nodig is om 
de derivatisatiereactie te laten doorgaan, ingekort door de chemische reactie te laten doorgaan in een  
conventionele microgolfoven. De toepasbaarheid van deze nieuw ontwikkelde techniek werd nagegaan voor de 
kwantitatieve bepaling van GHB en het anti-epilepticum gabapentine m.b.v. GC-MS. Voor het valideren van de 
methode werden lineariteit, precisie, accuraatheid, selectiviteit, overdracht, mogelijkheid tot verdunnen, 
stabiliteit alsook de invloed van het bloedvolume en hematocriet geëvalueerd. De calibratielijnen waren lineair 
van 10 tot 100 µg/mL voor GHB en van 1 tot 30 µg/mL voor gabapentine. De methode was voldoende accuraat 
en precies. Stabiliteitsstudies toonden aan dat zowel gabapentine als GHB stabiel waren in gedroogde 
bloedspots die gedurende 84 dagen bij kamertemperatuur bewaard werden. Analyse van patiëntenstalen 
toonde aan dat “microgolf-geassisteerde on-spot derivatisatie”, gevolgd door GC-MS, een snelle en 
betrouwbare aanpak is die ook toepasbaar is in routine toxicologie. Bovendien is de door ons ontwikkelde GC-
MS methode ook geschikt voor het detecteren van andere polaire laagmoleculaire verbinden met klinische 
en/of forensische toxicologische relevantie, zoals vigabatrine, beta-hydroxyboterzuur (BHB), 1,4- en 1,2-
butaandiol, propyleenglycol en diethyleenglycol.  
 
Behalve een gebrek aan patiëntenstalen en de afwezigheid van onderzoek naar de correlatie tussen veneuze en 
capillaire concentraties, wordt er ook vaak geen vergelijking gemaakt met andere biologische vloeistoffen zoals 
serum of plasma. Opdat gedroogde bloedspots echter als een alternatieve staalafname zouden kunnen worden 
beschouwd, dient de correlatie tussen concentraties bekomen in bloedspots en deze in een referentiematrix te 
worden nagegaan. In hoofdstuk 4 deden we dit voor het anti-epilepticum gabapentine. Vermits de 
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referentiewaarden voor deze component enkel beschikbaar zijn in plasma/serum, worden gabapentine 
bepalingen steeds uitgevoerd in plasma/serum. Bereiden van plasma/serum vereist echter de aanwezigheid 
van medisch personeel en labo-apparatuur. Aangezien het gebruik van gedroogde bloedspots hier dus zeker 
een voordeel zou bieden, hebben wij een vergelijkende studie opgezet waarbij de concentratie aan 
gabapentine zowel in capillaire bloedspots als in serum werd bepaald. Tijdens deze studie merkten we op dat 
de concentraties in bloed, zoals verwacht, ongeveer 15% lager lagen dan de concentraties in serum. Er bleek 
echter wel een goede correlatie te bestaan tussen de gemeten serum concentraties en de serum concentraties 
berekend uit de bloedconcentraties. Hiermee toonden we aan dat capillaire bloedspots een goed alternatief 
kunnen vormen voor de bepaling van gabapentine. 
 
Een andere polaire laagmoleculaire verbinding die kan worden opgespoord met onze nieuw ontwikkelde 
methode is BHB. Dit ketonlichaam is een structuuranaloog van GHB en wordt in verhoogde concentraties 
teruggevonden bij o.a. alcoholici en diabetici. Alhoewel sterk verhoogde BHB concentraties ook lethaal kunnen 
zijn, wordt de bepaling van BHB niet routinematig uitgevoerd in een forensisch toxicologisch laboratorium. 
Enkel wanneer er o.b.v. de verkregen achtergrondinformatie een vermoeden is van ketoacidose (i.e. een sterk 
verhoogde BHB concentratie in bloed) wordt een BHB analyse uitgevoerd. In hoofdstuk 5 onderzochten we of 
het relevant is om BHB routinematig te bepalen. Hierbij voerden we een retrospectieve BHB analyse uit op 553 
bloedstalen, 232 urinestalen en 62 oogvochtstalen en merkten we op dat in het overgrote deel van de gevallen 
een lage BHB concentratie teruggevonden werd. We merkten echter ook op dat in de stalen waarbij de BHB 
concentratie hoger was dan 100 µg/mL steeds aceton, een ander ketonlichaam, teruggevonden werd. De 
bepaling van aceton gebeurt al routinematig en vereist geen bijkomende analyse. Hieruit concludeerden we 
dat aceton een goede initiële merker is voor ketoacidose en dat de bepaling van BHB beperkt kan worden tot 
aceton-positieve stalen.  
 
In bovenstaande toepassingen worden gedroogde bloedspots steeds gebruikt voor het opsporen van kleine 
polaire moleculen m.b.v. analytische methoden, meer bepaald voor het opsporen van drugs (GHB), 
therapeutische geneesmiddelen (gabapentine) of lichaamseigen moleculen (BHB). Gedroogde bloedspots 
kunnen echter ook gebruikt worden voor het opsporen van heel wat andere componenten, zoals 
(sporen)elementen, proteïnen, mRNA en DNA. Laatstgenoemde toonden we aan in hoofdstuk 6 door, 
vertrekkend van gedroogde bloedspots, een nieuwe methode voor haptoglobine (Hp) genotypering te 
ontwikkelen.  
 
Hp is een glycoproteïne dat bindt aan vrij hemoglobine en op die manier bescherming biedt tegen 
weefselschade. Net zoals hoofdstuk 5 kan ook hoofdstuk 6 gelinkt worden aan diabetes. Grootschalige studies 
hebben immers aangetoond dat diabetici met het fenotype Hp 2-2 een verhoogd risico hebben op het 
ontwikkelen van complicaties. Dit toont het belang aan van Hp fenotypering. Aangezien er een perfecte 
correlatie is tussen het Hp geno- en fenotype, vormen Hp genotyperingsmethoden een volwaardig alternatief 
voor tijdrovende fenotyperingsmethoden. Bestaande methodes voor Hp genotypering hebben echter als 
Samenvatting 
 
  
150 
 
nadeel dat meer dan 1 PCR amplificatie-reactie nodig is. Bijgevolg hebben we een verbeterde PCR-reactie 
ontwikkeld waarmee het Hp genotype eenvoudig kan worden bepaald a.d.h.v. 1 PCR-reactie. Bovendien is onze 
methode direct toepasbaar op gedroogde bloedspots en is geen voorafgaande tijdrovende en dure DNA 
extractie vereist. Ook laat onze methode toe om tegelijkertijd het Hp A-61C polymorfisme, i.e. een 
polymorfisme dat kan worden gelinkt aan ahaptoglobinemie (= afwezigheid van Hp in het bloed), op te sporen.  
 
 
 
  
  
151 
 
 
 
APPENDIX 
  
  
  
152 
 
  
  
  
153 
 
Appendix 1 Overview of abused substances determined in DBS, as discussed in Chapter 1. 
Drug category Analyte Reference Analytical 
Technique 
LLOQ 
Assay Range 
C = complete DBS / P = DBS punch 
Sample Preparation 
Recovery 
Application Stability of DBS 
Cannabinoids THC, THC-COOH and its 
glucuronide, THC-OH 
[11] LC-MS/MS NS 
 
C: 5 µL (10 mm  punch covers 
complete spot) 
PAPER: Whatman® 903 
SAMPLE PREP: online extraction with 
ACN:15mM CH3COONH4 (97:3) 
No NS 
 THC and THC-COOH [26] GC-MS 5-100 ng/mL (THC) 
5-500 ng/mL (THC-COOH) 
C: 100 µL 
PAPER: NS 
SAMPLE PREP:  
        - 500 μL saturated borate buffer 
          (pH 10) + 2 mL butyl acetate 
        - separation in fraction A & B 
        - evaporated, reconstituted and  
          derivatized with MTBSTFA/  
          MSTFA (fraction A/B) 
RECOV: 41.2% (THC) 
              32.2% (THC-COOH) 
No NS 
 THC [12] 
 
LC-MS/MS ± 50 ng/mL  C: 5 µL 
PAPER: NS 
SAMPLE PREP: 100% MeOH  
(online extraction) 
No NS 
 THC and THC-COOH [94] LC-HRMS 1 ng/mL  C: 20 µL 
PAPER: Sartorius TFN 
SAMPLE PREP:  
        - 100 µL MeOH + 400 µL TBME 
        - 300 µL acetone (2nd extraction) 
        - solvents evaporated and  
          re-dissolved in ACN:H2O (60:40) 
RECOV: 19% (THC) 
               36% (THC-COOH) 
No 7 d at 4°C 
 THC, THC-OH and THC-
COOH 
[7] LC-MS/MS 2.5-2000 ng/mL (THC) 
5-2000 ng/mL (THC-OH & 
THC-COOH) 
!! [ ]’s are those in a 
MeOH solution spiked to 
the DBS  
P: 7 mm   
PAPER: Whatman® 903 
SAMPLE PREP:  
        - 1 mL MeOH 
        - evaporated and re-dissolved 
          in mobile phase 
RECOV: 81-85% 
Yes (capillary DBS of 
subjects undergoing drug 
addiction treatment)  
Comparison with plasma 
3 months at RT 
 THC, THC-OH and THC-
COOH 
[93] LC-MS/MS 15 ng/mL C: ± 30 µL  
PAPER: Whatman® 903 Protein Saver 
cards 
 
Yes (capillary DBS of drug 
abusers) 
Comparison with urine 
immunoassay  
3 months at RT 
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SAMPLE PREP: 
        - 10 µL IS + 990 µL MeOH 
        - evaporated and re-dissolved in 
          mobile phase 
RECOV: 81.1% (THC) 
              79.0% (THC-OH) 
              78.3% (THC-COOH) 
Cocaine and 
metabolites 
(benzoylecgonine 
(BE), cocaethylene 
(CE), ecgonine 
methylester (ECME), 
norcocaine) 
BE [19] RIA 10-600 ng/mL  P: 6.4 mm  
PAPER: Whatman® 903 
SAMPLE PREP: 200 µL PBS:Tween 20  
RECOV: >95%  
Yes (autopsy samples & 
newborn DBS) 
>1024 h at 25, 45, 55°C (BE) 
108 h at 45°C (cocaine) 
 BE [56] LC-MS/MS ± 2-166 ng/mL  P: 6.4 mm  (reconstituted blood) 
SAMPLE PREP:  
        - 200 µL 2mM aqueous 
          CH3COONH4       
        - PP: 1 mL MeOH 
        - supernatant filtered,  
          evaporated and re-dissolved in 
          mobile phase 
Yes (capillary DBS from 
drug abusers and DBS 
from newborns & 
mothers)  
Comparison with RIA 
screening 
NS  
 
 BE [97] RIA, LC-MS /  P: 6.4 mm  
Procedures of Henderson et al., 1993 
[19] & Sosnoff et al., 1996 [56] 
Yes (newborn DBS) / 
 Cocaine [77] LC-MS/MS 24.6 ng/mL 
50-2000 ng/mL 
 
C: 100 µL (reconstituted blood) 
PAPER: Whatman® 903 
SAMPLE PREP:  
        -  phosphate buffer (3.5 mL,  
           pH6) 
        -  SPE  
        -  evaporated and re-dissolved in 
           mobile phase 
RECOV: 90-97% 
No 1 month at -20°C & 4°C 
1 month at RT: 19.9% ↓ 
(DBS from spiked blood) 
 Cocaine, BE and CE [6] LC-FLUO 20-1000 ng/mL (cocaine 
& BE) 
12-1000 ng/mL (CE) 
C: 10 µL (10 mm  punch) 
PAPER: Whatman® 903 
SAMPLE PREP:  
        - 500 µL MeOH 
        - evaporated and re-dissolved  
          in mobile phase 
RECOV: 92-93%  
Yes (capillary DBS of drug 
abusers) 
Comparison with plasma 
NS 
 Cocaine [26] GC-MS 50-1000 ng/mL  C: 100 µL 
PAPER: NS 
SAMPLE PREP: 
        - 500 μL saturated borate buffer 
No NS 
  
  
155 
 
          (pH 10) + 2 mL butyl acetate 
        - separation in fraction A & B 
        - evaporated, reconstituted and  
          derivatized with MTBSTFA/  
          MSTFA (fraction A/B) 
RECOV: 83.2% 
 Cocaine and BE [12,13] 
 
LC-MS/MS ± 1 ng/mL 
 
C: 5 µL 
PAPER: NS 
SAMPLE PREP: 100% MeOH (online 
extraction) 
No NS 
 Cocaine, CE, BE and 
ECME 
[8] LC-MS/MS NS (screening technique) 
LOD < 1 ng/mL (cocaine 
and CE) 
LOD 1 ng/mL (BE) 
LOD 10 ng/mL (ECME) 
C: 5 µL (6 mm  punch) 
PAPER: Whatman® 903 
SAMPLE PREP: 100 µL MeOH 
(automated) 
RECOV: 49-60% (cocaine) 
              47-58% (CE) 
              10-34% (BE) 
              77% (ECME)        
Yes (post-mortem 
samples) 
Comparison with routine 
STA screening on whole 
blood, as well as with GC-
MS(MS) and LC-MS/MS 
quantitative analyses 
NS 
 Cocaine, BE, CE and 
ECME 
[31] LC-MS/MS 5-200 ng/mL 
 
P: 3 mm  of 30 µL DBS 
PAPER: Whatman® 903 
SAMPLE PREP: 150 µL H2O        
RECOV: 100% (cocaine)  
              99.4% (BE) 
              85.9% (ECME) 
Yes (venous) (BE) 
(DUID) 
Comparison with whole 
blood 
6 months at: 
   -20°C (cocaine, BE, ECME) 
    4°C (BE) 
    4°C: ±55% ↓ (cocaine) 
    4°C: ±90% ↓ (ECME) 
 Cocaine [94] LC-HRMS 0.25 ng/mL 
 
C: 20 µL 
PAPER: Sartorius TFN 
SAMPLE PREP:  
        - 100 µL MeOH + 400 µL TBME 
        - 300 µL acetone (2nd extraction) 
        - solvents evaporated and  
          re-dissolved in ACN:H2O (60:40) 
RECOV: 67% 
No 7 d at 4°C (cocaine) 
 Cocaine, BE [96] LC-MS/MS 3.5 ng/mL (cocaine) 
2.3 ng/mL (BE) 
20-400 ng/ml (cocaine & 
BE) 
C: 20 µL 
PAPER: Whatman® 2012-10 filter 
cards 
SAMPLE PREP:  
        - 5 mL MeOH 
        - evaporated and re-dissolved   
          in mobile phase 
 RECOV:103%  (cocaine) 
              100% (BE) 
Yes (venous DBS of 
polydrug abusers) 
Comparison with whole 
blood 
NS 
 Cocaine, BE, CE and 
ECME 
[47] LC-MS/MS 2 ng/mL 3 x 3 mm   punches 
PAPER: Bond Elut Dried Matrix 
Spotting cards 
 
Yes (post-mortem 
samples) 
Comparison with routine 
analysis 
NS 
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SAMPLE PREP:  
        - 900 µL MeOH/0.1% formic 
          acid 
        - evaporated and re-dissolved 
           in 100 µL of water with 0.1% 
           of formic acid 
RECOV: 12-54% (cocaine) 
              20-44% (BE) 
              11-45% (CE) 
              25-34% (ECME) 
 
 Cocaine, BE and 
norcocaine 
[63] LC-HRMS 1-200 ng/mL P: 3 mm  
PAPER: Whatman® 903  
SAMPLE PREP: 
        - 1 mL 1% formic acid in water  
        - SPE 
        - evaporated and re-dissolved 
          in mobile phase  
RECOV: 43.3-52.1% (cocaine) 
              48.6-64.5% (BE) 
              35.2-48.6% (norcocaine) 
Yes (capillary DBS 
following controlled 
intravenous cocaine 
administration) 
Comparison with venous 
blood 
24 h at RT, 72 h at 4°C, 72 h 
at -20°C, 3 freeze-thaw 
cycles 
 Cocaine and BE [93] LC-MS/MS 5 ng/mL C: ± 30 µL 
PAPER: Whatman® 903 Protein Saver 
cards 
SAMPLE PREP: 
        - 10 µL IS + 990 µL MeOH 
        - evaporated and re-dissolved in 
          mobile phase 
RECOV: 90.8% (cocaine) 
              89.9% (BE) 
Yes (capillary DBS of drug 
abusers) 
Comparison with urine 
immunoassay  
3 months at RT 
Opiates 6-monoacetylmorphine 
(6-MAM) 
[79] LC-MS/MS NS  C: 100 µL 
PAPER: Whatman® 903 
SAMPLE PREP: 0.5% NH4OH  LLE 
(chloroform/isopropanol) 
No 6 d at 4°C, RT & 40°C 
 Morphine and 6-MAM [67] LC-MS/MS 14 ng/mL (morphine) 
27 ng/mL (6-MAM) 
50-500 ng/mL (morphine 
& 6-MAM) 
 
C: 100 µL 
PAPER: Whatman® BFC 180 
SAMPLE PREP:  
        - 1mL 0.1M borate buffer (pH 
           8.5) 
        - 1.5 mL ethyl acetate (LLE) 
        - evaporated and reconstituted  
          in  suitable solvent 
RECOV: 23-37% (morphine) 
              76-86% (6-MAM) 
Yes (venous DBS) 
(drug abusers)  
Comparison with whole 
blood 
10% ↓ in both morphine & 
6-MAM upon drying 
 
Morphine:  
     7 d at 4°C, -20°C;  
     5 d at 40°C 
6-MAM:  
     5 d at 40°C: ±50% ↓ 
 Morphine, codeine and 
their glucuronides 
[11] LC-MS/MS NS 
 
C: 5 µL (10 mm  punch covers 
complete spot) 
No NS 
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PAPER: Whatman® 903 
SAMPLE PREP: online extraction with 
ACN:15 mM CH3COONH4 (97:3) 
 Oxycodone [116] LC-MS/MS 100 pg/mL RECOV: ±85% No NS 
 Morphine, morphine-3-
glucuronide (M3G) and 
morphine-6-glucuronide 
(M6G) 
[100] 
 
LC-MS/MS 
 
1-1000 ng/mL (morphine 
& M3G) 
2.5-1000 ng/mL 
(M6G) 
P: 6.4 mm  from 50 µL spot 
PAPER: Whatman® 903 
SAMPLE PREP:  
        - 100 µL H2O 
        - PP 
RECOV: 99.6-108.3% (morphine) 
              95.6-102% (M3G) 
              99.7-103.3% (M6G) 
Yes (method used in PK 
studies) 
≥ 3 freeze-thaw cycles; 
≥ 3 d at RT 
7 d at 4°C, -20°C, -80°C 
 Morphine, hydro-
morphone, oxycodone 
and noroxycodone 
[101] LC-MS/MS NS  C: 100 µL 
PAPER: Whatman® 903 
Yes (venous DBS) 
Comparison with whole 
blood 
NS 
 Morphine and codeine [26] GC-MS 10-1000 ng/mL  C: 100 µL 
PAPER: NS 
SAMPLE PREP:  
        - 500 μL saturated borate buffer 
          (pH 10) + 2 mL butyl acetate 
        - separation in fraction A & B 
        - evaporated, reconstituted and  
          derivatized with MTBSTFA/  
          MSTFA (fraction A/B) 
RECOV: 50% (morphine) 
              >75% (codeine) 
No NS 
 Morphine, codeine, 6-
MAM and hydrocodone 
[12,13] 
 
LC-MS/MS ± 20 ng/mL (morphine) 
± 5 ng/mL (codeine) 
± 1 ng/mL (6-MAM, 
hydrocodone) 
C: 5 µL 
PAPER: NS 
SAMPLE PREP: 100% MeOH (online 
extraction) 
No NS 
 Morphine, 6-MAM, M3G 
and codeine 
[8] LC-MS/MS NS (Screening technique) 
LOD 100 ng/mL 
(morphine) 
LOD 5 ng/mL (6-MAM) 
LOD 10 ng/mL (M3G) 
LOD 50 ng/mL (codeine) 
C: 5 µL (6 mm  punch) 
PAPER: Whatman® 903 
SAMPLE PREP: 100 µL MeOH 
(automated) 
RECOV: 20% (morphine) 
              38% (6-MAM) 
              17% (M3G) 
              40% (codeine) 
Yes (post-mortem 
samples) 
Comparison with routine 
STA screening on whole 
blood, as well as with GC-
MS(MS) and LC-MS/MS 
quantitative analyses 
NS 
 Morphine, 
hydromorphone, 
codeine, hydrocodone, 
oxymorphone, 
dihydrocodeine and 
oxycodone 
[45] LC-MS/MS 5-1000 ng/mL  
 
Except oxycodone 10-
1000 ng/mL 
2 x 5 mm  punches 
PAPER: Ahlstrom 226 
SAMPLE PREP:  5% formic acid 
RECOV: ±65% 
 
Yes  
Comparison with plasma 
32 d 
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Morphine, codeine, M3G 
and M6G 
[31] LC-MS/MS 5-200 ng/mL 
(morphine, codeine) 
10-200 ng/mL 
(M3G & M6G) 
P: 3 mm  of 30 µL DBS 
PAPER: Whatman® 903 
SAMPLE PREP: 150 µL H2O 
RECOV: 90% (morphine) 
              93.2% (codeine) 
Yes (venous DBS) 
Comparison with whole 
blood (morphine) 
6 months at -20°C 
 Morphine [61] LC-MS/MS 4-1000 ng/mL  P: 3 mm   
PAPER: Whatman® 903 
SAMPLE PREP: 100 µL MeOH:H2O 
(1:9)               
No NS 
 Codeine, morphine and 
6-MAM 
[96] LC-MS/MS 9.4 ng/mL (codeine) 
10 ng/mL (morphine) 
11 ng/mL (6-MAM) 
100-2000 ng/mL 
C: 20 µL 
PAPER: Whatman® 2012-10 filter 
cards 
SAMPLE PREP:  
        - 5 mL MeOH 
        - evaporated and re-dissolved   
          in mobile phase  
RECOV: 101% (codeine) 
              98% (morphine) 
              100% (6-MAM) 
Yes (venous DBS of 
polydrug abusers) 
Comparison with whole 
blood and plasma 
NS 
 Morphine and 6-MAM [47] LC-MS/MS 2 ng/mL 3 x 3 mm  punches 
PAPER: Bond Elut Dried Matrix 
Spotting cards 
SAMPLE PREP:  
        - 900 µL MeOH/0.1% formic 
          acid 
        - evaporated and re-dissolved 
          in 100 µL of water with 0.1% 
          of formic acid 
RECOV: 16-33% (morphine) 
              17-46% (6-MAM) 
Yes (post-mortem 
samples) 
Comparison with routine 
analysis 
 
NS 
 Morphine, codeine, 
oxycodone and 
hydrocodone 
[40] LC-MS/MS 1-500 ng/mL P: 2 mm   ≈ clamp size 
PAPER: Ahlstrom 226 
SAMPLE PREP: DBSA: 
        - automated flow-through 
          elution of DBS cards  
        - online SPE 
        - elution from the SPE cartridge 
          onto the LC column using the 
          LC mobile phase 
RECOV: 77.3-78.1% (morphine) 
              68.8-70.1% (codeine) 
              72.9-78.0% (oxycodone) 
              71.7-74.0% (hydrocodone) 
Yes (capillary DBS of 
volunteer who was 
administered 10 mg 
hydrocodone) 
Morphine: 30 d at RT, 55 d 
at 4°C, 95 d at -20°C 
Codeine, oxycodone, 
hydrocodone: 15 d at RT,  
95 d at 4°C & -20°C 
 Morphine, codeine and 
6-MAM 
[93] LC-MS/MS 5 ng/mL C: ± 30 µL 
PAPER: Whatman® 903 Protein Saver 
Yes (capillary DBS of drug 
abusers) 
3 months at RT 
  
  
159 
 
cards 
SAMPLE PREP: 
        - 10 µL IS + 990 µL MeOH 
        - evaporated and re-dissolved in 
          mobile phase 
RECOV: 83.6% (morphine) 
              88.0% (codeine) 
              89.2% (6-MAM) 
Comparison with urine 
immunoassay  
Non-opiate opioids Methadone and 
metabolites (EDDP, 
EMDP) 
[30] LC-MS/MS 0.1-100 ng/mL  P: 6.4 mm   
PAPER: Whatman® 903 
SAMPLE PREP:  
        - 100 µL H2O 
        - PP 
        - online extraction 
RECOV: NS 
No NS 
 Methadone [26] GC-MS 10-1000 ng/mL 
 
C: 100 µL 
PAPER: NS 
SAMPLE PREP:  
        - 500 μL saturated borate buffer 
          (pH 10) + 2 mL butyl acetate 
        - separation in fraction A & B 
        - evaporated, reconstituted and  
          derivatized with MTBSTFA/  
          MSTFA (fraction A/B) 
RECOV: 78.5% 
No NS 
 Methadone and EDDP [12,13] 
 
LC-MS/MS ± 1 ng/mL (methadone) 
± 5 ng/mL (EDDP) 
C: 5 µL 
PAPER: NS 
SAMPLE PREP: 100% MeOH (online 
extraction) 
NS NS 
 Methadone [8] LC-MS/MS NS  
Screening technique 
LOD < 1 ng/mL  
C: 5 µL (6 mm  punch) 
PAPER: Whatman® 903 
SAMPLE PREP: 100 µL MeOH 
(automated) 
RECOV: 36-56% (methadone) 
 
Yes (post-mortem 
samples) 
Comparison with routine 
STA screening on whole 
blood, as well as with GC-
MS(MS) and LC-MS/MS 
quantitative analyses 
NS 
 Methadone [45] LC-MS/MS 5-1000 ng/mL  2 x 5 mm  punches 
PAPER: Ahlstrom 226 
SAMPLE PREP:  5% formic acid 
RECOV: ±65% 
Yes  
Comparison with plasma 
32 d 
 Methadone [20] LC-
Coulometry 
4 ng/mL 
4-500 ng/mL (on-column 
concentration) 
C: Theoretical volume calculated  
from  
PAPER: Whatman® FTA® classic 
SAMPLE PREP:  
        - 250 μL phosphate buffer/ACN   
Yes (capillary DBS from 
methadone maintenance 
patients) 
Comparison with plasma 
1 month at RT  
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          (20:80): microwave-assisted      
           elution 
 - evaporated and re-dissolved in   
           250μL phosphate buffer     
         - SPE: MEPS  
         - evaporated and re-dissolved in  
           mobile phase  
RECOV: 90.1-94.8% 
 Methadone [10] LC-MS 2 ng/mL 
17.5-560 ng/mL 
C: 10 µL (8 mm Ø) 
PAPER: alginate and chitosan foam 
SAMPLE PREP: 
         - foam dissolved in 300 μL  
           1 mM HCl  
         - EME: 10 min, 21µL 10 mM 
           HCOOH 
         - diluted 1:1 with mobile phase 
RECOV: 105% (alginate) 
              115% (chitosan) 
No 50 d at -18°C, 4°C, RT & 
37°C 
 Methadone 
Pethidine 
[36] LC-MS/MS 0.3 ng/mL P: 3 mm  
PAPER: Agilent Bond Elut DMS 
SAMPLE PREP:  
         - 500 µL MeOH:0.1% HCOOH  
           (80:20) 
         - diluted with 10 mM HCl (1:1) 
         - EME (25 min; 25 µL 10 mM 
           HCl) 
RECOV: 48% (methadone) 
              17% (pethidine) 
No NS 
 Methadone [47] LC-MS/MS 0.2-50 ng/mL 3 x 3 mm  punches 
PAPER: Bond Elut Dried Matrix 
Spotting cards 
SAMPLE PREP:  
         - 900 µL MeOH/0.1% formic 
           acid 
         - evaporated and re-dissolved 
           in 100 µL of water with 0.1% 
           of formic acid 
RECOV: 15-31%  
Yes (post-mortem 
samples) 
Comparison with routine 
analysis 
 
NS 
 Methadone and EDDP [93] LC-MS/MS 5 ng/mL C: ± 30 µL 
PAPER: Whatman® 903 Protein Saver 
cards 
SAMPLE PREP: 
         - 10 µL IS + 990 µL MeOH 
         - evaporated and re-dissolved in 
           mobile phase 
Yes (capillary DBS of drug 
abusers) 
Comparison with urine 
immunoassay  
3 months at RT 
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RECOV: 81.7% (methadone) 
              79.5% (EDDP) 
 Buprenorphine and 
metabolites 
(norbuprenorphine and 
their glucuronides) 
[11] 
 
LC-MS/MS NS 
 
C: 5 µL (10 mm  punch covers 
complete spot) 
PAPER: Whatman
®
 903 
SAMPLE PREP: online extraction with 
ACN:15 mM CH3COONH4 (97:3) 
Yes (animal study) 
 
NS 
 Buprenorphine [116] LC-MS/MS NS (>25 pg/mL) RECOV: ±45% No NS 
 Buprenorphine [26] 
 
 
 
GC-MS 5-100 ng/mL 
 
C: 100 µL 
PAPER: NS 
SAMPLE PREP:  
         - 500 μL saturated borate buffer 
           (pH 10) + 2 mL butyl acetate 
         - separation in fraction A & B 
         - evaporated, reconstituted and  
           derivatized with MTBSTFA/  
           MSTFA (fraction A/B) 
RECOV: 49.8% 
No NS 
 Buprenorphine [13] LC-MS/MS NS C: 5 µL 
PAPER: NS 
SAMPLE PREP: 100% MeOH (online 
extraction) 
No NS 
 Buprenorphine [45] LC-MS/MS 1-100 ng/mL   2 x 5 mm  punches 
PAPER: Ahlstrom 226 
SAMPLE PREP: 5% formic acid 
RECOV: ±65% 
Yes  
Comparison with plasma 
21 d 
 Fentanyl and 
metabolites (norfentanyl 
and 
despropionylfentanyl) 
[103] LC-MS/MS 0.1-100 ng/mL (fentanyl) 
0.25-100 ng/mL 
(norfentanyl & 
despropionylfentanyl) 
P: 6.4 mm  from 50 µL spot 
PAPER: Whatman® 903 
SAMPLE PREP:  
         - 100 µL H2O 
         - PP 
RECOV: 75-78% 
Yes 
(PK study in neonates & 
children) 
DBS from spiked blood 
6 d at -20°C & -80°C 
3 d at RT (all 3 analytes) 
5 d at RT (fentanyl) 
 
 Fentanyl and norfentanyl [101] LC-MS/MS NS  C: 100 µL 
PAPER: Whatman® 903 
Yes (venous DBS) 
Comparison with whole 
blood 
NS 
 Fentanyl [12,13] 
 
LC-MS/MS ± 0.2 ng/mL  C: 5 µL 
PAPER: NS 
SAMPLE PREP: 100% MeOH (online 
extraction) 
NS NS 
 Fentanyl [45] LC-MS/MS 0.5-100 ng/mL  2 x 5 mm  punches 
PAPER: Ahlstrom 226 
SAMPLE PREP: 5% formic acid 
RECOV: ±65% 
Yes  
Comparison with plasma 
32 d 
 Fentanyl, alfentanyl, 
norfentanyl, sufentanyl 
[47] LC-MS/MS 0.2 ng/mL 3 x 3 mm  punches Yes (post-mortem 
samples) 
NS 
  
  
162 
 
PAPER: Bond Elut Dried Matrix 
Spotting cards 
SAMPLE PREP:  
         - 900 µL MeOH/0.1% formic 
           acid 
         - evaporated and re-dissolved 
           in 100 µL of water with 0.1% 
           of formic acid 
RECOV: 14-54% (fentanyl) 
              14-52% (alfentanyl) 
              22-48% (sufentanyl) 
              21-44% (norfentanyl) 
Comparison with routine 
analysis 
 
 Fentanyl [40] LC-MS/MS 0.1-50 ng/mL P: 2 mm   ≈ clamp size 
PAPER: Ahlstrom 226 
SAMPLE PREP: DBSA: 
         - automated flow-through 
           elution of DBS cards  
         - online SPE 
         - elution from the SPE cartridge 
           onto the LC column using the 
           LC mobile phase 
RECOV: 73.5-74.6%  
No Fentanyl: 30 d at RT, 55 d at 
4°C, 95 d at -20°C 
 Tramadol 
 
 
 
 
[26] 
 
 
 
 
GC-MS 50-5000 ng/mL C: 100 µL 
PAPER: NS 
SAMPLE PREP:  
         - 500 μL saturated borate buffer 
           (pH 10) + 2 mL butyl acetate 
         - separation in fraction A & B 
         - evaporated, reconstituted and  
           derivatized with MTBSTFA/  
           MSTFA (fraction A/B) 
RECOV: 78% 
No NS 
 Tramadol [12] 
 
LC-MS/MS ± 0.5 ng/mL  C: 5 µL 
PAPER: NS 
SAMPLE PREP: 100% MeOH (online 
extraction) 
NS NS 
 Tramadol and ODM-
tramadol 
[45] LC-MS/MS 5-1000 ng/mL  2 x 5 mm  punches 
PAPER: Ahlstrom 226 
SAMPLE PREP: 5% formic acid 
RECOV: ±65% 
Yes  
Comparison with plasma 
32 d 
Benzodiazepines Diazepam, 
flunitrazepam, 
lorazepam, nitrazepam, 
oxazepam and 
temazepam 
[77] 
 
 
 
 
LC-MS/MS 9.9 ng/mL (diazepam) 
15.8 ng/mL 
(flunitrazepam) 
11 ng/mL (lorazepam) 
18 ng/mL (nitrazepam) 
C: 100 µL (reconstituted blood) 
PAPER: Whatman® 903 
SAMPLE PREP:  
         - phosphate buffer (3.5 mL, 
           pH6) 
No (DBS from spiked blood) 
1 month at -20°C 
1 month at 4°C 
1 month at RT: 
Diazepam: 12.3% ↓        
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20.6 ng/mL (oxazepam) 
10.8 ng/mL (temazepam) 
50-2000 ng/mL 
         - SPE 
         - evaporated and re-dissolved 
           in mobile phase 
RECOV: 81-106% (diazepam) 
Flunitrazepam: 15% ↓ 
Lorazepam: 11% ↓; 
Nitrazepam:  15.5% ↓ 
Oxazepam: 12% ↓ 
Temazepam: 15% ↓ 
 Midazolam [117,118] LC-MS/MS 100 pg/mL 
 
P: 4 mm  of 20 µL DBS 
SAMPLE PREP: MeOH 
Yes At -80°C, -20°C and at RT 
 Diazepam, nordiazepam, 
oxazepam and oxazepam 
glucuronide 
[11] LC-MS/MS NS 
 
C: 5 µL (10 mm  punch covers 
complete spot) 
PAPER: Whatman® 903 
SAMPLE PREP: online extraction with 
ACN:15 mM CH3COONH4 (97:3) 
No NS 
 Midazolam [119] LC-MS/MS 0.35 ng/mL 
0.35-72 ng/mL  
P: 3 mm  
PAPER: Whatman® FTA® EluteTM 
SAMPLE PREP: 100 µL MeOH      
Yes (clinical samples) 5 d at RT 
 Alprazolam [120] LC-MS/MS 0.1-500 ng/mL  P:  4 mm  
PAPER: DMPK A, B and C cards 
SAMPLE PREP:  
         - 100 μl MeOH 
         - supernatant diluted with H2O  
           (1:1) 
No NS 
 Midazolam [46] LC-MS/MS 0.1-100 ng/mL  
Except when using a  
3-mm  punch:  
0.3-100 ng/mL 
P: 6 mm  (fully validated) 
    3 mm  (partially validated) 
    2 x 3 mm  (partially validated) 
PAPER: Ahlstrom 226 
SAMPLE PREP:   
         - 50 µL H2O to pre-wet 
         - 1000 µL MeOH 
         - evaporated and re-dissolved in  
           a suitable solvent  
RECOV: ±40% 
Yes (phenotyping study) 
Comparison with plasma 
and whole blood 
4 w at RT 
 Alprazolam [91] LC-MS/MS 0.7 ng/mL 
2.5-50 ng/mL 
 
C: 100µL (18 mm  punch covers 
complete spot) 
PAPER: Whatman® 903 
SAMPLE PREP:  
         - 1 mL borate buffer pH 8.5   
           + 1mL toluene/isoamylalc. 
           (95:5) => LLE 
         - evaporated and re-dissolved 
           in mobile phase 
Yes (venous DBS) 
(DUID study) 
Comparison with whole 
blood 
NS 
 Lorazepam, alprazolam, 
clonazepam, midazolam, 
nitrazepam, 
phenazepam, 
nordiazepam, oxazepam, 
[26] GC-MS 5-250 ng/mL (lorazepam) 
5-500 ng/mL (alprazolam 
& clonazepam) 
10-1000 ng/mL 
(midazolam & 
C: 100 µL 
PAPER: NS 
SAMPLE PREP:  
         - 500 μL saturated borate buffer 
           (pH 10) + 2 mL butyl acetate 
No NS 
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diazepam and 
temazepam) 
nitrazepam) 
20-1000 ng/mL 
(phenazepam) 
20-2000 ng/mL 
(nordiazepam) 
50-1250 ng/mL 
(oxazepam) 
50-2500 ng/mL 
(diazepam) 
50-5000 ng/mL 
(temazepam) 
         - separation in fraction A & B 
         - evaporated, reconstituted and  
           derivatized with MTBSTFA/  
           MSTFA (fraction A/B) 
RECOV: 87.4-96.6% 
 
 Midazolam, alprazolam 
and OH-alprazolam 
[37] LC-MS/MS 1-500 ng/mL  P: 3 mm  
PAPER: Ahlstrom 226 
SAMPLE PREP:  
         - 250 µL MeOH  
           (semi-automated extraction) 
         - evaporated and re-dissolved 
           in a suitable solvent 
No NS 
 Prazepam, clobazam, 
flurazepam, midazolam, 
triazolam, alprazolam, 7-
aminoflunitrazepam, 
nitrazepam, 
nordiazepam, 
temazepam, OH-
midazolam, 
flunitrazepam, 
lorazepam, clonazepam, 
diazepam and oxazepam 
[12,13] 
 
LC-MS/MS ± 0.1 ng/mL (prazepam) 
± 0.5 ng/mL (clobazam, 
flurazepam, midazolam, 
triazolam); ± 1 ng/mL 
(alprazolam, 7-
aminoflunitrazepam, 
nitrazepam, 
nordiazepam, 
temazepam), ± 2 ng/mL 
(OH-midazolam) 
± 5 ng/mL 
(flunitrazepam, 
lorazepam) 
± 10 ng/mL (clonazepam, 
diazepam, oxazepam) 
C: 5 µL 
PAPER: NS 
SAMPLE PREP: 100% MeOH (online 
extraction) 
No NS 
 Diazepam, 7-
aminoclonazepam, 
midazolam and OH-
midazolam 
[8] LC-MS/MS NS 
Screening technique 
LOD 50 ng/mL 
(diazepam) 
LOD 100 ng/mL (7-
aminoclonazepam) 
LOD <1 ng/mL 
(midazolam) 
LOD 5 ng/mL (OH-
midazolam) 
C: 5 µL (6 mm  punch) 
PAPER: Whatman® 903 
SAMPLE PREP: 100 µL MeOH 
(automated) 
RECOV: 42% (diazepam) 
              25% (7-aminoclonazepam) 
              48% (midazolam) 
              40% (OH-midazolam) 
Yes (post-mortem 
samples) 
Comparison with routine 
STA screening on whole 
blood, as well as with GC-
MS(MS) and LC-MS/MS 
quantitative analyses 
NS 
 Desmethylflunitrazepam, 
flurazepam, 
[5] 
 
LC-MS/MS 1ng/mL 
0.5-100 ng/mL 
C: 5 µL (6 mm  punch covers 
complete spot) 
Yes (venous DBS) 
(DUID)  
30 d at -20°C & RT 
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lormetazepam, 
triazolam, alprazolam, 
OH-alprazolam, 
clonazepam, 7-
aminoclonazepam, 
desalkylflurazepam, 
flunitrazepam, 7-
aminoflunitrazepam, 
lorazepam, midazolam, 
OH-midazolam, 
clobazam, diazepam, 
nitrazepam, 
nordiazepam, oxazepam, 
prazepam and 
temazepam 
(desmethylflunitrazepam, 
flurazepam, 
lormetazepam, 
triazolam) 
4 ng/mL 
2-500 ng/mL 
(alprazolam, OH-
alprazolam, clonazepam, 
7-aminoclonazepam, 
desalkylflurazepam, 
flunitrazepam, 7-
aminoflunitrazepam, 
lorazepam, midazolam, 
OH-midazolam) 
40 ng/mL 
20-5000 ng/mL 
(clobazam, diazepam, 
nitrazepam, 
nordiazepam, oxazepam, 
prazepam, temazepam) 
PAPER: Whatman® 903 
SAMPLE PREP: 100 µL MeOH (in-vial 
extraction) 
RECOV: 51.9-98% 
 
Comparison with routine 
LC-MS method 
 Midazolam [39] LC-HRMS 5-1000 ng/mL (online) 
 
P: 2 mm   ≈ clamp size 
SAMPLE PREP:  
         - SCAP: DBS cards were  
           automatically positioned into 
           the mobile phase flow path, 
           followed by online extraction,        
           using the mobile phase as 
           extraction solvent. 
RECOV: 80.6% DMPK-C 
              66.2% Auto DBS cards 
Yes (animal study) 50 d at RT 
 Alprazolam, 
bromazepam, 
clordiazepoxide, 
clobazam, clonazepam, 
clotiazepam, diazepam, 
estazolam, 
flunitrazepam, 
flurazepam, lorazepam, 
midazolam, nitrazepam, 
nordiazepam, oxazepam, 
prazepam, temazepam, 
triazolam, 7-
aminoclonazepam, 7-
aminoflunitrazepam, 7-
aminonitrazepam, OH-
[122] LC-MS/MS 4 ng/mL (alprazolam, 
clonazepam) 
2 ng/mL (bromazepam, 
chlordiazepoxide, 
clobazam, diazepam, 
estazolam, 
flunitrazepam, 
flurazepam, lorazepam, 
midazolam, nitrazepam, 
prazepam, triazolam, OH-
alprazolam, OH-
midazolam, OH-
triazolam, 
desalkylflurazepam)  
3.5 ng/mL (nordiazepam) 
P: 6 mm  
PAPER: FTA DMPK-C  
SAMPLE PREP:  
         - 300 µL MeOH:ACN (1/1) 
         - evaporated and re-dissolved in 
           100 µL mobile phase 
RECOV: 62.1-82.9% (alprazolam) 
              63.5-84.2% (bromazepam) 
              59.3-97.5% (chlordiazepo- 
              xide) 
              75.6-78.6% (clobazam) 
              59.1-79.3%  (clonazepam) 
              69.9-86.4% (diazepam) 
              71.4-86.4% (estazolam) 
              74.4-85.3% (flunitrazepam) 
No NS 
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alprazolam, OH-
midazolam,OH-triazolam 
and desalkylflurazepam 
3 ng/mL (oxazepam, 
temazepam) 
2.5 ng/mL (7-
aminoclonazepam, 7-
aminoflunitrazepam, 7-
aminonitrazepam) 
              62.7-78.1% (flurazepam) 
              53.6-74.9% (lorazepam) 
              65.0-89.9% (midazolam) 
              85.5-92.2% (nitrazepam) 
              66.7-85.1% (nordiazepam) 
              67.8-94.1% (oxazepam) 
              71.3-92.6% (prazepam) 
              72.5-87.1% (temazepam) 
              75.6 -82.7% (triazolam)  
              65.1-78.3% (7-aminoclonaze- 
              pam) 
              64.3-70.1% (7-aminoflunitra- 
              zepam) 
              60.7-79.8% (7-aminonitraze- 
              pam) 
              67.6-89.2% (OH-alprazolam)  
              67.4-79.0% (OH-midazolam) 
              58.7-79.0% (OH-triazolam) 
              73.2-93.7% (desalkylfluraze- 
              pam) 
 Medazepam, oxazepam, 
lorazepam, alprazolam, 
clonazepam, midazolam, 
nordiazepam, 
lormetazepam and 
diazepam 
[93] LC-MS/MS 1 ng/mL (medazepam,  
lorazepam, alprazolam, 
clonazepam, midazolam, 
nordiazepam, 
lormetazepam and 
diazepam) 
5 ng/mL (oxazepam) 
C: ± 30 µL 
PAPER: Whatman® 903 Protein Saver 
cards 
SAMPLE PREP: 
         - 10 µL IS + 990 µL MeOH 
         - evaporated and re-dissolved in 
           mobile phase 
RECOV: 84.8% (medazepam) 
              81.5% (oxazepam) 
              88.0% (lorazepam) 
              89.6% (alprazolam) 
              83.7% (clonazepam) 
              81.2% (midazolam) 
              88.4% (nordiazepam) 
              88.6% (lormetazepam) 
              89.3% (diazepam) 
Yes (capillary DBS of drug 
abusers) 
Comparison with urine 
immunoassay  
3 months at RT 
Z-drugs Zolpidem [9] LC-MS/MS (0.1-500 ng/mL) P: 3 mm  of 15 µL DBS 
PAPER: Bond Elut DMS 
SAMPLE PREP:  
         - 300 µL 0.1% HCOOH in 80% 
           MeOH 
         - evaporated and reconstituted 
           in mobile phase 
RECOV: 102-110% 
No NS 
 Zolpidem [12,13] LC-MS/MS ± 1 ng/mL  C: 5 µL No NS 
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 PAPER: NS 
SAMPLE PREP: 100% MeOH (online 
extraction) 
 Zolpidem [8] LC-MS/MS NS 
Screening technique 
LOD < 1 ng/mL  
C: 5µL (6 mm  punch) 
PAPER: Whatman
®
 903 
SAMPLE PREP: 100 µL MeOH 
(automated) 
RECOV: 35%  
 
Yes (post-mortem 
samples) 
Comparison with routine 
STA screening on whole 
blood, as well as with GC-
MS(MS) and LC-MS/MS 
quantitative analyses 
NS 
 Zolpidem [5] 
 
LC-MS/MS 4 ng/mL 
2-500 ng/mL  
C: 5 µL (6 mm  punch covers 
complete spot) 
PAPER: Whatman® 903 
SAMPLE PREP: 100 µL MeOH (in-vial 
extraction) 
RECOV: 66.4-81.6% 
Yes (venous DBS) 
(DUID) 
Comparison with routine 
LC-MS method 
30 d at -20°C & RT 
 Zolpidem [122] LC-MS/MS 2.5 ng/mL P: 6 mm  
PAPER: FTA DMPK-C  
SAMPLE PREP:  
         - 300 µL MeOH:ACN (1/1) 
         - evaporated and re-dissolved in 
           100 µL mobile phase 
RECOV: 63.4-83.3%  
No NS 
 Zopiclone  [26] GC-MS 10-1000 ng/mL 
 
C: 100 µL 
PAPER: NS 
SAMPLE PREP:  
        - 500 μL saturated borate buffer 
          (pH 10) + 2 mL butyl acetate 
        - separation in fraction A & B 
        - evaporated, reconstituted and  
          derivatized with MTBSTFA/  
          MSTFA (fraction A/B) 
RECOV: 79.3% 
No NS 
 Zopiclone [12,13] 
 
LC-MS/MS ± 2 ng/mL  C: 5 µL 
PAPER: NS 
SAMPLE PREP: 100% MeOH (online 
extraction) 
No NS 
 Zopiclone [91] 
 
LC-MS/MS 1.2 ng/mL  
2.5-50 ng/mL  
 
C: 100 µL 
PAPER: Whatman® 903 
SAMPLE PREP:  
         -  1 mL borate buffer pH 8.5  
            + 1mL toluene/isoamylalc. 
            (95:5) => LLE 
         -  evaporated and re-dissolved in  
            mobile phase 
Yes (venous DBS) 
(DRUID study) 
Comparison with whole 
blood 
NS 
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 Zopiclone and ACP (2-
amino-5-chloropyridine) 
[78] LC-MS/MS 6.4 ng/mL 
(zopiclone) 
0.14 ng/mL 
(ACP) 
 
C: 100 µL 
PAPER: Whatman® 903 
SAMPLE PREP:  
         - 1 mL borate buffer pH 8.5  
           + 1mL toluene/isoamylalc. 
           (95:5) => LLE 
         - evaporated and re-dissolved in  
           mobile phase 
RECOV: 67.1-79.7% (zopiclone) 
              80.4-83.8% (ACP) 
Yes Authentic & spiked DBS 
30 d at -20°C 
22 d at 4°C 
8-30 d at 20°C 
3 d at 40°C 
 Zopiclone [5] 
 
LC-MS/MS 4 ng/mL C: 5 µL (6 mm  punch covers 
complete spot) 
PAPER: Whatman® 903 
SAMPLE PREP: 100 µL MeOH (in-vial 
extraction) 
RECOV: 61.6-67.2% 
No 30 d at -20°C & RT 
 Zaleplon [5] 
 
LC-MS/MS 4 ng/mL C: 5 µL (6 mm  punch covers 
complete spot) 
PAPER: Whatman® 903 
SAMPLE PREP: 100 µL MeOH (in-vial 
extraction) 
RECOV: 77.4-89.8% 
No 30 d at -20°C & RT 
Amphetamine and 
analogues 
Amphetamine and 
MDMA 
[79] LC-MS/MS NS  C: 100 µL 
PAPER: Whatman® 903 
SAMPLE PREP: 0.1M NaOH  LLE 
(ethyl acetate) 
Yes (venous) 
Comparison with whole 
blood 
NS 
 Amphetamine, MDMA 
and MDA 
[91] 
 
LC-MS/MS 3.0 ng/mL  
5-50 ng/mL 
(amphetamine) 
5.7 ng/mL  
50-400 ng/mL (MDMA) 
0.4 ng/mL  
2.5-30 ng/mL (MDA) 
C: 100 µL (18 mm  punch covers 
complete spot) 
PAPER: Whatman® 903 
SAMPLE PREP:  
         - 1 mL 0.01 M NaOH  
         - LLE: 1.5 mL ethyl acetate 
         - acidified, evaporated and re- 
           dissolved in  mobile phase  
Yes (venous DBS) 
(DRUID study) 
Comparison with whole 
blood 
NS 
 MDMA and MDA [121] LC-MS/MS 5.7 ng/mL  
5-40 & 50-400 ng/mL 
(MDMA) 
0.40 ng/mL  
0.25-3 & 2.5-30 ng/mL 
(MDA) 
 
C: 100 µL (18 mm  punch covers 
complete spot) 
PAPER: Whatman® 903 
SAMPLE PREP:  
         - 1 mL 0.01 M NaOH  
         - LLE: 1.5 mL ethyl acetate 
         - acidified, evaporated and re- 
           dissolved in  mobile phase 
RECOV: >85% (MDMA)     
              >95% (MDA) 
Yes (venous DBS) 
(DRUID study) 
Comparison with whole 
blood 
NS 
 Amphetamine, [26] GC-MS 20-2000 ng/mL C: 100 µL No NS 
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methamphetamine, 
MDA and MDMA 
PAPER: NS 
SAMPLE PREP:  
         - 500 μL saturated borate buffer 
           (pH 10) + 2 mL butyl acetate 
         - separation in fraction A & B 
         - evaporated, reconstituted and  
           derivatized with MTBSTFA/  
           MSTFA (fraction A/B) 
RECOV: 87.3-98.6% 
 Amphetamine, MDMA, 
MDA, MDEA and 
methamphetamine 
[12,13] 
 
LC-MS/MS ± 40 ng/mL 
(amphetamine) 
± 2 ng/mL (MDMA) 
± 20 ng/mL (MDA) 
± 2 ng/mL (MDEA) 
± 50 ng/mL 
(methamphetamine) 
C: 5 µL 
PAPER: NS 
SAMPLE PREP: 100% MeOH (online 
extraction) 
No NS 
 Amphetamine, MDMA 
and methamphetamine 
[8] LC-MS/MS NS 
Screening technique 
LOD 1 ng/mL 
(amphetamine & MDMA) 
LOD 10 ng/mL 
(methamphetamine) 
C: 5 µL (6 mm  punch) 
PAPER: Whatman® 903 
SAMPLE PREP: 100 µL MeOH 
(automated) 
RECOV: 63% (amphetamine) 
              74% (MDMA) 
              105% (methamphetamine) 
Yes (post-mortem 
samples) 
Comparison with routine 
STA screening on whole 
blood, as well as with GC-
MS(MS) and LC-MS/MS 
quantitative analyses 
NS 
 MDMA and MDA [94] LC-HRMS (0.5-20 ng/mL) 
(qualitative) 
C: 20 µL 
PAPER: Sartorius TFN 
SAMPLE PREP:  
         - 100 µL MeOH + 400 µL TBME 
         - 300 µL acetone (2nd extraction) 
         - solvents evaporated and  
           re-dissolved in ACN:H2O (60:40) 
RECOV: 62% (MDMA)      
              78% (MDA) 
No 7 d at 4°C 
 Amphetamine, MDMA, 
MDA, MDEA and 
methamphetamine 
[31] LC-MS/MS 5-200 ng/mL 
 
 
P: 3 mm  of 30 µL DBS 
PAPER: Whatman® 903 
SAMPLE PREP: 150 µL H2O        
RECOV: 97.4% (amphetamine) 
              101.6% (MDMA) 
              121.6% (MDA) 
              88.6% (methamphetamine) 
              NS (MDEA) 
Yes (venous DBS) 
(DUID) 
Comparison with whole 
blood 
6 months at -20°C 
6 months at 4°C:  
± 40% ↓ (amphetamine)  
±25-30% ↓ (MDMA, MDA) 
±40-50% ↓ 
(methamphetamine) 
 Amphetamine, MDMA, 
MDA, MDEA and 
methamphetamine 
[80] LC-MS/MS NS  
Screening technique  
LOD 5.0 ng/mL 
(amphetamine) 
LOD 2.5 ng/mL (MDMA & 
C: 10 µL (10 mm ) 
PAPER: Bioanalysis cards 226 
SAMPLE PREP:  
         - 500 µL MeOH 
         - add to 10 µL 0.25% HCl in 
Yes (venous DBS) 
Comparison with blood 
2 w at RT & 4°C  
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MDA)  
LOD 1.0 ng/mL (MDEA)  
LOD 1.0 ng/mL 
(methamphetamine) 
           MeOH 
         - evaporated and re-dissolved in    
           mobile phase  
RECOV: 87.6-98.3% 
 Amphetamine, MDA, 
MDEA, MDMA and 
methamphetamine 
[47] LC-MS/MS 2 ng/mL 3 x 3 mm  punches 
PAPER: Bond Elut Dried Matrix 
Spotting cards 
SAMPLE PREP:  
         - 900 µL MeOH/0.1% formic 
           acid 
         - evaporated and re-dissolved 
           in 100 µL of water with 0.1% 
           of formic acid 
RECOV: 18-46% (amphetamine) 
              20-47% (MDA) 
              19-50% (MDEA) 
              19-54% (MDMA) 
              22-48% (methamphetamine) 
Yes (post-mortem 
samples) 
Comparison with routine 
analysis 
 
NS 
 Amphetamine, 
methamphetamine, 
MDMA and phentermine 
[41] LC-MS/MS 5-1000 ng/mL C: 5 µL (6 mm clamp covers complete 
spot) 
PAPER: Ahlstrom 226  
SAMPLE PREP: DBSA: 
         - automated flow-through 
           elution of DBS cards  
         - online SPE 
         - elution from the SPE cartridge 
           onto the LC column using the 
           LC mobile phase 
RECOV: 90.3-100% 
Yes (capillary DBS of 
volunteer who was 
administered 25 mg of 
phentermine) 
15 d at RT (amphetamine, 
methamphetamine, 
phentermine) 
30 d at RT (MDMA) 
15 d at RT under N2 flow 
(amphetamine, 
methamphetamine, 
phentermine) 
50 d at RT under N2 flow 
(MDMA) 
30 d at 4°C (amphetamine, 
methamphetamine) 
50 d at 4°C (MDMA, 
phentermine) 
50 d at -20°C 
(amphetamine, 
methamphetamine, MDMA, 
phentermine) 
 Amphetamine, 
methamphetamine, 
MDMA and MDA 
[93] LC-MS/MS 5 ng/mL C: ± 30 µL 
PAPER: Whatman® 903 Protein Saver 
cards 
SAMPLE PREP: 
         - 10 µL IS + 990 µL MeOH 
         - evaporated and re-dissolved in 
           mobile phase 
RECOV: 97.1% (amphetamine) 
              89.5% (methamphetamine) 
Yes (capillary DBS of drug 
abusers) 
Comparison with urine 
immunoassay  
3 months at RT 
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              99.8% (MDMA) 
              95.5% (MDA) 
GHB GHB [44] LC-MS/MS 1-128 µg/mL  3 x 3.2 mm  punches 
PAPER: Whatman® 903 
SAMPLE PREP:  
         - 200 µL MeOH 
         - evaporated and re-dissolved 
           in H2O 
RECOV: > 70% 
Yes 
(newborn DBS) 
NS 
 GHB [23] GC-MS 2-100 µg/mL C: 50 µL 
PAPER: Whatman® 903 
SAMPLE PREP:  
          - on-spot derivatization with 
            100 µL TFAA & HFB (2:1) 
          - evaporated and re-dissolved in 
            200 µL ethyl acetate 
Yes (venous DBS) 
(drug abuser) 
> 7 d at RT 
> 14 d at -20°C 
 GHB [24,25] GC-MS 2-100 µg/mL P: 6 mm  
PAPER: Whatman® 903 
SAMPLE PREP:  
          - on-spot derivatization with  
            50 µL TFAA & HFB (2:1) 
          - evaporated and re-dissolved 
            in 100 µL ethyl acetate 
Yes (fingerprick) 
Comparison with venous 
blood & DBS from venous 
blood 
> 148 d at RT 
Ketamine and 
norketamine 
Ketamine and 
norketamine 
[104] LC-MS/MS 5 ng/mL 
5-2500 ng/mL 
 
P: 3.2 mm  from 19 µL spot 
PAPER: NS 
SAMPLE PREP: MeOH/0.2M ZnSO4 
(7:3)  diluted with H2O (1:1) 
No NS 
 Ketamine [80] 
 
LC-MS/MS NS  
Screening technique  
LOD 1.0 ng/mL  
C: 10 µL (10 mm  ) 
PAPER: Bioanalysis cards 226 
SAMPLE PREP:  
          - 500 µL MeOH 
          - add to 10 µL 0.25 % HCl in  
            MeOH 
          - evaporated and re-dissolved 
            in mobile phase  
RECOV: 96.3%                
Yes (venous DBS) 
Comparison with blood 
2 w at RT & 4°C  
 Ketamine and 
norketamine 
[21] LC-DAD NS SAMPE PREP: ultrasound-assisted 
extraction followed by MEPS 
No NS 
 Ketamine and 
norketamine 
[47] LC-MS/MS 2 ng/mL 3 x 3 mm  punches  
PAPER: Bond Elut Dried Matrix 
Spotting cards 
SAMPLE PREP:  
          - 900 µL MeOH/0.1% formic 
            acid 
          - evaporated and re-dissolved 
Yes (post-mortem 
samples) 
Comparison with routine 
analysis 
 
NS 
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            in 100 µL of water with 0.1% 
            of formic acid 
RECOV: 18-45% (ketamine) 
              18-41% (norketamine) 
New psychoactive 
substances  
 
 
 
64, e.g. cathinones and 
piperazine derivatives 
[80] LC-MS/MS NS  
Screening technique  
LODs included for each 
compound  
C: 10 µL (10 mm ) 
PAPER: Bioanalysis cards 226 
SAMPLE PREP:  
          - 500 µL MeOH 
          - add to 10 µL 0.25 % HCl in 
            MeOH 
          - evaporated and re-dissolved in    
            mobile phase  
Yes (venous DBS) 
Comparison with blood 
2 w at RT & 4°C  
 Mephedrone  [41] LC-MS/MS 5-1000 ng/mL C: 5 µL (6 mm clamp covers complete 
spot) 
PAPER: Ahlstrom 226  
SAMPLE PREP: DBSA: 
          - automated flow-through 
            elution of DBS cards  
          - online SPE 
          - elution from the SPE cartridge 
            onto the LC column using the 
            LC mobile phase 
RECOV: 90.3-100% 
No 5 d at RT: 50%↓  
15 d at RT under N2 flow  
15 d at 4°C  
 
 
 
Alcohol markers Ethylglucuronide & 
ethylsulfate 
 
[110] LC-MS/MS 0.1-10 µg/mL C: 10 µL ( 1 cm  punch covers the 
whole spot) 
PAPER: 226-1004 Bioanalysis cards 
SAMPLE PREP:  
          - 500 µL MeOH 
          - evaporated and re-dissolved in  
            mobile phase 
RECOV: 43% (ethylglucuronide) 
              48% (ethylsulfate) 
Yes 
Comparison with whole 
blood 
3 w at 4°C & RT 
 PEth [111,112] 
 
LC-MS/MS 22.7 ng/mL (PEth 
18:1/18:1) 
87.3 ng/mL (PEth 
16:0/18:1) 
50-5000 ng/mL 
C: 100 µL 
PAPER: Whatman® 903 
SAMPLE PREP:  
          - 400 µL 0.5 M CH3COONa (pH 
            5) + 600 µL isopropanol  
          - 2 x 700 µL n-hexane  
          - evaporated and re-dissolved 
            in mobile phase   
RECOV: 26.6-42.5% (PEth 18:1/18:1) 
              68.9-90.7% (PEth 16:0/18:1) 
Yes 
(subjects in alcohol 
detoxification program) 
Comparison with whole 
blood 
> 30 d at -20°C & 20°C 
 PEth [43,113,114] 
 
LC-MS/MS 8 ng/mL (PEth 16:0/18:1) P: 3 X 3.2 mm  punches of 30 µL 
spot 
PAPER: Whatman® 903 
Yes (venous DBS) 
Comparison with whole 
blood 
No ex vivo de novo 
formation 
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SAMPLE PREP:  
          - 0.5 mL MeOH 
          - evaporated and re-dissolved in  
            mobile phase 
RECOV: 56.0-82.9% 
 PEth  [51] LC-MS/MS 10-2000 ng/mL (PEth 
16:0/18:1) 
10-1940 ng/mL (PEth 
18:1/18:1) 
19-3872 ng/mL (PEth 
16:0/16:0) 
C: 30 µL (venous DBS) 
P: 3 x 3 mm  (capillary DBS) 
PAPER: Whatman® 903 
SAMPLE PREP:  
          - 250 µL solution A (isopropanol, 
            10 mM ammonium acetate 
            buffer and formic acid 
            (6:4:0.2)) + 50 µL IS 
          - 1 mL n-hexane 
          - evaporated and re-dissolved in 
            250 µL (venous DBS) or 100 µL 
            (capillary DBS) solution B (50% 
            mobile phase A and 50 % 
            mobile phase B) 
RECOV: 58-74% (PEth 16:0/18:1) 
              59-77% (PEth 18:1/18:1) 
              55-78% (PEth 16:0/16:0)            
Yes  
Comparison between 
whole blood, venous DBS 
and capillary DBS 
6 months at RT 
Cotinine Cotinine [22] GC-MS NS ¼ of filled (± 200 µL) circle  ± 50 µL 
PAPER: NS 
SAMPLE PREP:  
          - 0.5 mL 0.2N NaOH  
          - heated for 1h at 80°C  
          - LLE: K2CO3 (0.5 mL, 25% 
            aqueous) + 1 mL CH2Cl2 
          - CH2Cl2.-layer transferred and 
            25 µL MeOH added  
          - evaporated to ±25 µL 
Yes (newborn DBS) NS 
 Cotinine [72] LC-MS/MS NS P: 6.35 mm  
PAPER: standard neonatal screening 
cards 
SAMPLE PREP:  
          - eluted with 200 µL H2O 
          - 1 mL MeOH added 
          - supernatant filtered, 
            evaporated and re-dissolved in 
             ± 200 µL MeOH  
          - evaporated and re-dissolved 
            in 100 µL H2O 
No 4 years at 4°C 
 Cotinine and trans 3’-
OH-cotinine 
[29] 
 
LC-MS/MS 0.2-0.3 ng cotinine/g  
(3 x 4.6 mm punches) 
P: 3.2 or 4.8 mm  (multiple 
punches) 
Yes  
Comparison with plasma 
11-26 months at -20°C 
9-11 months at RT 
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0.3-102 ng cotinine/g  PAPER: Ahlstrom 226 
SAMPLE PREP:  
          - 400 µL H2O 
          - SPE: Oasis MCX 96-well plate 
          - evaporated and re-dissolved in  
            a suitable solvent 
 
 Cotinine [49] LC-MS/MS 3.13 ng/mL  P: 6.35 mm (multiple punches) 
PAPER: Whatman® 903 
SAMPLE PREP:  
          - 450 µL H2O  
          - sonicated 75 min at 55°C 
          - PP: 50 µL 30% HClO4 
          - LLE: 1 mL 3.6M K3PO4 + CH2Cl2 
           -      acidified, evaporated and  
            re-dissolved in suitable solvent 
Yes (newborn DBS) 
Comparison with umbilical 
cord blood 
7 months at RT 
 Cotinine [115]  NS P:  2 x 6.35 mm  
PAPER: NS 
SAMPLE PREP: NS 
Yes NS 
 Nicotine 
Cotinine 
Trans-3’-OH-cotinine 
Anabasine 
[35] Paper 
spray MS 
1 ng/mL 
3 ng/mL 
2 ng/mL 
1 ng/mL 
Print paper (Xerox) 
NO SAMPLE PREP 
Yes (rat DBS) 
Comparison with blood 
NS 
 Nicotine, nornicotine, 
cotinine, trans-3’-OH-
cotinine, anabasine and 
anatabine 
[42] LC-
HRMS/MS 
15-2000 ng/mL P: 6 mm   ≈ clamp size 
PAPER: FTA® DMPK-C cards 
SAMPLE PREP: DBSA: 
          - automated flow-through 
            elution of DBS cards  
          - online SPE 
          - elution from the SPE 
            cartridge onto the LC column 
            using the LC mobile phase 
RECOV: 43.4% (nicotine) 
              38.1% (cotinine) 
              39.0% (trans-3’-OH-cotinine) 
              44.4% (nornicotine) 
              42.2% (anabasine) 
              25.4% (anatabine) 
Yes (authentic samples) 30 d at RT 
 
6-MAM: 6-monoacetylmorphine; ACN: acetonitrile; ACP: 2-amino-5-chloropyridine; BE: benzoylecgonine; C: complete DBS; CE: cocaethylene; d: days; DAD: diode array 
detection; DBS: dried blood spot(s); DRUID: driving under the influence of drugs, alcohol and medicines; DUID: driving under the influence of drugs; ECME: ecgonine 
methylester; EDDP: 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; EMDP: 2-ethyl-5-methyl-3,3-diphenylpyrroline; EME: electromembrane extraction; FID: flame 
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ionization detection; GC-MS: gas chromatography coupled to mass spectrometry; GHB: gamma-hydroxybutyric acid; h: hours; HFB: heptafluorobutanol; HRMS: high 
resolution mass spectrometry; IS: internal standard(s); LC-MS/MS: liquid chromatography coupled to tandem mass spectrometry; LLE: liquid-liquid extraction; LLOQ: lower 
limit of quantification; LOD: limit of detection; MDA: 3,4-methylenedioxyamphetamine; MDEA: 3,4-methylenedioxy-N-ethylamphetamine; MDMA: 3,4-
methylenedioxymethamphetamine; MeOH: methanol; MEPS: microextraction packed sorbent; MS: mass spectrometry; MSTFA: N-methyl-N-
(trimethylsilyl)trifluoroacetamide; MTBSTFA: N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide; M3G: morphine-3-glucuronide; M6G: morphine-6-glucuronide; NS: not 
studied; P: punch; PEth: phosphatidylethanol; PK: pharmacokinetics; PP: protein precipitation; RECOV: recovery; RIA: radioimmunoassay; RT: room temperature; SAMPLE 
PREP: sample preparation; SPE: solid phase extraction; STA: systematic toxicological analysis; TBME: tert-butyl methyl ether; TFAA: trifluoroacetic anhydride; THC: Δ9-
tetrahydrocannabinol; THC-COOH: tetrahydrocannabinol carboxylic acid; THC-OH: 11-hydroxy- Δ9-tetrahydrocannabinol; w: weeks 
 
  
  
176 
 
  
  
  
177 
 
Appendix 2 Cut-off concentrations for abused substances proposed by DRUID [50]. A distinction is made between analyses of complete DBS and analyses of DBS punches. 
The shaded columns contain these DBS methods achieving sufficient sensitivity to allow detection at DRUID LLOQ levels, when starting from complete ≤ 10-µL DBS and/or  
≤ 6.4-mm diameter DBS punches. 
 
COMPOUND DRUID CUT-OFF in ng/mL IN BLOOD 
(BELGIAN LEGAL LIMIT in ng/mL IN PLASMA)  
COMPLETE DBS 
LLOQ in ng/mL (blood volume) [reference] 
DBS PUNCH 
LLOQ in ng/mL ( punch) [reference] 
THC 1 (1)  1 (20 µL) [94] 
5 (100 µL) [26] 
50 (5 µL) [12] 
15 (30 µL) [93] 
 2.5 (7 mm ) [7]  
 
THC-COOH 5   1 (20 µL) [94]  
5 (100 µL) [26] 
15 (30 µL) [93] 
 5 (7 mm ) [7] 
THC-OH 1   15 (30 µL) [93]  5 (7 mm ) [7] 
      
Benzoylecgonine 50 (25) 1 (5 µL) [12,13]  
1 (5 µL) [8] 
20 (10 µL) [6] 
2.3 (20 µL) [96] 
5 (30 µL) [93] 
2 (6.4 mm ) [56]  
5 (3 mm ) [31]  
10 (6.4 mm ) [19] 
1 (3 mm ) [63] 
2 (3 x 3 mm ) [47] 
 
Cocaine 10 (25) < 1 (5 µL) [8] 
1 (5 µL) [12,13]  
 
0.25 (20 µL) [94] 
3.5 (20 µL) [96]  
20 (10 µL) [6]  
24.6 (100 µL) [77] 
50 (100 µL) [26] 
5 (30 µL) [93] 
5 (3 mm ) [31] 
1 (3 mm ) [63] 
2 (3 x 3 mm ) [47] 
 
Ecgonine methylester 5   10 (5 µL) [8] 5 (3 mm ) [31] 
 
2 (3 x 3 mm ) [47] 
      
6-MAM 10 (10) 1 (5 µL) [12,13]  
5 (5 µL) [8] 
11 (20 µL) [96]  
27 (100 µL) [67] 
5 (30 µL) [93] 
2 (3 x 3 mm ) [47]  
Codeine 10  5 (5 µL) [12,13]  
 
9.4 (20 µL) [96]  
10 (100 µL) [26] 
50 (5 µL) [8] 
5 (30 µL) [93] 
5 (2 x 5 mm ) [45]  
5 (3 mm ) [31] 
1 (2mm ) [40] 
 
Morphine 10 (10)  10 (100 µL) [26] 
10 (20 µL) [96]  
14 (100 µL) [67] 
1 (6.4 mm ) [100] 
4 (3 mm ) [61] 
5 (2 x 5 mm ) [45]  
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20 (5 µL) [12,13] 
100 (5 µL) [8] 
5 (30 µL) [93] 
5 (3 mm ) [31] 
1 (2mm ) [40] 
2 (3 x 3 mm ) [47] 
      
Buprenorphine 1   5 (100 µL) [26]  1 (2 x 5 mm ) [45] 
Methadone 10  < 1 (5 µL) [8]  
1 (5 µL) [12,13] 
2 (10 µL) [10] 
4 (theoretical volume 
calculated from ) [20] 
10 (100 µL) [26] 
5 (30 µL) [93] 
0.1 (6.4 mm ) [30] 
0.3 (3 mm ) [36] 
5 (2 x 5 mm ) [45] 
0.2 (3 x 3 mm ) [47] 
 
 
Tramadol 50  0.5 (5 µL) [12] 50 (100 µL) [26] 5 ( 2 x 5 mm ) [45]  
      
7-aminoclonazepam 10  4 (5 µL) [5] 100 (5 µL) [8] 2.5 (6 mm ) [122]  
7-aminoflunitrazepam 2  1 (5 µL) [12,13] 4 (5 µL) [5]  2.5 (6 mm ) [122] 
Alprazolam 10  1 (5 µL) [12,13] 
4 (5 µL) [5] 
0.7 (100 µL) [91]  
5 (100 µL) [26] 
1 (30 µL) [93] 
0.1 (4 mm ) [120]  
1 ( 3 mm ) [37] 
4 (6 mm ) [122] 
 
Clobazam 5  0.5 (5 µL) [12,13] 40 (5 µL) [5] 2 (6 mm ) [122]  
Clonazepam 10  4 (5 µL) [5] 
10 (5 µL) [12,13] 
5 (100 µL) [26] 
1 (30 µL) [93]  
 
4 (6 mm ) [122]  
Desalkylflurazepam 2   4 (5 µL) [5] 2 (6 mm ) [122]  
Desmethylflunitrazepam 1  1 (5 µL) [5]    
Diazepam 20  10 (5 µL) [12,13] 9.9 (100 µL) [77] 
40 (5 µL) [5]  
50 (100 µL) [26] 
50 (5 µL) [8]  
1 (30 µL) [93] 
2 (6 mm ) [122]  
Flunitrazepam 2   4 (5µL) [5]  
5 (5 µL) [12,13] 
15.8 (100 µL) [77] 
2 (6 mm ) [122]  
Flurazepam 2  0.5 (5 µL) [12,13]  
1 (5 µL) [5] 
 2 (6 mm ) [122]  
Lorazepam 10  4 (5 µL) [5]  
5 (5 µL) [12,13] 
 
5 (100 µL) [26]  
11 (100 µL) [77] 
1 (30 µL) [93] 
2 (6 mm ) [122]  
Lormetazepam 1  1 (5 µL) [5] 1 (30 µL) [93]   
Midazolam 10  0.5 (5 µL) [12,13]  
<1 (5 µL) [8] 
10 (100 µL) [26] 
1 (30 µL) [93] 
0.1 (4 mm ) [117,118] 
0.1 (6 mm  or  
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4 (5 µL) [5]  
 
 2 x 3 mm ) [46]  
0.3 (3 mm ) [46] 
0.35 (3 mm ) [119] 
1 ( 3 mm ) [37] 
5 (2 mm ) [39] 
2 (6 mm ) [122] 
Nitrazepam 1  1 (5 µL) [12,13] 
 
10 (100 µL) [26] 
18 (100 µL) [77] 
40 (5 µL) [5]  
 2 (6 mm ) [122] 
Nordiazepam 20  1 (5 µL) [12,13] 20 (100 µL) [26] 
40 (5 µL) [5]  
1 (30 µL) [93] 
3.5 (6 mm ) [122]  
OH-alprazolam 1   4 (5 µL) [5] 1 (3 mm ) [37] 2 (6 mm ) [122] 
OH-midazolam 1   2 (5 µL) [12,13] 
4 (5 µL) [5] 
5 (5 µL) [8] 
 2 (6 mm ) [122] 
Oxazepam 50  10 (5 µL) [12,13] 
40 (5 µL) [5]  
20.6 (100 µL) [77] 
50 (100 µL) [26] 
5 (30 µL) [93] 
3 (6 mm ) [122]  
Temazepam 20  1 (5 µL) [12,13] 
 
10.8 (100 µL) [77] 
40 (5 µL) [5]  
50 (100 µL) [26] 
3 (6 mm ) [122]  
Triazolam 1  0.5 (5 µL) [12,13]  
1 (5 µL) [5] 
  2 (6 mm ) [122] 
      
Zolpidem 20  < 1 (5 µL) [8]  
1 (5 µL) [12,13] 
4 (5 µL) [5] 
 0.1 (3 mm ) [9] 
2.5 (6 mm ) [122] 
 
Zopiclone 10  2 (5 µL) [12,13] 
4 (5 µL) [5] 
1.2 (100 µL) [91]  
6.4 (100 µL) [78] 
10 (100 µL) [26] 
  
      
Amphetamine 20 (25) 1 (5 µL) [8] 
5 (10 µL) [80]  
5 (5 µL) [41] 
 
3 (100 µL) [91] 
20 (100 µL) [26] 
40 (5 µL) [12,13] 
5 (30 µL) [93] 
5 (3 mm ) [31] 
2 (3 x 3 mm ) [47] 
 
MDA 20  2.5 (10 µL) [80] 
20 (5 µL) [12,13] 
0.4 (100 µL) [91] 
0.4 (100 µL) [121] 
20 (100 µL) [26]  
5 (30 µL) [93] 
5 (3 mm ) [31] 
2 (3 x 3 mm ) [47] 
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MDEA 20  1 (10 µL) [80] 
2 (5 µL) [12,13]  
 5 (3 mm ) [31] 
2 (3 x 3 mm ) [47] 
 
MDMA 20 (25) 1 (5 µL) [8] 
2 (5 µL) [12,13] 
2.5 (10 µL) [80]  
5 (5 µL) [41] 
5.7 (100 µL) [91] 
5.7 (100 µL) [121] 
20 (100 µL) [26] 
5 (30 µL) [93] 
5 (3 mm ) [31] 
2 (3 x 3 mm ) [47] 
 
Methamphetamine 20  1 (10 µL) [80] 
10 (5 µL) [8] 
5 (5 µL) [41] 
 
20 (100 µL) [26]  
50 (5 µL) [12,13] 
5 (30 µL) [93] 
5 (3 mm ) [31] 
2 (3 x 3 mm ) [47] 
 
      
Ketamine 20  1 (10 µL) [80]  5 (3.2 mm ) [104] 
2 (3 x 3 mm ) [47] 
 
 
6-MAM: 6-monoacetylmorphine; DBS: dried blood spot(s); DRUID: driving under the influence of drugs, alcohol and medicines; LLOQ: lower limit of quantification; MDA: 
3,4-methylenedioxyamphetamine; MDEA: 3,4-methylenedioxy-N-ethylamphetamine; MDMA: 3,4-methylenedioxymethamphetamine; THC: Δ9-tetrahydrocannabinol; THC-
COOH: tetrahydrocannabinol carboxylic acid; THC-OH: 11-hydroxy- Δ
9
-tetrahydrocannabinol; 
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